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Abstract
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly
1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and
links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/
doi/bph.15542. Enzymes are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ion channels, nuclear hormone receptors,
catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for
further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2021, and supersedes data presented in the 2019/20,
2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International
Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
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Overview: Enzymes are protein catalysts facilitating the
conversion of substrates into products. The Nomenclature
Committee of the International Union of Biochemistry and
Molecular Biology (NC-IUBMB) classifies enzymes into families,
using a four number code, on the basis of the reactions they







Although there are many more enzymes than receptors in
biology, and many drugs that target prokaryotic enzymes are
effective medicines, overall the number of enzyme drug targets is
relatively small [525, 569], which is not to say that they are of
modest importance.
The majority of drugs which act on enzymes act as inhibitors;
one exception is ingenol mebutate, which is a non-selective
protein kinase C activator approved for the topical treatment of
actinic keratoses. Kinetic assays allow discrimination of
competitive, non-competitive, and un-competitive inhibitors.
The majority of inhibitors are competitive (acting at the
enzyme’s ligand recognition site), non-competitive (acting at a
distinct site; potentially interfering with co-factor or co-enzyme
binding) or of mixed type. One rare example of an
uncompetitive inhibitor is lithium ions, which are effective
inhibitors at inositol monophosphatase only in the presence of
high substrate concentrations. Some inhibitors are irreversible,
including a group known as suicide substrates, which bind to the
ligand recognition site and then couple covalently to the
enzyme. It is beyond the scope of the Guide to give mechanistic
information about the inhibitors described, although generally
this information is available from the indicated literature.
Many enzymes require additional entities for functional activity.
Some of these are used in the catalytic steps, while others
promote a particular conformational change. Co-factors are
tightly bound to the enzyme and include metal ions and heme
groups. Co-enzymes are typically small molecules which accept
or donate functional groups to assist in the enzymatic reaction.
Examples include ATP, NAD, NADP and S-adenosylmethionine,
as well as a number of vitamins, such as riboflavin (vitamin B1)
and thiamine (vitamin B2). Where co-factors/co-enzymes have






S321 Amino acid hydroxylases
S322 L-Arginine turnover




S324 Nitric oxide synthases
S325 Carbonic anhydrases


















S336 Chromatin modifying enzymes
– 1.14.11.- Histone demethylases
S336 2.1.1.- Protein arginine N-methyltransferases
– 2.1.1.43 Histone methyltransferases (HMTs)
– 2.3.1.48 Histone acetyltransferases (HATs)
S337 3.5.1.- Histone deacetylases (HDACs)
– 3.6.1.3 ATPases
– Enzymatic bromodomain-containing proteins
– Bromodomain kinase (BRDK) family
– TAF1 family
– TIF1 family
S338 Cyclic nucleotide turnover/signalling
S338 Adenylyl cyclases (ACs)
– Cyclic GMP-AMP synthase
S340 Exchange protein activated by cyclic AMP
(EPACs)




S345 CYP2 family: drug metabolising subset
S346 CYP2 family: physiological enzymes subset
S346 CYP3 family
S347 CYP4 family
S348 CYP5, CYP7 and CYP8 families
S349 CYP11, CYP17, CYP19, CYP20 and CYP21
families
S350 CYP24, CYP26 and CYP27 families
S350 CYP39, CYP46 and CYP51 families
– DNA glycosylases
S351 DNA topoisomerases
S351 E3 ubiquitin ligase components
S352 Endocannabinoid turnover
S353 N-Acylethanolamine turnover





S359 Leukotriene and lipoxin metabolism
– G-alpha family G(q) subfamily
S359 GABA turnover
S361 Glycerophospholipid turnover
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S361 Phosphoinositide-specific phospholipase C
S363 Phospholipase A2
S364 Phosphatidylcholine-specific phospholipase D
S365 Lipid phosphate phosphatases
S366 Phosphatidylinositol kinases
S368 Phosphatidylinositol phosphate kinases
– Glycine recycling
S369 Haem oxygenase
S370 Hydrogen sulphide synthesis
S371 Hydrolases
S373 Inositol phosphate turnover
S373 Inositol 1,4,5-trisphosphate 3-kinases
S373 Inositol polyphosphate phosphatases
S374 Inositol monophosphatase
– Itaconate biosynthesis
S374 Kinases (EC 2.7.x.x)
– AGC: Containing PKA, PKG, PKC families
– DMPK family
– GEK subfamily
– Other DMPK family kinases
S375 Rho kinase
– G protein-coupled receptor kinases (GRKs)






– Protein kinase A (PKA) family
– Akt (Protein kinase B, PKB) family





– Protein kinase G (PKG) family













– Alpha kinase family
– ChaK subfamily
– eEF2K subfamily
– Other alpha kinase family kinases
– BCR family
– Bromodomain kinase (BRDK) family
– G11 family












– Pyruvate dehydrogenase kinase (PDHK) family
– TAF1 family
– TIF1 family




















– Death-associated kinase (DAPK) family




– Myosin Light Chain Kinase (MLCK) family
– Phosphorylase kinase (PHK) family
– PIM family
– Protein kinase D (PKD) family
– PSK family
– RAD53 family
– Testis specific kinase (TSSK) family
– Trbl family
– Trio family
– CK1: Casein kinase 1
– Casein kinase 1 (CK1) family
– Tau tubulin kinase (TTBK) family
– Vaccina related kinase (VRK) family
– CMGC: Containing CDK, MAPK, GSK3, CLK
families
– CLK family












– Cyclin-dependent kinase-like (CDKL) family
– Dual-specificity tyrosine-(Y)-phosphorylation





– Glycogen synthase kinase (GSK) family
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S379 GSK subfamily








– Lipid modifying kinases
– 1-phosphatidylinositol 4-kinase family
– Phosphatidylinositol-4-phosphate 3-kinase
family





– Type I PIP kinases
(1-phosphatidylinositol-4-phosphate 5-kinase
family)




– Other protein kinases
– CAMKK family
– Meta subfamily
– Aurora kinase (Aur) family
– Bub family
– Bud32 family














– Numb-associated kinase (NAK) family
– Other-unique family









– Tousled-like kinase (TLK) family
– TTK family




– Miscellaneous protein kinases






















– TK: Tyrosine kinase










– TKL: Tyrosine kinase-like
– Interleukin-1 receptor-associated kinase (IRAK)
family
– Leucine-rich repeat kinase (LRRK) family
– LIM domain kinase (LISK) family
– LIMK subfamily
– TESK subfamily







– Receptor interacting protein kinase (RIPK) family
– TKL-unique family
S385 Lanosterol biosynthesis pathway
– LPA synthesis








S389 Paraoxonase (PON) family
S390 Peptidases and proteinases
S390 Blood coagulation components
– AA: Aspartic (A) Peptidases
S391 A1: Pepsin
– AD: Aspartic (A) Peptidases
S391 A22: Presenilin
– CA: Cysteine (C) Peptidases
– C1: Papain
– C2: Calpain
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– C12: Ubiquitin C-terminal hydrolase
– C19: Ubiquitin-specific protease
– C54: Aut2 peptidase
– C101: OTULIN peptidase
– CD: Cysteine (C) Peptidases
– C13: Legumain
S392 C14: Caspase
– CE: Cysteine (C) Peptidases
– C48: Ulp1 endopeptidase
– M-: Metallo (M) Peptidases
– M79: Prenyl protease 2
– MA: Metallo (M) Peptidases
S392 M1: Aminopeptidase N
S393 M2: Angiotensin-converting enzymes (ACE and
ACE2)
S393 M10: Matrix metallopeptidase
S394 M12: Astacin/Adamalysin
– M13: Neprilysin
– M49: Dipeptidyl-peptidase III
– MC: Metallo (M) Peptidases
– M14: Carboxypeptidase A
– ME: Metallo (M) Peptidases
– M16: Pitrilysin
– MF: Metallo (M) Peptidases
– M17: Leucyl aminopeptidase
– MG: Metallo (M) Peptidases
– M24: Methionyl aminopeptidase
– MH: Metallo (M) Peptidases
– M18: Aminopeptidase I
– M20: Carnosine dipeptidase
S394 M28: Aminopeptidase Y
– MJ: Metallo (M) Peptidases
S395 M19: Membrane dipeptidase
– MP: Metallo (M) Peptidases
– M67: PSMD14 peptidase
– PA: Serine (S) Peptidases
S395 S1: Chymotrypsin
– PB: Threonine (T) Peptidases
– C44: Phosphoribosyl pyrophosphate
amidotransferase
S396 T1: Proteasome
– T2: Glycosylasparaginase precursor
– PC: Cysteine (C) Peptidases
– C26: Gamma-glutamyl hydrolase
– SB: Serine (S) Peptidases
S397 S8: Subtilisin
– SC: Serine (S) Peptidases
S397 S9: Prolyl oligopeptidase
– S10: Carboxypeptidase Y
– S28: Lysosomal Pro-Xaa carboxypeptidase
– S33: Prolyl aminopeptidase
S397 Peptidyl-prolyl cis/trans isomerases
– Phosphatases
– Metal-dependent protein phosphatase (PPM)
family
– Protein tyrosine phosphatases non-receptor type
(PTPN)
– Sugar phosphatases
S399 Poly ADP-ribose polymerases
S399 Prolyl hydroxylases
S400 Sphingosine 1-phosphate turnover
S400 Sphingosine kinase
S402 Sphingosine 1-phosphate phosphatase
S402 Sphingosine 1-phosphate lyase
S403 Thyroid hormone turnover
– UDP glucuronosyltransferases (UGT)
– 1.-.-.- Oxidoreductases
– 1.1.1.42 Isocitrate dehydrogenases
– 1.4.3.13 Lysyl oxidases
– 1.13.11.- Dioxygenases
S404 1.14.13.9 Kynurenine 3-monooxygenase
– 1.17.4.1 Ribonucleoside-diphosphate reductases
– 2.1.1.- Methyltransferases





– 2.3.2.27 RING-type E3 ubiquitin transferase
– 2.4.2.1 Purine-nucleoside phosphorylase
– 2.5.1.18 Glutathione transferases
S405 2.5.1.58 Protein farnesyltransferase
– 2.6.1.42 Branched-chain-amino-acid
transaminase
– 2.7.1.40 Pyruvate kinases
– 3.1.-.- Ester bond enzymes
– 3.1.1.- Carboxylic Ester Hydrolases
– 3.2.1.- Glycosidases
– 3.4.21.46 Complement factor D
S337 3.5.1.- Histone deacetylases (HDACs)
– 3.5.1.2 Glutaminases
S405 3.5.3.15 Peptidyl arginine deiminases (PADI)
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Acetylcholine turnover
Enzymes → Acetylcholine turnover
Overview: Acetylcholine is familiar as a neurotransmitter in the
central nervous system and in the periphery. In the somatic
nervous system, it activates nicotinic acetylcholine receptors at
the skeletal neuromuscular junction. It is also employed in the
autonomic nervous system, in both parasympathetic and
sympathetic branches; in the former, at the smooth muscle
neuromuscular junction, activating muscarinic acetylcholine
receptors. In the latter, acetylcholine is involved as a
neurotransmitter at the ganglion, activating nicotinic
acetylcholine receptors. Acetylcholine is synthesised in neurones
through the action of choline O-acetyltransferase and
metabolised after release through the extracellular action of
acetylcholinesterase and cholinesterase. Choline is accumulated
from the extracellular medium by selective transporters (see
SLC5A7 and the SLC44 family). Acetylcholine is accumulated in
synaptic vesicles through the action of the vesicular
acetylcholine transporter SLC18A3.
Further reading on Acetylcholine turnover
Akıncıoğlu H et al. (2020) Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer’s Disease
Mini Rev Med Chem 20: 703-715 [PMID:31902355]
Lockridge O. (2015) Review of human butyrylcholinesterase structure, function, genetic variants,
history of use in the clinic, and potential therapeutic uses. Pharmacol Ther 148: 34-46
[PMID:25448037]
Sussman JL et al. (2020) Computational studies on cholinesterases: Strengthening our
understanding of the integration of structure, dynamics and function Neuropharmacology 179:
108265 [PMID:32795461]
Taylor P et al. (2021) Ligand design for human acetylcholinesterase and nicotinic acetylcholine
receptors, extending beyond the conventional and canonical J Neurochem [PMID:33638151]
Winek K et al. (2021) Regulators of cholinergic signaling in disorders of the central nervous system
J Neurochem [PMID:33638173]
Nomenclature choline O-acetyltransferase acetylcholinesterase (Cartwright blood group) butyrylcholinesterase
Common abbreviation ChAT AChE BChE
HGNC, UniProt CHAT, P28329 ACHE, P22303 BCHE, P06276
EC number 2.3.1.6: acetyl CoA + choline = acetylcholine + coenzyme A 3.1.1.7: acetylcholine + H2O = acetic acid + choline + H+ 3.1.1.7: acetylcholine + H2O = acetic acid + choline + H+
Inhibitors naphthylvinylmethylpyridine (pIC50 6.5) [252] – Mouse tacrine (pKi 7.5) [73], galantamine (pIC50 6.3) [116],
rivastigmine (pIC50 5.4) [439]
rivastigmine (pIC50 7.4) [439], tacrine (pKi 7.2) [73]
Sub/family-selective
inhibitors
– physostigmine (pIC50 7.6–7.8) [439] physostigmine (pIC50 7.6–7.8) [439]
Selective inhibitors – donepezil (pIC50 7.7–8.3) [83, 221, 439], BW284C51
(pIC50 7.7) [235]
bambuterol (pIC50 8.5) [235]
Comments Splice variants of choline O-acetyltransferase are suggested
to be differentially distributed in the periphery and CNS
(see [46]).
– –
Comments: A number of organophosphorus compounds inhibit acetylcholinesterase and cholinesterase irreversibly, including pesticides such as chlorpyrifos-oxon, and nerve agents such as tabun,
soman and sarin. AChE is unusual in its exceptionally high turnover rate which has been calculated at 740 000/min/molecule [737].
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Adenosine turnover
Enzymes → Adenosine turnover
Overview: A multifunctional, ubiquitous molecule, adenosine
acts at cell-surface G protein-coupled receptors, as well as
numerous enzymes, including protein kinases and adenylyl
cyclase. Extracellular adenosine is thought to be produced either
by export or by metabolism, predominantly through
ecto-5’-nucleotidase activity (also producing inorganic
phosphate). It is inactivated either by extracellular metabolism
via adenosine deaminase (also producing ammonia) or, following
uptake by nucleoside transporters, via adenosine deaminase or
adenosine kinase (requiring ATP as co-substrate). Intracellular
adenosine may be produced by cytosolic 5’-nucleotidases or
through S-adenosylhomocysteine hydrolase (also producing
L-homocysteine).
Further reading on Adenosine turnover
Boison D et al. (2021) Adenosine kinase: A key regulator of purinergic physiology. Biochem
Pharmacol 187: 114321 [PMID:33161022]
Gao ZW et al. (2021) The roles of adenosine deaminase in autoimmune diseases. Autoimmun Rev
20: 102709 [PMID:33197575]
Giuliani AL et al. (2020) Ectonucleotidases in Acute and Chronic Inflammation. Front Pharmacol
11: 619458 [PMID:33613285]
Jeffrey JL et al. (2020) Targeting Metabolism of Extracellular Nucleotides via Inhibition of
Ectonucleotidases CD73 and CD39. J Med Chem 63: 13444-13465 [PMID:32786396]
Vizán P et al. (2021) Functional and Pathological Roles of AHCY. Front Cell Dev Biol 9: 654344
[PMID:33869213]
Yegutkin GG. (2021) Adenosine metabolism in the vascular system. Biochem Pharmacol 187:
114373 [PMID:33340515]
Zimmermann H. (2021) History of ectonucleotidases and their role in purinergic signaling.
Biochem Pharmacol 187: 114322 [PMID:33161020]
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Nomenclature Adenosine deaminase Adenosine kinase Ecto-5’-Nucleotidase S-Adenosylhomocysteine
hydrolase
Systematic nomenclature – – CD73 –
Common abbreviation ADA ADK NT5E SAHH
HGNC, UniProt ADA, P00813 ADK, P55263 NT5E, P21589 AHCY, P23526
EC number 3.5.4.4: adenosine + H2O
= inosine + NH3
2.7.1.20 3.1.3.5 3.3.1.1
Rank order of affinity 2’-deoxyadenosine >
adenosine
adenosine adenosine 5’-monophosphate, 5’-GMP,
5’-inosine monophosphate, 5’-UMP >
5’-dAMP, 5’-dGMP
–
Endogenous substrates – – – S-adenosylhomocysteine
Products 2’-deoxyinosine, inosine adenosine 5’-monophosphate adenosine, guanine, inosine, uridine adenosine
Inhibitors – – – DZNep (pKi 12.3) [240]
– Hamster
Selective inhibitors pentostatin (pIC50 10.8)
[8], EHNA (pKi 8.8) [8]
A134974 (pIC50 10.2) [464], ABT702 (pIC50 8.8) [336] αβ-methyleneADP (pIC50 8.7) [71] 3-deazaadenosine (pIC50
8.5) [265]
Comments – The enzyme exists in two isoforms derived from alternative splicing of a single
gene product: a short isoform, ADK-S, located in the cytoplasm is responsible for
the regulation of intra- and extracellular levels of adenosine and hence adenosine
receptor activation; a long isoform, ADK-L, located in the nucleus contributes to
the regulation of DNA methylation [62, 735].
Pharmacological inhibition of CD73 is
being investigated as a novel cancer
immunotherapy strategy [714].
–
Comments: An extracellular adenosine deaminase activity,
termed ADA2 or adenosine deaminase growth factor (ADGF,
CECR1, Q9NZK5) has been identified [126, 444], which is
insensitive to EHNA [773]. Other forms of adenosine deaminase
act on ribonucleic acids and may be divided into two families:
ADAT1 (Q9BUB4) deaminates transfer RNA; ADAR (EC 3.5.4.37,
also known as 136 kDa double-stranded RNA-binding protein,
P136, K88DSRBP, Interferon-inducible protein 4); ADARB1 (EC
3.5.-.-, , also known as dsRNA adenosine deaminase) and
ADARB2 (EC 3.5.-.-, also known as dsRNA adenosine deaminase
B2, RNA-dependent adenosine deaminase 3) act on
double-stranded RNA. Particular polymorphisms of the ADA
gene result in loss-of-function and severe combined
immunodeficiency syndrome. Adenosine deaminase is able to
complex with dipeptidyl peptidase IV (EC 3.4.14.5, DPP4, also
known as T-cell activation antigen CD26, TP103, adenosine
deaminase complexing protein 2) to form a cell-surface
activity [351].
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Amino acid hydroxylases
Enzymes → Amino acid hydroxylases
Overview: The amino acid hydroxylases (monooxygenases), EC.1.14.16.-, are iron-containing enzymes which utilise molecular oxygen and sapropterin as co-substrate and co-factor, respectively. In
humans, as well as in other mammals, there are two distinct L-Tryptophan hydroxylase 2 genes. In humans, these genes are located on chromosomes 11 and 12 and encode two different homologous
enzymes, TPH1 and TPH2.
Further reading on Amino acid hydroxylases
Daubner SC et al. (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch
Biochem Biophys 508: 1-12 [PMID:21176768]
Flydal MI et al. (2013) Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life
65: 341-9 [PMID:23457044]
Tekin I et al. (2014) Complex molecular regulation of tyrosine hydroxylase. J Neural Transm 121:
1451-81 [PMID:24866693]
Walen K et al. (2017) Tyrosine and tryptophan hydroxylases as therapeutic targets in human
disease. Expert Opin Ther Targets 21: 167-180 [PMID:27973928]
Nomenclature L-Phenylalanine hydroxylase L-Tyrosine hydroxylase L-Tryptophan hydroxylase 1 L-Tryptophan hydroxylase 2
HGNC, UniProt PAH, P00439 TH, P07101 TPH1, P17752 TPH2, Q8IWU9
EC number 1.14.16.1: L-phenylalanine + O2 -> L-tyrosine 1.14.16.2: L-tyrosine + O2 -> levodopa 1.14.16.4 1.14.16.4
Endogenous substrates L-phenylalanine L-tyrosine L-tryptophan L-tryptophan
Products L-tyrosine levodopa 5-hydroxy-L-tryptophan 5-hydroxy-L-tryptophan
Cofactors sapropterin sapropterin, Fe2+ – –
Endogenous activators Protein kinase A-mediated phosphorylation
(Rat) [2]
Protein kinase A-mediated phosphorylation
[340]
Protein kinase A-mediated phosphorylation
[341]
Protein kinase A-mediated phosphorylation
[341]
Inhibitors – – rodatristat (pIC50 7.5) [243], compound
23a (pIC50 7.4) [31], telotristat ethyl (pIC50
7.2) [31, 364], LP533401 (pIC50 6.2) [31]
rodatristat (pIC50 8.1) [243]






Comments PAH is an iron bound homodimer or -tetramer
from the same structural family as tyrosine
3-monooxygenase and the tryptophan
hydroxylases. Deficiency or loss-of-function of
PAH is associated with phenylketonuria
TH is a homotetramer, which is inhibited
by dopamine and other catecholamines in
a physiological negative feedback pathway
[139].
– –
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L-Arginine turnover
Enzymes → L-Arginine turnover
Overview: L-arginine is a basic amino acid with a guanidino
sidechain. As an amino acid, metabolism of L-arginine to form
L-ornithine, catalysed by arginase, forms the last step of the urea
production cycle. L-Ornithine may be utilised as a precursor of
polyamines (see Carboxylases and Decarboxylases) or recycled
via L-argininosuccinic acid to L-arginine. L-Arginine may itself
be decarboxylated to form agmatine, although the prominence
of this pathway in human tissues is uncertain. L-Arginine may be
used as a precursor for guanidoacetic acid formation in the
creatine synthesis pathway under the influence of
arginine:glycine amidinotransferase with L-ornithine as a
byproduct. Nitric oxide synthase uses L-arginine to generate
nitric oxide, with L-citrulline also as a byproduct.
L-Arginine in proteins may be subject to post-translational
modification through methylation, catalysed by protein arginine
methyltransferases. Subsequent proteolysis can liberate
asymmetric NG,NG-dimethyl-L-arginine (ADMA), which is an
endogenous inhibitor of nitric oxide synthase activities. ADMA
is hydrolysed by dimethylarginine dimethylhydrolase activities
to generate L-citrulline and dimethylamine.
Further reading on L-Arginine turnover
Cziráki A et al. (2020) L-Arginine-Nitric Oxide-Asymmetric Dimethylarginine Pathway and the
Coronary Circulation: Translation of Basic Science Results to Clinical Practice. Front Pharmacol
11: 569914 [PMID:33117166]
Hartley AV et al. (2020) Modulating the modulators: regulation of protein arginine
methyltransferases by post-translational modifications. Drug Discov Today 25: 1735-1743
[PMID:32629172]
Moncada S et al. (1997) International Union of Pharmacology Nomenclature in Nitric Oxide
Research. Pharmacol Rev 49: 137-42 [PMID:9228663]
Pekarova M et al. (2015) The crucial role of l-arginine in macrophage activation: What you need
to know about it. Life Sci 137: 44-8 [PMID:26188591]
Pudlo M et al. (2017) Arginase Inhibitors: A Rational Approach Over One Century. Med Res Rev 37:
475-513 [PMID:27862081]
Wu Q et al. (2021) Protein arginine methylation: from enigmatic functions to therapeutic
targeting. Nat Rev Drug Discov [PMID:33742187]
2.1.1.- Protein arginine N-methyltransferases
Enzymes → L-Arginine turnover → 2.1.1.- Protein arginine N-methyltransferases
Overview: Protein arginine N-methyltransferases (PRMT, EC
2.1.1.-) encompass histone arginine N-methyltransferases
(PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein
N-methyltransferases (PRMT7, EC 2.1.1.126). They are dimeric or
tetrameric enzymes which use S-adenosyl methionine as a
methyl donor, generating S-adenosylhomocysteine as a
by-product. They generate both mono-methylated and
di-methylated products; these may be symmetric (SDMA) or
asymmetric (NG,NG-dimethyl-L-arginine) versions, where both
guanidine nitrogens are monomethylated or one of the two is
dimethylated, respectively.
Information on members of this family may be found in the online database.
Arginase
Enzymes → L-Arginine turnover → Arginase
Overview: Arginase (EC 3.5.3.1) are manganese-containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is
associated more with the kidney.
Information on members of this family may be found in the online database.
Comments: Nω-hydroxyarginine, an intermediate in NOS metabolism of L-arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although
isoform-selective inhibitors of arginase are not available, examples of inhibitors selective for arginase compared to NOS are Nω-hydroxy-nor-L-arginine [678], S-(2-boronoethyl)-L-cysteine [119, 365] and
2(S)-amino-6-boronohexanoic acid [37, 119].
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Arginine:glycine amidinotransferase
Enzymes → L-Arginine turnover → Arginine:glycine amidinotransferase
Overview: Arginine:glycine amidinotransferase is a mitochondrial enzyme that is involved in creatine biosynthesis.
Nomenclature Arginine:glycine amidinotransferase
Common abbreviation AGAT
HGNC, UniProt GATM, P50440
EC number 2.1.4.1
Comments: Missense mutations in GATM which disrupt creatine synthesis, underlie creatine deficiency syndromes which are characterised by cognitive disability, language impairment, and
behavioural disorders.
Dimethylarginine dimethylaminohydrolases
Enzymes → L-Arginine turnover → Dimethylarginine dimethylaminohydrolases
Overview: Dimethylarginine dimethylaminohydrolases (DDAH, EC 3.5.3.18) are cytoplasmic enzymes which hydrolyse NG,NG-dimethyl-L-arginine to form dimethylamine and L-citrulline.
Nomenclature NG,NG-Dimethylarginine dimethylaminohydrolase 1 NG,NG-Dimethylarginine dimethylaminohydrolase 2
Common abbreviation DDAH1 DDAH2
HGNC, UniProt DDAH1, O94760 DDAH2, O95865
EC number 3.5.3.18 3.5.3.18
Cofactors Zn2+ –
Inhibitors compound 2e (pKi 5.7) [377] –
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Nitric oxide synthases
Enzymes → L-Arginine turnover → Nitric oxide synthases
Overview: Nitric oxide synthases (NOS, E.C. 1.14.13.39) are a
family of oxidoreductases that synthesize nitric oxide (NO.) via
the NADPH and oxygen-dependent consumption of L-arginine
with the resultant by-product, L-citrulline. There are 3 NOS
isoforms and they are related by their capacity to produce NO,
highly conserved organization of functional domains and
significant homology at the amino acid level. NOS isoforms are
functionally distinguished by the cell type where they are
expressed, intracellular targeting and transcriptional and
post-translation mechanisms regulating enzyme activity. The
nomenclature suggested by NC-IUPHAR of NOS I, II and III
[483] has not gained wide acceptance, and the 3 isoforms are
more commonly referred to as neuronal NOS (nNOS), inducible
NOS (iNOS) and endothelial NOS (eNOS) which reflect the
location of expression (nNOS and eNOS) and inducible
expression (iNOS). All are dimeric enzymes that shuttle electrons
from NADPH, which binds to a C-terminal reductase domain,
through the flavins FAD and FMN to the oxygenase domain of
the other monomer to enable the BH4-dependent reduction of
heme bound oxygen for insertion into the substrate, L-arginine.
Electron flow from reductase to oxygenase domain is controlled
by calmodulin binding to canonical calmodulin binding motif
located between these domains. eNOS and nNOS isoforms are
activated at concentrations of calcium greater than 100 nM,
while iNOS shows higher affinity for Ca2+/calmodulin (CALM1
CALM2 CALM3, P62158) with great avidity and is essentially
calcium-independent and constitutively active. Efficient
stimulus-dependent coupling of nNOS and eNOS is achieved via
subcellular targeting through respective N-terminal PDZ and
fatty acid acylation domains whereas iNOS is largely cytosolic
and function is independent of intracellular location. nNOS is
primarily expressed in the brain and neuronal tissue, iNOS in
immune cells such as macrophages and eNOS in the endothelial
layer of the vasculature although exceptions in other cells have
been documented. L-NAME and related modified arginine
analogues are inhibitors of all three isoforms, with IC50 values in
the micromolar range.
Further reading on Nitric oxide synthases
García-Ortiz A et al. (2018) Nitric Oxide Signaling in T Cell-Mediated Immunity. Trends Mol Med
24: 412-427 [PMID:29519621]
Kapil V et al. (2020) The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The
Nitrate-Nitrite-Nitric Oxide Pathway. Pharmacol Rev 72: 692-766
[PMID:32576603]
Lundberg JO et al. (2015) Strategies to increase nitric oxide signalling in cardiovascular disease.
Nat Rev Drug Discov 14: 623-41 [PMID:26265312]
Oliveira-Paula GH et al. (2016) Endothelial nitric oxide synthase: From biochemistry and gene
structure to clinical implications of NOS3 polymorphisms. Gene 575: 584-99
[PMID:26428312]
Stuehr DJ et al. (2019) Nitric oxide synthase enzymology in the 20 years after the Nobel Prize. Br J
Pharmacol 176: 177-188 [PMID:30402946]
Wallace JL. (2019) Nitric oxide in the gastrointestinal tract: opportunities for drug development.
Br J Pharmacol 176: 147-154 [PMID:30357812]
Nomenclature Endothelial NOS Inducible NOS Neuronal NOS
Common abbreviation eNOS iNOS nNOS
HGNC, UniProt NOS3, P29474 NOS2, P35228 NOS1, P29475
EC number 1.14.13.39 1.14.13.39 1.14.13.39
Endogenous Substrate L-arginine L-arginine L-arginine
Products NO, L-citrulline NO, L-citrulline NO, L-citrulline
Cofactors heme, flavin adenine dinucleotide, flavin
mononucleotide, NADPH, oxygen, BH4, Zn2+
heme, flavin adenine dinucleotide, flavin mononucleotide, NADPH,
oxygen, BH4, Zn2+
heme, flavin adenine dinucleotide, flavin
mononucleotide, NADPH, oxygen, BH4, Zn2+
Inhibitors – – NANT
Selective inhibitors – 1400W (pIC50 8.2) [231], 2-amino-4-methylpyridine (pIC50 7.4) [188],
PIBTU (pIC50 7.3) [232], NIL (pIC50 5.5) [484], aminoguanidine [123]
3-bromo-7NI (pIC50 6.1–6.5) [58], 7NI (pIC50 5.3)
[28]
Comments: The reductase domain of NOS catalyses the reduction of cytochrome c and other redox-active dyes [458]. NADPH:O2 oxidoreductase catalyses the formation of superoxide anion/H2O2 in
the absence of L-arginine and sapropterin.
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Carbonic anhydrases
Enzymes → Carbonic anhydrases
Overview: Carbonic anhydrases facilitate the interconversion of water and carbon dioxide to bicarbonate ions and protons (EC 4.2.1.1), with over a dozen gene products identified in man. The
enzymes function in acid-base balance and the movement of carbon dioxide and water. They are targetted for therapeutic gain by particular antiglaucoma agents and diuretics.
Further reading on Carbonic anhydrases
Angeli A et al. (2020) Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor
Microenvironment. Metabolites 10: [PMID:33066524]
Kumar S et al. (2021) Recent advances in the medicinal chemistry of carbonic anhydrase
inhibitors. Eur J Med Chem 209: 112923 [PMID:33121862]
Mishra CB et al. (2020) Progress in the development of human carbonic anhydrase inhibitors and
their pharmacological applications: Where are we today? Med Res Rev 40: 2485-2565
[PMID:32691504]
Supuran CT. (2020) Exploring the multiple binding modes of inhibitors to carbonic anhydrases for
novel drug discovery. Expert Opin Drug Discov 15: 671-686 [PMID:32208982]
Nomenclature carbonic anhydrase 1 carbonic anhydrase 7 carbonic anhydrase 12 carbonic anhydrase 13 carbonic anhydrase 14
Common abbreviation CA I CA VII CA XII CA XIII CA XIV
HGNC, UniProt CA1, P00915 CA7, P43166 CA12, O43570 CA13, Q8N1Q1 CA14, Q9ULX7
EC number 4.2.1.1 4.2.1.1 4.2.1.1 4.2.1.1 4.2.1.1
Inhibitors chlorthalidone (pKi 6.5) methazolamide (pKi 8.7) [615], acetazolamide (pKi 8.6) [27],
brinzolamide (pKi 8.6) [615], chlorthalidone (pKi 8.6) [677]
SLC-0111 (pKi 8.4) [120] – –
Carboxylases and decarboxylases
Enzymes → Carboxylases and decarboxylases
Further reading on Carboxylases and decarboxylases
Bale S et al. (2010) Structural biology of S-adenosylmethionine decarboxylase. Amino Acids 38:
451-60 [PMID:19997761]
Bisello G et al. (2020) Oxygen reactivity with pyridoxal 5’-phosphate enzymes: biochemical
implications and functional relevance. Amino Acids 52: 1089-1105 [PMID:32844248]
Di Bartolomeo F et al. (2017) Cell biology, physiology and enzymology of
phosphatidylserine decarboxylase. Biochim Biophys Acta Mol Cell Biol Lipids 1862: 25-38
[PMID:27650064]
Graus F et al. (2020) GAD antibodies in neurological disorders - insights and challenges Nat Rev
Neurol 16: 353-365 [PMID:32457440]
Montioli R et al. (2021) Aromatic Amino Acid Decarboxylase Deficiency: The Added Value of
Biochemistry. Int J Mol Sci 22: 3146 [PMID:33808712]
Salie MJ et al. (2016) Regulation and structure of the heteromeric acetyl-CoA carboxylase. Biochim
Biophys Acta 1861: 1207-1213 [PMID:27091637]
Sanchez-Jiménez F et al. (2016) Structural and functional analogies and differences between
histidine decarboxylase and aromatic l-amino acid decarboxylase molecular networks:
Biomedical implications. Pharmacol Res 114: 90-102 [PMID:27769832]
Shen J et al. (2021) Elevated Brain Glutamate Levels in Bipolar Disorder and Pyruvate
Carboxylase-Mediated Anaplerosis. Front Psychiatry 12: 640977 [PMID:33708149]
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Carboxylases
Enzymes → Carboxylases and decarboxylases → Carboxylases
Overview: The carboxylases allow the production of new carbon-carbon bonds by introducing HCO3- or CO2 into target molecules. Two groups of carboxylase activities, some of which are
bidirectional, can be defined on the basis of the cofactor requirement, making use of biotin (EC 6.4.1.-) or vitamin K hydroquinone (EC 4.1.1.-).
Nomenclature Pyruvate carboxylase Acetyl-CoA carboxylase 1 Acetyl-CoA carboxylase 2 Propionyl-CoA carboxylase γ-Glutamyl carboxylase
Common abbreviation PC ACC1 ACC2 PCCA,PCCB GGCX
HGNC, UniProt PC, P11498 ACACA, Q13085 ACACB, O00763 – GGCX, P38435
Subunits – – – Propionyl-CoA carboxylase α subunit,
Propionyl-CoA carboxylase β subunit
–
EC number 6.4.1.1 6.4.1.2 6.4.1.2 6.4.1.3 4.1.1.90
Endogenous substrates ATP, pyruvic acid ATP, acetyl CoA ATP, acetyl CoA ATP, propionyl-CoA glutamyl peptides
Products ADP, oxalacetic acid, Pi malonyl-CoA, ADP, Pi malonyl-CoA, ADP, Pi ADP, methylmalonyl-CoA, Pi carboxyglutamyl
peptides
Cofactors biotin biotin biotin biotin NADPH, vitamin K
hydroquinone
Inhibitors – – compound 2e (pIC50 8.7) [664],
A-908292 (pIC50 7.6) [718]
– anisindione
Selective inhibitors – compound 21 (pIC50 8) [256], TOFA
(pIC50 4.9) [781]





– firsocostat (Negative) (pIC50 8.7) [283] firsocostat (Negative) (pIC50 8.2) [283] – –
Comments – Citrate and other dicarboxylic acids are
allosteric activators of acetyl-CoA
carboxylase.
Citrate and other dicarboxylic acids are
allosteric activators of acetyl-CoA
carboxylase.
Propionyl-CoA carboxylase is able to
function in both forward and reverse







Comments: Dicarboxylic acids including citric acid are able to activate ACC1/ACC2 activity allosterically. PCC is able to function in forward and reverse modes as a ligase (carboxylase) or lyase
(decarboxylase) activity, respectively. Loss-of-function mutations in GGCX are associated with clotting disorders.
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Decarboxylases
Enzymes → Carboxylases and decarboxylases → Decarboxylases
Overview: The decarboxylases generate CO2 and the indicated products from acidic substrates, requiring pyridoxal 5-phosphate or pyruvic acid as a co-factor.
Nomenclature Glutamic acid decarboxylase 1 Glutamic acid decarboxylase 2 Histidine decarboxylase
Common abbreviation GAD1 GAD2 HDC
HGNC, UniProt GAD1, Q99259 GAD2, Q05329 HDC, P19113
EC number 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.22
Endogenous substrates L-glutamic acid, L-aspartic acid L-glutamic acid, L-aspartic acid L-histidine
Products GABA GABA histamine
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate pyridoxal 5-phosphate
Selective inhibitors s-allylglycine s-allylglycine AMA, FMH [227]
Comments L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic
acid decarboxylase generating β-alanine [743]. Autoantibodies against GAD1
and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders
(see Further reading).
L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic
acid decarboxylase generating β-alanine [743]. Autoantibodies against GAD1
and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders
(see Further reading).
–








ADC AADC MLYCD ODC PSDC SAMDC
HGNC, UniProt AZIN2, Q96A70 DDC, P20711 MLYCD, O95822 ODC1, P11926 PISD, Q9UG56 AMD1, P17707
EC number 4.1.1.19 4.1.1.28: levodopa -> dopamine + CO2
5-hydroxy-L-tryptophan ->
5-hydroxytryptamine + CO2
This enzyme also catalyses the following
reaction:: L-tryptophan -> tryptamine + CO2





malonyl-CoA L-ornithine phosphatidylserine S-adenosyl
methionine









– APA (pIC50 7.5) [647], eflornithine (pKd
4.9) [560]
– sardomozide (pIC50 8)
[646]
Comments The presence of a
functional ADC activity in
human tissues has been
questioned [118].




The activity of ODC is regulated by the
presence of an antizyme
(ENSG00000104904) and an ODC
antizyme inhibitor (ENSG00000155096).
S-allylglycine is also an
inhibitor of SAMDC
[526].
S-allylglycine is also an
inhibitor of SAMDC
[526].
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Catecholamine turnover
Enzymes → Catecholamine turnover
Overview: Catecholamines are defined by the presence of two
adjacent hydroxyls on a benzene ring with a sidechain
containing an amine. The predominant catacholamines in
mammalian biology are the neurotransmitter/hormones
dopamine, (-)-noradrenaline (norepinephrine) and (-)-adrenaline
(epinephrine). These hormone/transmitters are synthesized by
sequential metabolism from L-phenylalanine via L-tyrosine.
Hydroxylation of L-tyrosine generates levodopa, which is
decarboxylated to form dopamine. Hydroxylation of the
ethylamine sidechain generates (-)-noradrenaline
(norepinephrine), which can be methylated to form
(-)-adrenaline (epinephrine). In particular neuronal and adrenal
chromaffin cells, the catecholamines dopamine,
(-)-noradrenaline and (-)-adrenaline are accumulated into vesicles
under the influence of the vesicular monoamine transporters
(VMAT1/SLC18A1 and VMAT2/SLC18A2). After release into the
synapse or the bloodstream, catecholamines are accumulated
through the action cell-surface transporters, primarily the
dopamine (DAT/SLC6A3) and norepinephrine transporter
(NET/SLC6A2). The primary routes of metabolism of these
catecholamines are oxidation via monoamine oxidase activities
of methylation via catechol O-methyltransferase.
Further reading on Catecholamine turnover
Bastos P et al. (2017) Catechol-O-Methyltransferase (COMT): An Update on Its Role in Cancer,
Neurological and Cardiovascular Diseases. Rev Physiol Biochem Pharmacol 173: 1-39
[PMID:28456872]
Deshwal S et al. (2017) Emerging role of monoamine oxidase as a therapeutic target for
cardiovascular disease. Curr Opin Pharmacol 33: 64-69 [PMID:28528298]
Kolla NJ et al. (2020) The role of monoamine oxidase A in the neurobiology of aggressive,
antisocial, and violent behavior: A tale of mice and men. Prog Neurobiol 194: 101875
[PMID:32574581]
Manzoor S et al. (2020) A comprehensive review of monoamine oxidase inhibitors as
Anti-Alzheimer’s disease agents: A review. Eur J Med Chem 206: 112787 [PMID:32942081]
Silva TB et al. (2020) Liver says no: the ongoing search for safe catechol O-methyltransferase
inhibitors to replace tolcapone. Drug Discov Today 30295-6 [PMID:32687872]
Walen K et al. (2017) Tyrosine and tryptophan hydroxylases as therapeutic targets in human
disease. Expert Opin Ther Targets 21: 167-180 [PMID:27973928]
Nomenclature L-Phenylalanine hydroxylase Tyrosine aminotransferase L-Tyrosine hydroxylase Dopamine beta-hydroxylase
(dopamine beta-monooxygenase)
Common abbreviation – TAT – DBH
HGNC, UniProt PAH, P00439 TAT, P17735 TH, P07101 DBH, P09172
EC number 1.14.16.1: L-phenylalanine + O2 ->
L-tyrosine
2.6.1.5: L-tyrosine + α-ketoglutaric acid ->
4-hydroxyphenylpyruvic acid + L-glutamic acid
1.14.16.2: L-tyrosine + O2 ->
levodopa
1.14.17.1: dopamine + O2 =
(-)-noradrenaline + H2O
Endogenous substrates L-phenylalanine – L-tyrosine –
Products L-tyrosine – levodopa –
Cofactors sapropterin pyridoxal 5-phosphate sapropterin, Fe2+ L-ascorbic acid, Cu2+
Endogenous activators Protein kinase A-mediated
phosphorylation (Rat) [2]
– Protein kinase A-mediated
phosphorylation [340]
–





nepicastat (pIC50 8) [649]
Comments PAH is an iron bound homodimer or
-tetramer from the same structural
family as tyrosine 3-monooxygenase
and the tryptophan hydroxylases.
Deficiency or loss-of-function of PAH is
associated with phenylketonuria
Tyrosine may also be metabolized in the liver by tyrosine
transaminase to generate 4-hydroxyphenylpyruvic acid,
which can be further metabolized to homogentisic acid.
TAT is a homodimer, where loss-of-function mutations are
associated with type II tyrosinemia.
TH is a homotetramer, which is
inhibited by dopamine and other
catecholamines in a physiological
negative feedback pathway [139].
DBH is a homotetramer.
A protein structurally-related to DBH
(MOXD1, Q6UVY6) has been described
and for which a function has yet to be
identified [93].
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Nomenclature L-Aromatic amino-acid decarboxylase Phenylethanolamine
N-methyltransferase
Catechol-O-methyltransferase
Common abbreviation AADC PNMT COMT
HGNC, UniProt DDC, P20711 PNMT, P11086 COMT, P21964
EC number 4.1.1.28: levodopa -> dopamine + CO2
5-hydroxy-L-tryptophan -> 5-hydroxytryptamine + CO2









3,4-dihydroxymandelic acid -> vanillylmandelic acid
dopamine -> 3-methoxytyramine
Endogenous substrates 5-hydroxy-L-tryptophan, L-tryptophan, levodopa – –
Products 5-hydroxytryptamine, dopamine – –
Cofactors pyridoxal 5-phosphate S-adenosyl methionine S-adenosyl methionine
Inhibitors – LY134046 (pKi 7.6) [214] tolcapone (soluble enzyme) (pKi 9.6) [429], tolcapone (membrane-bound
enzyme) (pKi 9.5) [429], entacapone (soluble enzyme) (pKi 9.5) [429],
entacapone (membrane-bound enzyme) (pKi 8.7) [429]
Selective inhibitors 3-hydroxybenzylhydrazine, L-α-methyldopa, benserazide [136], carbidopa – –
Comments AADC is a homodimer. – COMT appears to exist in both membrane-bound and soluble forms. COMT
has also been described to methylate steroids, particularly hydroxyestradiols
Nomenclature Monoamine oxidase A Monoamine oxidase B
Common abbreviation MAO-A MAO-B
HGNC, UniProt MAOA, P21397 MAOB, P27338
EC number 1.4.3.4
dopamine -> 3,4-dihydroxyphenylacetaldehyde + NH3
(-)-noradrenaline -> 3,4-dihydroxymandelic acid + NH3
(-)-adrenaline -> 3,4-dihydroxymandelic acid + NH3
5-hydroxytryptamine -> 5-hydroxyindole acetaldehyde + NH3
tyramine -> 4-hydroxyphenyl acetaldehyde + NH3
1.4.3.4
Cofactors flavin adenine dinucleotide flavin adenine dinucleotide
Inhibitors moclobemide (pKi 8.3) [333], phenelzine (Irreversible inhibition) (pKi 7.3) [56],
tranylcypromine (pIC50 4.7) [764], selegiline (pKi 4.2) [475], befloxatone [134],
clorgiline, pirlindole [467]
rasagiline (pIC50 7.8) [769], phenelzine (Irreversible inhibition) (pKi 7.8) [56], lazabemide (pKi 7.1)
[268, 687], selegiline (pKi 5.7–6) [154, 475], tranylcypromine (pIC50 4.7) [764]
Selective inhibitors – safinamide (pKi 6.3) [55]
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Ceramide turnover
Enzymes → Ceramide turnover
Overview: Ceramides are a family of sphingophospholipids
synthesized in the endoplasmic reticulum, which mediate cell
stress responses, including apoptosis, autophagy and senescence,
Serine palmitoyltransferase generates 3-ketosphinganine, which
is reduced to dihydrosphingosine (dihydrosphingosine).
N-Acylation allows the formation of dihydroceramides, which
are subsequently reduced to form ceramides. Once synthesized,
ceramides are trafficked from the ER to the Golgi bound to the
ceramide transfer protein, CERT (COL4A3BP, Q9Y5P4). Ceramide
can be metabolized via multiple routes, ensuring tight regulation
of its cellular levels. Addition of phosphocholine generates
sphingomyelin while carbohydrate is added to form glucosyl- or
galactosylceramides. Ceramidase re-forms sphingosine or
sphinganine from ceramide or dihydroceramide.
Phosphorylation of ceramide generates ceramide phosphate. The
determination of accurate kinetic parameters for many of the
enzymes in the sphingolipid metabolic pathway is complicated
by the lipophilic nature of the substrates.
Further reading on Ceramide turnover
Brachtendorf S et al. (2019) Ceramide synthases in cancer therapy and chemoresistance. Prog Lipid
Res 74: 160-185 [PMID:30953657]
Chen Y et al. (2017) The sphingomyelin synthase family: proteins, diseases, and inhibitors. Biol
Chem 398: 1319-1325 [PMID:28742512]
Fang Z et al. (2019) Ceramide and sphingosine 1-phosphate in adipose dysfunction. Prog Lipid Res
74: 145-159 [PMID:30951736]
Gomez-Larrauri A et al. (2021) Regulation of cell growth, survival and migration by ceramide
1-phosphate - implications in lung cancer progression and inflammation. Cell Signal 83:
109980 [PMID:33727076]
Iqbal J et al. (2017) Sphingolipids and Lipoproteins in Health and Metabolic Disorders. Trends
Endocrinol Metab 28: 506-518 [PMID:28462811]
Ishay Y et al. (2020) The role of the sphingolipid pathway in liver fibrosis: an emerging new
potential target for novel therapies. Am J Physiol Cell Physiol 318: C1055-C1064
[PMID:32130072]
Kim JL et al. (2021) Ceramide synthases: Reflections on the impact of Dr. Lina M. Obeid. Cell
Signal 82: 109958 [PMID:33607256]
Ogretmen B. (2018) Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 18:
33-50 [PMID:29147025]
Pant DC et al. (2020) Ceramide signalling in inherited and multifactorial brain metabolic diseases.
Neurobiol Dis 143: 105014 [PMID:32653675]
Parashuraman S et al. (2019) Visualizing sphingolipid biosynthesis in cells. Chem Phys Lipids 218:
103-111 [PMID:30476485]
Presa N et al. (2020) Novel signaling aspects of ceramide 1-phosphate. Biochim Biophys Acta Mol
Cell Biol Lipids 1865: 158630 [PMID:31958571]
Rodriguez-Cuenca S et al. (2017) Sphingolipids and glycerophospholipids - The "ying and yang" of
lipotoxicity in metabolic diseases. Prog Lipid Res 66: 14-29 [PMID:28104532]
Snider JM et al. (2019) Approaches for probing and evaluating mammalian sphingolipid
metabolism. Anal Biochem 575: 70-86 [PMID:30917945]
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Serine palmitoyltransferase
Enzymes → Ceramide turnover → Serine palmitoyltransferase
Overview: The functional enzyme is a heterodimer of SPT1 (LCB1) with either SPT2 (LCB2) or SPT3 (LCB2B); the small subunits of SPT (ssSPTa or ssSPTb) bind to the heterodimer to enhance enzymatic
activity. The complexes of SPT1/SPT2/ssSPTa and SPT1/SPT2/ssSPTb were most active with palmitoylCoA as substrate, with the latter complex also showing some activity with stearoylCoA [274].
Complexes involving SPT3 appeared more broad in substrate selectivity, with incorporation of myristoylCoA prominent for SPT1/SPT3/ssSPTa complexes, while SP1/SPT3/ssSPTb complexes had similar
activity with C16, C18 and C20 acylCoAs [274].
Nomenclature serine palmitoyltransferase long
chain base subunit 1
serine palmitoyltransferase long
chain base subunit 2
serine palmitoyltransferase long





Common abbreviation SPT1 SPT2 SPT3 SPTSSA SPTSSB
HGNC, UniProt SPTLC1, O15269 SPTLC2, O15270 SPTLC3, Q9NUV7 SPTSSA, Q969W0 SPTSSB, Q8NFR3
EC number 2.3.1.50: L-serine + palmitoyl-CoA
-> 3-ketosphinganine + coenzyme
A + CO2
2.3.1.50: L-serine + palmitoyl-CoA
-> 3-ketosphinganine + coenzyme
A + CO2
2.3.1.50: L-serine + palmitoyl-CoA
-> 3-ketosphinganine + coenzyme
A + CO2
– –
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate pyridoxal 5-phosphate – –
Inhibitors – – – – compound 18 (pKi 5.8) [304]
Selective inhibitors myriocin (pKi 9.6) [476] – Mouse myriocin [476] myriocin [476] – –
Ceramide synthase
Enzymes → Ceramide turnover → Ceramide synthase
Overview: This family of enzymes, also known as sphingosine N-acyltransferase, is located in the ER facing the cytosol with an as-yet undefined topology and stoichiometry. Ceramide synthase in vitro
is sensitive to inhibition by the fungal derived toxin, fumonisin B1.
Nomenclature ceramide synthase 1 ceramide synthase 2 ceramide synthase 3 ceramide synthase 4 ceramide synthase 5 ceramide synthase 6
Common abbreviation CERS1 CERS2 CERS3 CERS4 CERS5 CERS6
HGNC, UniProt CERS1, P27544 CERS2, Q96G23 CERS3, Q8IU89 CERS4, Q9HA82 CERS5, Q8N5B7 CERS6, Q6ZMG9




sphingosine + acylCoA ->





sphingosine + acylCoA ->
ceramide + coenzyme A
2.3.1.24: acylCoA +
dihydrosphingosine ->
dihydroceramide + coenzyme A
sphingosine + acylCoA ->
ceramide + coenzyme A
2.3.1.24: acylCoA +
dihydrosphingosine ->
dihydroceramide + coenzyme A
sphingosine + acylCoA ->





sphingosine + acylCoA ->





sphingosine + acylCoA ->
ceramide + coenzyme A
Substrates C18-CoA [702] C24- and C26-CoA [393] C26-CoA and longer [479, 562] C18-, C20- and C22-CoA [578] C16-CoA [389, 578] C14- and C16-CoA [478]
Searchable database: http://www.guidetopharmacology.org/index.jsp Ceramide synthase S331
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Sphingolipid Δ4-desaturase
Enzymes → Ceramide turnover → Sphingolipid Δ4-desaturase
Overview: DEGS1 and DEGS2 are 4TM proteins.
Nomenclature delta 4-desaturase, sphingolipid 1 delta 4-desaturase, sphingolipid 2
HGNC, UniProt DEGS1, O15121 DEGS2, Q6QHC5
EC number 1.14.-.- 1.14.-.-
Cofactors NAD NAD
Inhibitors SKI II (pKi 6.5) [115], RBM2-1B (pIC50 4.7) [78] –
Comments Myristoylation of DEGS1 enhances its activity and targets it to the mitochondria [43]. –
Comments: DEGS1 activity is inhibited by a number of natural products, including curcumin and Δ9-tetrahydrocannabinol [187].
Sphingomyelin synthase
Enzymes → Ceramide turnover → Sphingomyelin synthase
Overview: Following translocation from the ER to the Golgi under the influence of the ceramide transfer protein, sphingomyelin synthases allow the formation of sphingomyelin by the transfer of
phosphocholine from the phospholipid phosphatidylcholine.
Sphingomyelin synthase-related protein 1 is structurally related but lacks sphingomyelin synthase activity.
Nomenclature sphingomyelin synthase 1 sphingomyelin synthase 2 sterile alpha motif domain containing 8
HGNC, UniProt SGMS1, Q86VZ5 SGMS2, Q8NHU3 SAMD8, Q96LT4
EC number 2.7.8.27: ceramide + phosphatidylcholine
-> sphingomyelin + diacylglycerol
2.7.8.27: ceramide + phosphatidylcholine -> sphingomyelin + diacylglycerol 2.7.8.-: ceramide + phosphatidylethanolamine
-> ceramide phosphoethanolamine
Inhibitors compound 1j (pIC50 5.7) [408] compound D24 (pIC50 4.9) [146] –
Comments – Palmitoylation of sphingomyelin synthase 2 may allow targeting to the plasma membrane [671]. –
Searchable database: http://www.guidetopharmacology.org/index.jsp Sphingomyelin synthase S332
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Sphingomyelin phosphodiesterase
Enzymes → Ceramide turnover → Sphingomyelin phosphodiesterase













HGNC, UniProt SMPD1, P17405 SMPD2, O60906 SMPD3, Q9NY59 SMPD4, Q9NXE4 SMPDL3A, Q92484 SMPDL3B, Q92485












Inhibitors compound 21b (pIC50 6.5) [760],
WJYK50 (pIC50 6.3) [759],
WJYK50 (pIC50 6.1) [760]
inhibitor A (pKi 5.8) [763] –
Bovine
– – – –
Neutral sphingomyelinase coupling factors
Enzymes → Ceramide turnover → Neutral sphingomyelinase coupling factors
Overview: Protein FAN [4] and polycomb protein EED [544] allow coupling between TNF receptors and neutral sphingomyelinase phosphodiesterases.
Nomenclature embryonic ectoderm development neutral sphingomyelinase activation associated factor
HGNC, UniProt EED, O75530 NSMAF, Q92636
Selective inhibitors A-395 (Binding) (pKi 9.4) [295] –
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Ceramide glucosyltransferase
Enzymes → Ceramide turnover → Ceramide glucosyltransferase
Nomenclature UDP-glucose ceramide glucosyltransferase
HGNC, UniProt UGCG, Q16739
EC number 2.4.1.80: UDP-glucose + ceramide = uridine diphosphate + glucosylceramide
Inhibitors miglustat (pKi 5.1) [74]
Comments Glycoceramides are an extended family of sphingolipids, differing in the content and organization of the sugar moieties, as well as the acyl sidechains.
Acid ceramidase
Enzymes → Ceramide turnover → Acid ceramidase
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature N-acylsphingosine amidohydrolase 1
HGNC, UniProt ASAH1, Q13510
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid
Comments This lysosomal enzyme is proteolysed to form the mature protein made up of two chains from the same gene product [371].
Neutral ceramidases
Enzymes → Ceramide turnover → Neutral ceramidases
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature N-acylsphingosine amidohydrolase 2 N-acylsphingosine amidohydrolase 2B
HGNC, UniProt ASAH2, Q9NR71 ASAH2B, P0C7U1
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid –
Comments The enzyme is associated with the plasma membrane [670]. –
Comments: ASAH2B appears to be an enzymatically inactive protein, which may result from gene duplication and truncation.
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Alkaline ceramidases
Enzymes → Ceramide turnover → Alkaline ceramidases
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature alkaline ceramidase 1 alkaline ceramidase 2 alkaline ceramidase 3
HGNC, UniProt ACER1, Q8TDN7 ACER2, Q5QJU3 ACER3, Q9NUN7
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid 3.5.1.23: ceramide -> sphingosine + a fatty acid 3.5.1.-
Comments ACER1 is associated with the ER [657]. ACER2 is associated with the Golgi apparatus [752]. ACER3 is associated with the ER and Golgi apparatus [448].
Ceramide kinase
Enzymes → Ceramide turnover → Ceramide kinase
Nomenclature ceramide kinase
HGNC, UniProt CERK, Q8TCT0
EC number 2.7.1.138: ceramide + ATP -> ceramide 1-phosphate + ADP
Inhibitors NVP 231 (pIC50 7.9) [250]
Comments: A ceramide kinase-like protein has been identified in the human genome (CERKL, Q49MI3).
Searchable database: http://www.guidetopharmacology.org/index.jsp Ceramide kinase S335
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Chromatin modifying enzymes
Enzymes → Chromatin modifying enzymes
Overview: Chromatin modifying enzymes, and other
chromatin-modifying proteins, fall into three broad categories:
writers, readers and erasers. The function of these proteins is
to dynamically maintain cell identity and regulate processes such
as differentiation, development, proliferation and genome
integrity via recognition of specific ’marks’ (covalent
post-translational modifications) on histone proteins and DNA
[378]. In normal cells, tissues and organs, precise co-ordination
of these proteins ensures expression of only those genes required
to specify phenotype or which are required at specific times, for
specific functions. Chromatin modifications allow DNA
modifications not coded by the DNA sequence to be passed on
through the genome and underlies heritable phenomena such as
X chromosome inactivation, aging, heterochromatin formation,
reprogramming, and gene silencing (epigenetic control).
To date at least eight distinct types of modifications are found on
histones. These include small covalent modifications such as
acetylation, methylation, and phosphorylation, the attachment
of larger modifiers such as ubiquitination or sumoylation, and
ADP ribosylation, proline isomerization and deimination.
Chromatin modifications and the functions they regulate in cells
are reviewed by Kouzarides (2007) [378].
Writer proteins include the histone methyltransferases, histone
acetyltransferases, some kinases and ubiquitin ligases.
Readers include proteins which contain
methyl-lysine-recognition motifs such as bromodomains,
chromodomains, tudor domains, PHD zinc fingers, PWWP
domains and MBT domains.
Erasers include the histone demethylases and histone
deacetylases (HDACs and sirtuins).
Dysregulated epigenetic control can be associated with human
diseases such as cancer [185], where a wide variety of cellular and
protein abberations are known to perturb chromatin structure,
gene transcription and ultimately cellular pathways [41, 626].
Due to the reversible nature of epigenetic modifications,
chromatin regulators are very tractable targets for drug discovery
and the development of novel therapeutics. Indeed, small
molecule inhibitors of writers (e.g. azacitidine and decitabine
target the DNA methyltransferases DNMT1 and DNMT3 for the
treatment of myelodysplastic syndromes [228, 730]) and erasers
(e.g. the HDAC inhibitors vorinostat, romidepsin and belinostat
for the treatment of T-cell lymphomas [203, 361]) are already
being used in the clinic. The search for the next generation of
compounds with improved specificity against
chromatin-associated proteins is an area of intense basic and
clinical research [76]. Current progress in this field is
reviewed by Simó-Riudalbas and Esteller (2015) [627].
Further reading on Chromatin modifying enzymes
Bates SE. (2020) Epigenetic Therapies for Cancer. N Engl J Med 383: 650-663 [PMID:32786190]
Beyer JN et al. (2021) Advances and Opportunities in Epigenetic Chemical Biology. Chembiochem
22: 17-42 [PMID:32786101]
Carter B et al. (2021) The epigenetic basis of cellular heterogeneity. Nat Rev Genet 22: 235-250
[PMID:33244170]
Hogg SJ et al. (2020) Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug
Discov 19: 776-800 [PMID:32929243]
Oh ES et al. (2021) Origins of human disease: the chrono-epigenetic perspective. Nat Rev Genet
[PMID:33903745]
Tsai K et al. (2020) Epigenetic and epitranscriptomic regulation of viral replication. Nat Rev
Microbiol 18: 559-570 [PMID:32533130]
2.1.1.- Protein arginine N-methyltransferases
Enzymes → Chromatin modifying enzymes → 2.1.1.- Protein arginine N-methyltransferases
Overview: Protein arginine N-methyltransferases (PRMT, EC
2.1.1.-) encompass histone arginine N-methyltransferases
(PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein
N-methyltransferases (PRMT7, EC 2.1.1.126). They are dimeric or
tetrameric enzymes which use S-adenosyl methionine as a
methyl donor, generating S-adenosylhomocysteine as a
by-product. They generate both mono-methylated and
di-methylated products; these may be symmetric (SDMA) or
asymmetric (NG,NG-dimethyl-L-arginine) versions, where both
guanidine nitrogens are monomethylated or one of the two is
dimethylated, respectively.
Information on members of this family may be found in the online database.
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3.5.1.- Histone deacetylases (HDACs)
Enzymes → Chromatin modifying enzymes → 3.5.1.- Histone deacetylases (HDACs)
Overview: Histone deacetylases act as erasers of epigenetic
acetylation marks on lysine residues in histones. Removal of the
acetyl groups facilitates tighter packing of chromatin
(heterochromatin formation) leading to transcriptional
repression.
The histone deacetylase family has been classified in to five
subfamilies based on phylogenetic comparison with yeast
homologues:
Class I contains HDACs 1, 2, 3 and 8
Class IIa contains HDACs 4, 5, 7 and 9
Class IIb contains HDACs 6 and 10
Class III contains the sirtuins (SIRT1-7)
Class IV contains only HDAC11.
Classes I, II and IV use Zn+ as a co-factor, whereas catalysis by
Class III enzymes requires NAD+ as a co-factor, and members of
this subfamily have ADP-ribosylase activity in addition to
protein deacetylase function [600].
HDACs have more general protein deacetylase activity, being
able to deacetylate lysine residues in non-histone proteins [111]
such as microtubules [316], the hsp90 chaperone [379] and the
tumour suppressor p53 [436].
Dysregulated HDAC activity has been identified in cancer cells
and tumour tissues [413, 586], making HDACs attractive
molecular targets in the search for novel mechanisms to treat
cancer [732]. Several small molecule HDAC inhibitors are already
approved for clinical use: romidepsin, belinostat, vorinostat,
panobinostat, belinostat, valproic acid and tucidinostat. HDACs
and HDAC inhibitors currently in development as potential
anti-cancer therapeutics are reviewed by Simó-Riudalbas and
Esteller (2015) [627].
Further reading on 3.5.1.- Histone deacetylases (HDACs)
Bahl S et al. (2021) Regulation of histone deacetylase activities and functions by phosphorylation
and its physiological relevance. Cell Mol Life Sci 78: 427-445 [PMID:32683534]
Ho TCS et al. (2020) Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. J Med Chem 63:
12460-12484 [PMID:32608981]
Kunadis E et al. (2021) Targeting post-translational histone modifying enzymes in glioblastoma.
Pharmacol Ther 220: 107721 [PMID:33144118]
Liu T et al. (2020) Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer
Therapy. J Med Chem 63: 8977-9002 [PMID:32320239]
Zhang XH et al. (2021) A Review of Progress in Histone Deacetylase 6 Inhibitors Research:
Structural Specificity and Functional Diversity. J Med Chem 64: 1362-1391 [PMID:33523672]
Nomenclature histone deacetylase 6
HGNC, UniProt HDAC6, Q9UBN7
EC number 3.5.1.98
Inhibitors trichostatin A (pKi 9) [67], vorinostat (pKi 8.8) [67], romidepsin (pKi 8) [67]
Selective inhibitors ricolinostat (pIC50 8.3) [597]
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Cyclic nucleotide turnover/signalling
Enzymes → Cyclic nucleotide turnover/signalling
Overview: Cyclic nucleotides are second messengers generated
by cyclase enzymes from precursor triphosphates and hydrolysed
by phosphodiesterases. The cellular actions of these cyclic
nucleotides are mediated through activation of protein kinases
(cAMP- and cGMP-dependent protein kinases), ion channels
(cyclic nucleotide-gated, CNG, and hyperpolarization and cyclic
nucleotide-gated, HCN) and guanine nucleotide exchange
factors (GEFs, Epac).
For details of the enzymes involved in cGMP synthesis see the
Receptor Guanylyl Cyclase (RGC) family, in the Catalytic
receptors section.
Adenylyl cyclases (ACs)
Enzymes → Cyclic nucleotide turnover/signalling → Adenylyl cyclases (ACs)
Overview: Adenylyl cyclase, E.C. 4.6.1.1, converts ATP to cyclic
AMP and pyrophosphate. Mammalian membrane-delimited
adenylyl cyclases (nomenclature as approved by the
NC-IUPHAR Subcommittee on Adenylyl cyclases [149])
are typically made up of two clusters of six TM domains
separating two intracellular, overlapping catalytic domains that
are the target for the nonselective activators Gαs (the stimulatory
G protein α subunit) and forskolin (except AC9, [556]).
Adenosine and its derivatives (e.g. 2’,5’-dideoxyadenosine),
acting through the P-site,are inhibitors of adenylyl cyclase
activity [680]. Four families of membranous adenylyl cyclase are
distinguishable: calmodulin (CALM1 CALM2 CALM3,
P62158)-stimulated (AC1, AC3 and AC8), Ca2+- and
Gβγ-inhibitable (AC5, AC6 and AC9), Gβγ-stimulated and
Ca2+-insensitive (AC2, AC4 and AC7), and forskolin-insensitive
(AC9) forms. A soluble adenylyl cyclase (AC10) lacks membrane
spanning regions and is insensitive to G proteins.It functions as a
cytoplasmic bicarbonate (pH-insensitive) sensor [99].
Further reading on Adenylyl cyclases (ACs)
Antoni FA. (2020) The chilling of adenylyl cyclase 9 and its translational potential. Cell Signal 70:
109589 [PMID:32105777]
Dessauer CW et al. (2017) International Union of Basic and Clinical Pharmacology. CI. Structures
and Small Molecule Modulators of Mammalian Adenylyl Cyclases. Pharmacol Rev 69: 93-139
[PMID:28255005]
Halls ML et al. (2017) Adenylyl cyclase signalling complexes - Pharmacological challenges and
opportunities. Pharmacol Ther 172: 171-180 [PMID:28132906]
Wiggins SV et al. (2018) Pharmacological modulation of the CO_2/HCO_3-/pH-, calcium-, and
ATP-sensing soluble adenylyl cyclase. Pharmacol Ther 190: 173-186 [PMID:29807057]
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Nomenclature adenylyl cyclase 1 adenylyl cyclase 2 adenylyl cyclase 3 adenylyl cyclase 4 adenylyl cyclase 5
Common abbreviation AC1 AC2 AC3 AC4 AC5
HGNC, UniProt ADCY1, Q08828 ADCY2, Q08462 ADCY3, O60266 ADCY4, Q8NFM4 ADCY5, O95622
EC number 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1






calmodulin (CALM1 CALM2 CALM3,
P62158), PKC-evoked
phosphorylation [109, 332]
Gβγ [223] PKC-evoked phophorylation, Gβγ,
Raf-evoked phophorylation [159,
226, 358]
Activators compound 45 (pIC50 7.7) [583] –
Bovine
FD1 [520] – – FD6 [520]
Endogenous inhibitors Gαi, Gαo, Gβγ [674, 675] – RGS2, Gβγ, CaM kinase II-evoked




phosphorylation, Gβγ, NO [226,
302, 327, 331, 675]
Inhibitors – SKF-83566 [122] – – NKY80 (pIC50 5.2) [68, 520]
Selective inhibitors ST034307 (pIC50 5.6) [70] – – – –
Nomenclature adenylyl cyclase 6 adenylyl cyclase 7 adenylyl cyclase 8 adenylyl cyclase 9 adenylyl cyclase 10
Common abbreviation AC6 AC7 AC8 AC9 AC10
HGNC, UniProt ADCY6, O43306 ADCY7, P51828 ADCY8, P40145 ADCY9, O60503 ADCY10, Q96PN6
EC number 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1 –
Endogenous activators Gβγ, Raf-evoked phosphorylation [159, 226] Gβγ, PKC-evoked phosphorylation
[45, 725]
calmodulin (CALM1 CALM2 CALM3,
P62158) [77]
– Bicarbonate, Ca2+ [99, 415]
Endogenous inhibitors Gαi, Ca2+, PKA-evoked phosphorylation,
PKC-evoked phosphorylation, NO [100, 302,
390, 675, 767]
– PKA-evoked phosphorylation [736] Ca2+/calcineurin [534] –
Inhibitors NKY80 (pIC50 4.8) [68] – – – KH7 (pIC50 5–5.5) [300],
LRE1 (pIC50 5) [565]
Comments: Many of the activators and inhibitors listed are only somewhat selective or have not been tested against all AC isoforms [68, 122]. AC3 shows only modest in vitro activation by Ca2+/CaM.
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Exchange protein activated by cyclic AMP (EPACs)
Enzymes → Cyclic nucleotide turnover/signalling → Exchange protein activated by cyclic AMP (EPACs)
Overview: Epacs are members of a family of guanine nucleotide
exchange factors (ENSFM00250000000899), which also includes
RapGEF5 (GFR, KIAA0277, MR-GEF, Q92565) and RapGEFL1
(Link-GEFII, Q9UHV5). They are activated endogenously by
cyclic AMP and with some pharmacological selectivity by
8-pCPT-2’-O-Me-cAMP [178]. Once activated, Epacs induce an
enhanced activity of the monomeric G proteins, Rap1 and Rap2
by facilitating binding of guanosine-5’-triphosphate in place of
guanosine 5’-diphosphate, leading to activation of
phospholipase C [603].
Further reading on Exchange protein activated by cyclic AMP (EPACs)
Bouvet M et al. (2019) The Epac1 Protein: Pharmacological Modulators, Cardiac Signalosome and
Pathophysiology Cells 8: 1543 [PMID:31795450]
Fujita T et al. (2017) The role of Epac in the heart. Cell Mol Life Sci 74: 591-606 [PMID:27549789]
Luchowska-Sta«ska U et al. (2019) Selective small-molecule EPAC activators Biochem Soc Trans 47:
1415-1427 [PMID:31671184]
Robichaux 3rd WG et al. (2018) Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology,
and Therapeutics Development. Physiol Rev 98: 919-1053 [PMID:29537337]
Wang P et al. (2017) Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic
targets. Bioorg Med Chem Lett 27: 1633-1639 [PMID:28283242]
Nomenclature Rap guanine nucleotide exchange factor 3 Rap guanine nucleotide exchange factor 4
Common abbreviation Epac1 Epac2
HGNC, UniProt RAPGEF3, O95398 RAPGEF4, Q8WZA2
Inhibitors ESI-09 (pIC50 5.5) [19], CE3F4 HJC 0350 (pIC50 6.5) [95], ESI-09 (pIC50 4.4–5.2) [19, 96]
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Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Enzymes → Cyclic nucleotide turnover/signalling → Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Overview: 3’,5’-Cyclic nucleotide phosphodiesterases (PDEs, 3’,5’-cyclic-nucleotide 5’-nucleotidohydrolase), E.C. 3.1.4.17, catalyse the hydrolysis of a 3’,5’-cyclic nucleotide (usually cyclic AMP or
cyclic GMP). Isobutylmethylxanthine is a nonselective inhibitor with an IC50 value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2’,3’-cyclic nucleotide 3’-phosphodiesterase (E.C.
3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS.
Further reading on Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Baillie GS et al. (2019) Therapeutic targeting of 3’,5’-cyclic nucleotide phosphodiesterases:
inhibition and beyond. Nat Rev Drug Discov 18: 770-796 [PMID:31388135]
Bolger GB. (2021) The PDE-Opathies: Diverse Phenotypes Produced by a Functionally Related
Multigene Family. Trends Genet 37: 669-681 [PMID:33832760]
Lugnier C et al. (2020) Cyclic nucleotide phosphodiesterases: New targets in the metabolic
syndrome? Pharmacol Ther 208: 107475 [PMID:31926200]
Peng T et al. (2020) Advances in the Development of Phosphodiesterase-4 Inhibitors. J Med Chem
63: 10594-10617 [PMID:32255344]
Piazza GA et al. (2020) PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block
Wnt/β-catenin transcription, cancer cell growth, and tumor immunity. Drug Discov Today 25:
1521-1527 [PMID:32562844]
Samidurai A et al. (2021) Role of phosphodiesterase 1 in the pathophysiology of diseases and
potential therapeutic opportunities. Pharmacol Ther 226: 107858 [PMID:33895190]
Turner MJ et al. (2021) Cyclic nucleotide phosphodiesterase inhibitors as therapeutic
interventions for cystic fibrosis. Pharmacol Ther 224: 107826 [PMID:33662448]
Nomenclature phosphodiesterase 1A phosphodiesterase 1B phosphodiesterase 1C phosphodiesterase 2A phosphodiesterase 3A phosphodiesterase 3B
Common abbreviation PDE1A PDE1B PDE1C PDE2A PDE3A PDE3B
HGNC, UniProt PDE1A, P54750 PDE1B, Q01064 PDE1C, Q14123 PDE2A, O00408 PDE3A, Q14432 PDE3B, Q13370
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of affinity cyclic GMP > cyclic AMP cyclic GMP > cyclic AMP cyclic GMP = cyclic AMP cyclic AMP  cyclic GMP – –






cyclic GMP – –
Endogenous inhibitors – – – – cyclic GMP cyclic GMP
Inhibitors crisaborole (pIC50 5.2) [13] – – milrinone (pIC50 <6.5) [655] cilostazol (pIC50 6.7) [655],
inamrinone (pIC50 4.8) [630]
–
Selective inhibitors SCH51866 (pIC50 7.2) [700],
vinpocetine (pIC50 5.1) [431]
SCH51866 (pIC50 7.2) [700] compound 3m (pIC50 8.5)




[61], EHNA (pIC50 5.3) [472]
cilostamide (pIC50 7.5)
[655], anagrelide (pIC50




[655], cilostazol (pIC50 6.4)
[655], milrinone (pIC50 6)
[655], inamrinone (pIC50
4.5) [655]
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Nomenclature phosphodiesterase 4A phosphodiesterase 4B phosphodiesterase 4C phosphodiesterase 4D phosphodiesterase 5A
Common abbreviation PDE4A PDE4B PDE4C PDE4D PDE5A
HGNC, UniProt PDE4A, P27815 PDE4B, Q07343 PDE4C, Q08493 PDE4D, Q08499 PDE5A, O76074
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of affinity cyclic AMP  cyclic GMP cyclic AMP  cyclic GMP cyclic AMP  cyclic GMP cyclic AMP  cyclic GMP cyclic GMP > cyclic AMP
Activators – – – PKA-mediated phosphorylation
[311]
Protein kinase A, protein kinase G
[124]
Inhibitors ibudilast (pIC50 7.3) [372],
RS-25344 (pIC50 7.2) [594]
roflumilast (pIC50 9.4) [435],
ibudilast (pIC50 7.2) [372],
RS-25344 (pIC50 6.5) [594],
roflupram (Knocking down the
expression of PDE4B in primary
microglial cells led to enhanced
level of LC-3 II and decreased
activation of inflammasome.) [768]
RS-25344 (pIC50 8.1) [594],
ibudilast (pIC50 6.6) [372]
RS-25344 (pIC50 8.4) [594],
difamilast (pIC50 >7.3) [517],
CBS-3595 (pIC50 6.1) [16]
gisadenafil (pIC50 8.9) [572],




rolipram (pIC50 9) [715], CDP840
(pKi 8) [540], Ro20-1724 (pIC50
6.5) [715]
rolipram (pIC50 9) [715],
Ro20-1724 (pIC50 6.4) [715]
CDP840 (pKi 7.7) [540], rolipram
(pIC50 6.5) [715], Ro20-1724
(pIC50 5.4) [715]
CDP840 (pKi 8.1) [540], rolipram
(pIC50 7.2) [715], Ro20-1724
(pIC50 6.2) [715]
–
Selective inhibitors YM976 (pIC50 8.3) [22], apremilast
(pIC50 7.8) [601]
– apremilast (pIC50 6.9) [601] apremilast (pIC50 7.5) [601] vardenafil (pIC50 9.7) [66], T0156
(pIC50 9.5) [480], sildenafil (pIC50
8.4–9) [692, 713], tadalafil (pIC50
8.5) [482], SCH51866 (pIC50 7.2)
[700], zaprinast (pIC50 6.8) [692]
Nomenclature phosphodiesterase 6A phosphodiesterase 6B phosphodiesterase 6C phosphodiesterase 6D phosphodiesterase 6G phosphodiesterase 6H
Common abbreviation PDE6A PDE6B PDE6C PDE6D PDE6G PDE6H
HGNC, UniProt PDE6A, P16499 PDE6B, P35913 PDE6C, P51160 PDE6D, O43924 PDE6G, P18545 PDE6H, Q13956
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Inhibitors compound 53 (pIC50 8) [317] – sildenafil (pIC50 7.4) [713], PDE4
inhibitor 16 (pIC50 5.5) [778]
– – –
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Nomenclature phosphodiesterase 7A phosphodiesterase 7B phosphodiesterase 8A phosphodiesterase 8B
Common abbreviation PDE7A PDE7B PDE8A PDE8B
HGNC, UniProt PDE7A, Q13946 PDE7B, Q9NP56 PDE8A, O60658 PDE8B, O95263
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of affinity cyclic AMP  cyclic GMP [470] cyclic AMP  cyclic GMP [230] cyclic AMP  cyclic GMP [196] cyclic AMP  cyclic GMP [292]
Inhibitors crisaborole (pIC50 6.1) [13] BRL50481 (pIC50 4.9) [14] – –
Selective inhibitors BRL50481 (pIC50 6.7–6.8) [14, 636] dipyridamole (pIC50 5.7–6) [230,
599], SCH51866 (pIC50 5.8) [599]
PF-04957325 (pIC50 7.4) [457],
dipyridamole (pIC50 5.1) [196]
dipyridamole (pIC50 4.3) [292]
Comments PDE7A appears to be membrane-bound or soluble for
PDE7A1 and 7A2 splice variants, respectively
– – –
Nomenclature phosphodiesterase 9A phosphodiesterase 10A phosphodiesterase 11A
Common abbreviation PDE9A PDE10A PDE11A
HGNC, UniProt PDE9A, O76083 PDE10A, Q9Y233 PDE11A, Q9HCR9
EC number 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of affinity cyclic GMP  cyclic AMP [197] cyclic AMP, cyclic GMP [212] cyclic AMP, cyclic GMP [191]
Inhibitors SCH51866 (pIC50 5.8) [197], zaprinast (pIC50 4.5) [197] – tadalafil (pIC50 6.5) [482], BC11-38 (pIC50 6.5) [90]
Selective inhibitors – mardepodect (pIC50 9.4) [704] –
Comments: PDE1A, 1B and 1C appear to act as soluble
homodimers, while PDE2A is a membrane-bound homodimer.
PDE3A and PDE3B are membrane-bound.
PDE4 isoforms are essentially cyclic AMP specific. The potency of
YM976 at other members of the PDE4 family has not been
reported. PDE4B-D long forms are inhibited by extracellular
signal-regulated kinase (ERK)-mediated phosphorylation [305,
306]. PDE4A-D splice variants can be membrane-bound or
cytosolic [311]. PDE4 isoforms may be labelled with
[3H]rolipram.
PDE6 is a membrane-bound tetramer composed of two catalytic
chains (PDE6A or PDE6C and PDE6B), an inhibitory chain
(PDE6G or PDE6H) and the PDE6D chain. The enzyme is
essentially cyclic GMP specific and is activated by the α-subunit
of transducin (Gαt) and inhibited by sildenafil, zaprinast and
dipyridamole with potencies lower than those observed for
PDE5A. Defects in PDE6B are a cause of retinitis pigmentosa and
congenital stationary night blindness.
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Cytochrome P450
Enzymes → Cytochrome P450
Overview: The cytochrome P450 enzyme superfamily (CYP),
E.C. 1.14.-.-, are haem-containing monooxygenases with a vast
range of both endogenous and exogenous substrates. These
include sterols, fatty acids, eicosanoids, fat-soluble vitamins,
hormones, pesticides and carcinogens as well as drugs. Listed
below are the human enzymes, their relationship with rodent
CYP enzyme activities is obscure in that the species orthologue
may not metabolise the same substrates. Some of the CYP
enzymes located in the liver are particularly important for drug
metabolism, both hepatic and extrahepatic CYP enzymes also
contribute to patho/physiological processes. Genetic variation of
CYP isoforms is widespread and likely underlies a proportion of
individual variation in drug disposition. The superfamily has the
root symbol CYP, followed by a number to indicate the family, a
capital letter for the subfamily with a numeral for the individual
enzyme. Some CYP are able to metabolise multiple substrates,
others are oligo- or mono- specific.
Further reading on Cytochrome P450
Guengerich FP. (2017) Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic
and Endogenous Substrates: Relevance to Toxicity and Drug Interactions. Chem Res Toxicol 30:
2-12 [PMID:27472660]
Jones G et al. (2014) Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 55: 13-31
[PMID:23564710]
Lorbek G et al. (2012) Cytochrome P450s in the synthesis of cholesterol and bile acids–from
mouse models to human diseases. FEBS J 279: 1516-33
[PMID:22111624]
Orr ST et al. (2012) Mechanism-based inactivation (MBI) of cytochrome P450 enzymes:
structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
J Med Chem 55: 4896-933 [PMID:22409598]
Rendic SP et al. (2018) Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and
environmental compounds: mechanisms, induction, and inhibition - toxic effects and
benefits. Drug Metab Rev 50: 256-342 [PMID:30717606]
Shahabi P et al. (2014) Human cytochrome P450 epoxygenases: variability in expression and role
in inflammation-related disorders. Pharmacol Ther 144: 134-61 [PMID:24882266]
CYP1 family
Enzymes → Cytochrome P450 → CYP1 family
Overview: CYP1 enzymes catalyse the generation of highly mutagenic compounds via activation of procarcinogens (such as polycyclic aromatic hydrocarbons and aromatic amines) that are present in
combustion products. They can also deactivate many anticancer agents [463].
Nomenclature CYP1A1 CYP1A2 CYP1B1
HGNC, UniProt CYP1A1, P04798 CYP1A2, P05177 CYP1B1, Q16678
EC number 1.14.1.1 1.14.1.1 1.14.1.1
Inhibitors 65PF (pIC50 6.8) [417] 5H78PF (pIC50 7.8) [417] stilbenes [172]
Comments CYP1A1 is an extra-hepatic enzyme. It
shows a preference for linear planar
aromatic molecules [645].
CYP1A2 is constitutively expressed in
liver. It shows a preference for triangular
planar aromatic molecules [645].
Mainly expressed in extra-hepatic tissues such as breast, prostate and uterus. Can metabolise 17β-estradiol
into a mutagen [172], as well as leukotrienes and eicosanoids [160]. Gene variants have been associated
with primary congenitial glaucoma [699].
Comments: Targeting these enzymes for inhibition is a possible cancer prevention strategy and possible therapeutic target due to over-expression of the CYP1 family in many cancers.
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CYP2 family: drug metabolising subset
Enzymes → Cytochrome P450 → CYP2 family: drug metabolising subset
Overview: CYP1, 2 and 3 family enzymes are involved in the biotransformation of xenobiotics, including clinically used drugs. Polymorphisms, particularly in the CYP2 family, impact upon an
individual’s response to drugs [772], including the risk of adverse drug reactions, drug efficacy and dose requirement.
Nomenclature CYP2A6 CYP2A7 CYP2A13 CYP2B6 CYP2C8 CYP2C9
HGNC, UniProt CYP2A6, P11509 CYP2A7, P20853 CYP2A13, Q16696 CYP2B6, P20813 CYP2C8, P10632 CYP2C9, P11712
EC number 1.14.14.1 1.14.14.1 1.14.14.1 1.14.14.1 1.14.14.1 1.14.14.51
(S)-limonene + [reduced NADPH–hemoprotein
reductase] + O(2) <=> (-)-trans-carveol + [oxidized
NADPH–hemoprotein reductase] + H(2)O
Competitive inhibitor – – – – – sulphaphenazole [474]
Substrates nicotine, tegafur – – – – sulfaphenazole
Inhibitors esculetin (pIC50
6.4) [558]
– kaempferol (pKi 6.9) [63] ticlopidine (pIC50 6.7)
[201], sibutramine (pIC50
5.8) [32], thiotepa (pKi
5.3) [712]
















Converts arachidonic acid to
11(R)-12(S)-epoxyeicosatrienoic acid
or 14(R)-15(S)-epoxyeicosatrienoic
acid [774]. Drug substrates include
amodiaquine and paclitaxel [30].
Drug substrates include tolbutamide, losartan,
phenytoin, warfarin [138, 474, 660].
Nomenclature CYP2C19 CYP2D6 CYP2E1 CYP2F1 CYP2J2
HGNC, UniProt CYP2C19, P33261 CYP2D6, P10635 CYP2E1, P05181 CYP2F1, P24903 CYP2J2, P51589
EC number 1.14.14.51 1.14.14.1 1.14.14.1 1.14.14.1 1.14.14.1
Inhibitors compound 30 (pKi 7.7) [204], compound
51 (pIC50 7.3) [130]
berberine (pIC50 5.4) [363] compound 23 (pKi 7.4) [761],
12-Imidazolyl-1-dodecanol (pKi 6.2) [156]
– compound 4 (pIC50 6.8) [388], terfenadine
(pIC50 5.1) [388]
Comments Drug substrates include omeprazole,
proguanil, mephenytoin, diazepam [51,
150, 297]. Common genetic




Substrates: Ethanol, p-nitrophenol [443]. Substrate:
naphthalene [403].
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CYP2 family: physiological enzymes subset
Enzymes → Cytochrome P450 → CYP2 family: physiological enzymes subset
Overview: Compared to the other CYP2 family enzymes, this subset have physiological rather than drug metabolising enzyme activities.
Nomenclature CYP2R1 CYP2S1 CYP2U1 CYP2W1
HGNC, UniProt CYP2R1, Q6VVX0 CYP2S1, Q96SQ9 CYP2U1, Q7Z449 CYP2W1, Q8TAV3
EC number 1.14.13.15 1.14.14.1 1.14.14.1 1.14.14.-
Comments Converts vitamin D3 to calcifediol [102].
Expressed in CD34+ human cord blood
hematopoietic stem and early progenitor
cells [753].
Considered an orphan CYP [758]. Possibly
involved in polyunsaturated fatty acid ω-1
hydroxylation [192].
Thymus and brain specific catalysis of ω- and
(ω-1)-hydroxylation of fatty acids [112]. Oxidation of
N-arachidonoylserotonin [624]. Mutations have been
associated with hereditary spastic paraplegia [152].
Appears to have cancer specific expression
[528]. Potential drug target in colorectal
cancer [113].
CYP3 family
Enzymes → Cytochrome P450 → CYP3 family
Overview: CYP1, 2 and 3 family enzymes are involved in the biotransformation of xenobiotics, including clinically used drugs. CYP3A4 is the major enzyme involved in drug metabolism by the liver.
Nomenclature CYP3A4 CYP3A5 CYP3A7 CYP3A43




Substrates midazolam [734], nifedipine [262] – – –
Inhibitors troleandomycin (pKi 7.8) [616], ketoconazole (pKi 7) [253], ritonavir (pKi
>7) [362]
ritonavir (pKi 6.9) [201] – –
Comments Metabolises a vast range of xenobiotics, including antidepressants,
benzodiazepines, calcium channel blockers, and chemotherapeutic agents
[780]. The active site is plastic, with both homotropic and heterotropic
cooperativity observed with some substrates [616]. CYP3A4 catalyses the
25-hydroxylation of trihydroxycholestane [218].
CYP3A5 is expressed
extrahepatically, including in the
small intestine. It has overlapping
substrate specificity with CYP3A4
[137, 734].
Fetal form, rarely expressed in
adults. Has overlapping substrate
specificity with CYP3A4 [137, 734].
Fetal expression only and considered
an orphan CYP [261]. Testosterone
may be a substrate [257].
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CYP4 family
Enzymes → Cytochrome P450 → CYP4 family
Overview: CYP4 family enzymes catalyse the ω-oxidation of endogenous fatty acids and eicosanoids [176]. They have been proposed as molecular targets for the treatment of fatty acid-linked orphan
diseases.
Nomenclature CYP4A11 CYP4A22 CYP4B1 CYP4F2 CYP4F3 CYP4F8
HGNC, UniProt CYP4A11, Q02928 CYP4A22, Q5TCH4 CYP4B1, P13584 CYP4F2, P78329 CYP4F3, Q08477 CYP4F8, P98187







Inhibitors epalrestat (pIC50 5.7)
[757]
– – sesamin (pIC50 6.4) [722],
17-octadecynoic acid (pKi 5.9) [619]
– –




Appears to be an
orphan CYP [171].
Converts 4-ipomeanol
into a toxicant, and is also
important in oxidation of
endobiotic fatty acids and
fatty alcohols [682].
Responsible for ω-hydroxylation of
LTB4, LXB4 [477], and tocopherols,
including vitamin E [643]. Associated
with the warfarin response [777].
Responsible for ω-hydroxylation of LTB4,
LXB4 [477] and polyunsaturated fatty
acids [194, 282], and ω-hydroxylation of




8,9-EET or 11,12-EET to
18-hydroxy-8,9-EET or
18-hydroxy-11,12-EET [504].
Nomenclature CYP4F11 CYP4F12 CYP4F22 CYP4V2 CYP4X1 CYP4Z1
HGNC, UniProt CYP4F11, Q9HBI6 CYP4F12, Q9HCS2 CYP4F22, Q6NT55 CYP4V2, Q6ZWL3 CYP4X1, Q8N118 CYP4Z1, Q86W10
EC number 1.14.14.1
1.14.14.78
1.14.14.1 1.14.14.- 1.14.14.79 1.14.14.1 1.14.14.1
Inhibitors – HET0016 (pIC50 7.9) [757] – – – compound 7 (pIC50 5.2) [380]





described as being highly
similar to CYP4F12
Converts arachidonic acid to 16-HETE
and 18-HETE [504]. Involved in
production of acylceramide and skin
barrier integrity [516]. Variants may
influence ichthyosis [184, 193, 506].








influence age of onset of sporadic
Creutzfeldt-Jakob diseases [550].
Converts lauric acid to
12-hydroxylauric acid. Only
expressed in mammary tissue.
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CYP5, CYP7 and CYP8 families
Enzymes → Cytochrome P450 → CYP5, CYP7 and CYP8 families
Overview: Members of this enzyme family catalyse reactions in the pathways that synthesise or catabolise important lipid mediators, steroids and cholesterol.
Nomenclature CYP5A1 CYP7A1 CYP7B1 CYP8A1 CYP8B1
Common abbreviation Thromboxane-A synthase Cholesterol 7 alpha-hydroxylase – Prostacyclin synthase –
HGNC, UniProt TBXAS1, P24557 CYP7A1, P22680 CYP7B1, O75881 PTGIS, Q16647 CYP8B1, Q9UNU6
EC number 5.3.99.5: PGH2 = thromboxane A2 1.14.14.23 1.14.14.29 5.3.99.4 1.14.14.139
1.14.18.8
Inhibitors dazoxiben (pIC50 8.5) [566],
ozagrel (pIC50 8.4) [303],
furegrelate sodium (pIC50 7.8)




– compound 7p (pIC50 >6) [190],
tranylcypromine [258]
–




Converts prostaglandin H2 (PGH2)






(in rabbit) [326] in the
biosynthesis of bile acids.
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CYP11, CYP17, CYP19, CYP20 and CYP21 families
Enzymes → Cytochrome P450 → CYP11, CYP17, CYP19, CYP20 and CYP21 families
Overview: The reactions catalysed by this family of cytochrome P450 monooxygenases are required for steroid biosynthesis.
Nomenclature CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP20A1 CYP21A2




– Aromatase – Steroid 21-hydroxylase
HGNC, UniProt CYP11A1, P05108 CYP11B1, P15538 CYP11B2,
P19099
CYP17A1, P05093 CYP19A1, P11511 CYP20A1,
Q6UW02
CYP21A2, P08686



















abiraterone (pIC50 7.1–7.3) [270,
554]





5.4) [589] – Rat
Selective inhibitors – – – galeterone (pIC50 6.5) [278] letrozole (pKi 10.7) [459],
letrozole (pIC50 7.9) [53],
exemestane (pKi 7.6) [239],
exemestane (pIC50 7.4) [239],
testolactone (pKi 4.5) [127]
– –
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CYP24, CYP26 and CYP27 families
Enzymes → Cytochrome P450 → CYP24, CYP26 and CYP27 families
Overview: CYP24s deactivate vitamin D metabolites and CYP27s are required for the biosynthesis of vitamin D from cholesterol. CYP26 enzymes metabolise excess all-trans-retinol to limit toxicity.
Nomenclature CYP24A1 CYP26A1 CYP26B1 CYP26C1 CYP27A1 CYP27B1 CYP27C1
Common abbreviation Vitamin D3 24-hydroxylase – – – Sterol 27-hydroxylase 25-Hydroxyvitamin D
1-alpha-hydroxylase
–
HGNC, UniProt CYP24A1, Q07973 CYP26A1, O43174 CYP26B1, Q9NR63 CYP26C1, Q6V0L0 CYP27A1, Q02318 CYP27B1, O15528 CYP27C1, Q4G0S4
EC number 1.14.15.16 1.14.-.- 1.14.-.- 1.14.-.- 1.14.15.15 1.14.15.18 1.14.19.53
Inhibitors CTA091 (pIC50 8.2) [553],
lunacalcipol (pIC50 7.6) [553],
compound 4d (pIC50 4.8) [3]
R116010 (pIC50 8.4) [681],
liarozole (pIC50 5.7) [681],
talarozole [681]
– – compound 4d (pIC50
7.2) [3], CTA091 (pIC50
<6) [348]
CTA091 (pIC50 6.3) [348] –


























CYP39, CYP46 and CYP51 families
Enzymes → Cytochrome P450 → CYP39, CYP46 and CYP51 families
Overview: Enzymes in this family are involved in cholesterol turnover and the biosynthesis of the crucial steroid precursor, lanosterol.
Nomenclature CYP39A1 CYP46A1 CYP51A1
Common abbreviation – Cholesterol 24-hydroxylase Lanosterol 14-α-demethylase
HGNC, UniProt CYP39A1, Q9NYL5 CYP46A1, Q9Y6A2 CYP51A1, Q16850
EC number 1.14.14.26 1.14.14.25 1.14.14.154
1.14.15.36
Inhibitors – – azalanstat (pKi 9.1) [709], compound 10 (Irreversible inhibition) (pIC50 >6) [209]




Converts lanosterol to 4,4-dimethylcholesta-8.14.24-trienol. Proteins within the cholesterol pathway are
being investigated as potential oncology targets. Small molecule inhibitors of human CYP51A1 have been
reported to exhibit anti-proliferative activity in various cancer cells [209].
Searchable database: http://www.guidetopharmacology.org/index.jsp CYP39, CYP46 and CYP51 families S350
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DNA topoisomerases
Enzymes → DNA topoisomerases
Overview: DNA topoisomerases regulate the supercoiling of nuclear DNA to influence the capacity for replication or transcription. The enzymatic function of this series of enzymes involves cutting the
DNA to allow unwinding, followed by re-attachment to reseal the backbone. Members of the family are targetted in anti-cancer chemotherapy.
Further reading on DNA topoisomerases
Baglini E et al. (2021) Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and
Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs. Eur
J Pharm Sci 156: 105594 [PMID:33059042]
Bizard AH et al. (2020) The many lives of type IA topoisomerases. J Biol Chem 295: 7138-7153
[PMID:32277049]
Buzun K et al. (2020) DNA topoisomerases as molecular targets for anticancer drugs. J Enzyme
Inhib Med Chem 35: 1781-1799 [PMID:32975138]
Capranico G et al. (2017) Type I DNA Topoisomerases. J Med Chem 60: 2169-2192
[PMID:28072526]
Dehshahri A et al. (2020) Topoisomerase inhibitors: Pharmacology and emerging nanoscale
delivery systems. Pharmacol Res 151: 104551 [PMID:31743776]
Riccio AA et al. (2020) Molecular mechanisms of topoisomerase 2 DNA-protein crosslink
resolution. Cell Mol Life Sci 77: 81-91 [PMID:31728578]
Nomenclature DNA topoisomerase I DNA topoisomerase II alpha
HGNC, UniProt TOP1, P11387 TOP2A, P11388
EC number 5.99.1.2 5.99.1.2
Inhibitors irinotecan [162, 672] – Bovine etoposide (pIC50 7.3), teniposide [166] – Mouse
E3 ubiquitin ligase components
Enzymes → E3 ubiquitin ligase components
Overview: Ubiquitination (a.k.a. ubiquitylation) is a protein
post-translational modification that typically requires the
sequential action of three enzymes: E1 (ubiquitin-activating
enzymes), E2 (ubiquitin-conjugating enzymes), and E3
(ubiquitin ligases) [487]. Ubiquitination of proteins can target
them for proteasomal degradation, or modulate cellular
processes including cell cycle progression, transcriptional
regulation, DNA repair and signal transduction.
E3 ubiquitin ligases, of which there are >600 in humans, are a
family of highly heterogeneous proteins and protein complexes
that recruit ubiquitin-loaded E2 enzymes to mediate transfer of
the ubiquitin molecule from the E2 to protein substrates. Target
substrate specificity is determined by a substrate recognition
subunit within the E3 complex.
Further reading on E3 ubiquitin ligase components
Asatsuma-Okumura T et al. (2019) Molecular mechanisms of cereblon-based drugs. Pharmacol Ther
202: 132-139 [PMID:31202702]
Chamberlain PP et al. (2019) Development of targeted protein degradation therapeutics Nat Chem
Biol 15: 937-944 [PMID:31527835]
Searchable database: http://www.guidetopharmacology.org/index.jsp E3 ubiquitin ligase components S351
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Nomenclature cereblon
HGNC, UniProt CRBN, Q96SW2
Ligands thalidomide (Binding) (pKd 8.1) [329]
Comments Cereblon is the substrate-recognition module of the cullin-RING type E3 ubiquitin ligase CRL4
Endocannabinoid turnover
Enzymes → Endocannabinoid turnover
Overview: The principle endocannabinoids are 2-acylglycerol
esters, such as 2-arachidonoylglycerol (2-AG), and
N-acylethanolamines, such as anandamide
(N-arachidonoylethanolamine, AEA). The glycerol esters and
ethanolamides are synthesised and hydrolysed by parallel,
independent pathways. Mechanisms for release and re-uptake of
endocannabinoids are unclear, although potent and selective
inhibitors of facilitated diffusion of endocannabinoids across cell
membranes have been developed [271]. FABP5 (Q01469) has
been suggested to act as a canonical intracellular
endocannabinoid transporter in vivo [105]. For the generation of
2-arachidonoylglycerol, the key enzyme involved is
diacylglycerol lipase (DAGL), whilst several routes for
anandamide synthesis have been described, the best
characterized of which involves
N-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD,
[628]). A transacylation enzyme which forms
N-acylphosphatidylethanolamines has been identified as a
cytosolic enzyme, PLA2G4E (Q3MJ16) [513]. In vitro experiments
indicate that the endocannabinoids are also substrates for
oxidative metabolism via cyclooxygenase, lipoxygenase and
cytochrome P450 enzyme activities [17, 205, 638].
Further reading on Endocannabinoid turnover
Blankman JL et al. (2013) Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65:
849-71 [PMID:23512546]
deRoon-Cassini TA et al. (2020) Meet Your Stress Management Professionals: The
Endocannabinoids. Trends Mol Med 26: 953-968 [PMID:32868170]
Di Marzo V. (2018) New approaches and challenges to targeting the endocannabinoid system. Nat
Rev Drug Discov 17: 623-639 [PMID:30116049]
Fowler CJ et al. (2017) Endocannabinoid Turnover. Adv Pharmacol 80: 31-66 [PMID:28826539]
Janssen FJ et al. (2016) Inhibitors of diacylglycerol lipases in neurodegenerative and metabolic
disorders. Bioorg Med Chem Lett 26: 3831-7 [PMID:27394666]
Maccarrone M. (2017) Metabolism of the Endocannabinoid Anandamide: Open Questions after
25 Years. Front Mol Neurosci 10: 166 [PMID:28611591]
van Egmond N et al. (2021) Targeting Endocannabinoid Signaling: FAAH and MAG Lipase
Inhibitors. Annu Rev Pharmacol Toxicol 61: 441-463 [PMID:32867595]
Searchable database: http://www.guidetopharmacology.org/index.jsp Endocannabinoid turnover S352
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N-Acylethanolamine turnover
Enzymes → Endocannabinoid turnover → N-Acylethanolamine turnover
Nomenclature N-Acylphosphatidylethanolamine-
phospholipase D
Fatty acid amide hydrolase Fatty acid amide hydrolase-2 N-Acylethanolamine acid amidase
Common abbreviation NAPE-PLD FAAH FAAH2 NAAA
HGNC, UniProt NAPEPLD, Q6IQ20 FAAH, O00519 FAAH2, Q6GMR7 NAAA, Q02083
EC number 3.1.4.54 3.5.1.99: anandamide + H2O <=> arachidonic
acid + ethanolamine
oleamide + H2O <=> oleic acid + NH3
The enzyme is responsible for the catabolism of
neuromodulatory fatty acid amides, including
anandamide and oleamide: anandamide + H2O
<=> arachidonic acid + ethanolamine
oleamide + H2O <=> oleic acid + NH3
3.5.1.99: anandamide + H2O <=>
arachidonic acid + ethanolamine
oleamide + H2O <=> oleic acid + NH3
The enzyme is responsible for the catabolism of
neuromodulatory fatty acid amides, including
anandamide and oleamide: anandamide +
H2O <=> arachidonic acid + ethanolamine
oleamide + H2O <=> oleic acid + NH3
3.5.1.-
Rank order of affinity – anandamide > oleamide > N-oleoylethanolamide
> N-palmitoylethanolamine [727]
oleamide > N-oleoylethanolamide >
anandamide > N-palmitoylethanolamine [727]
N-palmitoylethanolamine > MEA >
SEA ≥ N-oleoylethanolamide >
anandamide [694]
Inhibitors hexachlorophene (pIC50 5) [9],
bithionol (pIC50 5) [9], ARN19874
(pIC50 4.5) [88]
– – –
Selective inhibitors LEI-401 (pKi 7.6) [481] ASP8477 (pIC50 8.4) [721], JNJ1661010 (pIC50
7.8) [360], PF750 (pIC50 6.3–7.8) [10], OL135
(pIC50 7.4) [727], MM-433593 (pIC50 7), URB597
(pIC50 6.3–7) [727], PF3845 (pIC50 6.6) [11]
OL135 (pIC50 7.9–8.4) [357, 727], URB597
(pIC50 7.5–8.3) [357, 727], ASP8477 (pIC50
7.2) [721]
F215 (pIC50 8.1) [406, 407], ARN726
(Irreversible inhibition) (pIC50 7.6)
[576], S-OOPP (pIC50 6.4) [640] – Rat,
CCP (pIC50 5.3) [689]
Comments NAPE-PLD activity appears to be
enhanced by polyamines in the





Microdeletion in a FAAH pseudogene that is
expressed in dorsal root ganglia and brain
(FAAH-OUT), and a functional single-nucleotide
polymorphism in FAAH conferring reduced
expression and activity, have been identified in a
patient with high anandamide concentrations and
pain insensitivity, a discovery that points to a new
mechanistic target for developing FAAH-based
analgesic therapeutics [267].
The FAAH2 gene is found in many primate
genomes, marsupials, and other distantly
related vertebrates, but not a variety of lower
placental mammals, including mouse and rat
[727].
–
Comments: Routes for N-acylethanolamine biosynthesis other than through NAPE-PLD activity have been identified [690].
Searchable database: http://www.guidetopharmacology.org/index.jsp N-Acylethanolamine turnover S353
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2-Acylglycerol ester turnover
Enzymes → Endocannabinoid turnover → 2-Acylglycerol ester turnover
Nomenclature Diacylglycerol lipase α Diacylglycerol lipase β Monoacylglycerol lipase αβ-Hydrolase 6 αβ-Hydrolase 12
Common abbreviation DAGLα DAGLβ MAGL ABHD6 ABHD12
HGNC, UniProt DAGLA, Q9Y4D2 DAGLB, Q8NCG7 MGLL, Q99685 ABHD6, Q9BV23 ABHD12, Q8N2K0
EC number 3.1.1.- 3.1.1.- 3.1.1.23 3.1.1.23 3.1.1.23
Endogenous substrates diacylglycerol diacylglycerol 2-oleoyl glycerol =
2-arachidonoylglycerol 
anandamide [234]
1-arachidonoylglycerol > 2-arachidonoylglycerol >
1-oleoylglycerol > 2-oleoyl glycerol [501]
–
Inhibitors LEI105 (pIC50 8.5) [35],
DH376 (pIC50 8.2) [511],
DO34 (pIC50 8.2) [511],
KT-109 (pIC50 5.6) [314]
DH376 (pIC50 8.6) [511],
DO34 (pIC50 8.1) [511],
LEI105 (pIC50 8.1) [35],
KT-109 (pIC50 7.1) [314]
MJN110 (pIC50 8) [505] – –
Selective inhibitors – – JJKK 048 (pIC50 9.3) [1],
JNJ-42226314 (pIC50 8.9)
[750], KML29 (pIC50 8.5) [94],
JZL184 (pIC50 8.1) [426]
WWL70 (pIC50 7.2) [404], WWL123 (pIC50 6.4) [29] DO264 (pIC50 8) [512]
Comments – – – ABHD6 has also been shown to accept diacylglycerol as a
substrate, thereby producing 2-acylglycerols [697].
WWL70 has been suggested to have activity at oxidative
metabolic pathways independent of ABHD6 [668].
–
Comments on Endocannabinoid turnover: Many of the
compounds described as inhibitors are irreversible and so
potency estimates will vary with incubation time. FAAH2 is not
found in rodents [727] and a few of the inhibitors described have
been assessed at this enzyme activity. 2-arachidonoylglycerol has
been reported to be hydrolysed by multiple enzyme activities
from neural preparations [36], including ABHD2 (P08910) [473],
ABHD12 (Q8N2K0) [59] and carboxylesterase 1 (CES1, P23141
[751]). ABHD2 (P08910) has also been described as a
triacylglycerol lipase and ester hydrolase [441], while ABHD12
(Q8N2K0) is also able to hydrolyse lysophosphatidylserine [686].
ABHD12 (Q8N2K0) has been described to be inhibited
selectively by pentacyclic triterpenoids, such as oleanolic
acid [533].
Searchable database: http://www.guidetopharmacology.org/index.jsp 2-Acylglycerol ester turnover S354
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Eicosanoid turnover
Enzymes → Eicosanoid turnover
Overview: Eicosanoids are 20-carbon fatty acids, where the
usual focus is the polyunsaturated analogue arachidonic acid and
its metabolites. Arachidonic acid is thought primarily to derive
from phospholipase A2 action on membrane
phosphatidylcholine, and may be re-cycled to form phospholipid
through conjugation with coenzyme A and subsequently
glycerol derivatives. Oxidative metabolism of arachidonic acid is
conducted through three major enzymatic routes:
cyclooxygenases; lipoxygenases and cytochrome P450-like
epoxygenases, particularly CYP2J2. Isoprostanes are structural
analogues of the prostanoids (hence the nomenclature D-, E-,
F-isoprostanes and isothromboxanes), which are produced in the
presence of elevated free radicals in a non-enzymatic manner,
leading to suggestions for their use as biomarkers of oxidative
stress. Molecular targets for their action have yet to be defined.
Further reading on Eicosanoid turnover
Ackermann JA et al. (2017) The double-edged role of 12/15-lipoxygenase during inflammation and
immunity. Biochim Biophys Acta 1862: 371-381 [PMID:27480217]
Haeggström JZ. (2018) Leukotriene biosynthetic enzymes as therapeutic targets. J Clin Invest 128:
2680-2690 [PMID:30108195]
Häfner AK et al. (2019) Beyond leukotriene formation-The noncanonical functions of
5-lipoxygenase. Prostaglandins Other Lipid Mediat 142: 24-32 [PMID:30930090]
Imig JD. (2020) Eicosanoid blood vessel regulation in physiological and pathological states. Clin
Sci (Lond) 134: 2707-2727 [PMID:33095237]
Mitchell JA et al. (2019) Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular
system. Br J Pharmacol 176: 1038-1050 [PMID:29468666]
Orafaie A et al. (2020) An overview of lipoxygenase inhibitors with approach of in vivo studies.
Prostaglandins Other Lipid Mediat 148: 106411 [PMID:31953016]
Seo MJ et al. (2017) Prostaglandin synthases: Molecular characterization and involvement in
prostaglandin biosynthesis. Prog Lipid Res 66: 50-68 [PMID:28392405]
Thulasingam M et al. (2020) Integral Membrane Enzymes in Eicosanoid Metabolism: Structures,
Mechanisms and Inhibitor Design. J Mol Biol 432: 4999-5022 [PMID:32745470]
Xu D et al. (2021) Pathophysiological role of prostaglandin E synthases in liver diseases.
Prostaglandins Other Lipid Mediat 154: 106552 [PMID:33930567]
Cyclooxygenase
Enzymes → Eicosanoid turnover → Cyclooxygenase
Overview: Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor : oxygen oxidoreductase) activity,
catalyses the formation of PGG2 from arachidonic acid. Hydroperoxidase activity inherent in the enzyme catalyses the formation of PGH2 from PGG2. COX-1 and -2 can be nonselectively inhibited by
ibuprofen, ketoprofen, naproxen, indomethacin and paracetamol (acetaminophen). PGH2 may then be metabolised to prostaglandins and thromboxanes by various prostaglandin synthases in an
apparently tissue-dependent manner.
Further reading on Cyclooxygenase
Mitchell JA et al. (2021) Cyclooxygenases and the cardiovascular system. Pharmacol Ther 217:
107624 [PMID:32640277]
Searchable database: http://www.guidetopharmacology.org/index.jsp Cyclooxygenase S355
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Nomenclature COX-1 COX-2
HGNC, UniProt PTGS1, P23219 PTGS2, P35354
EC number 1.14.99.1: Hydrogen donor + arachidonic acid + 2O2 = hydrogen acceptor + H2O + PGH2
arachidonic acid => PGG2 => PGH2
This enzyme is also associated with the following reaction:: docosahexaenoic acid => PGH3
1.14.99.1: Hydrogen donor + arachidonic acid + 2O2 = hydrogen acceptor + H2O + PGH2
arachidonic acid => PGG2 => PGH2
This enzyme is also associated with the following reaction:: docosahexaenoic acid => PGH3
Inhibitors bromfenac (pIC50 8.1) [26], diclofenac (pIC50 7.9) [787], meclofenamic acid (pIC50 7.3)
[349], flurbiprofen (pIC50 7.1) [720], fenoprofen (pIC50 6.8) [26], ketoprofen (pIC50 6.5)
[52], suprofen (pIC50 6.2) [52]
benzquinamide (pIC50 8.3) [26], flurbiprofen (pIC50 8) [42], meclofenamic acid (pIC50 7.4)
[349], carprofen (pIC50 7) [301], ketorolac (pIC50 6.9) [706], nimesulide (pIC50 6.2) [524],
ketoprofen (pIC50 6.2) [52]
Selective inhibitors ketorolac (pIC50 9.7) [720], FK-881 (pIC50 8.3) [323], SC-560 (pIC50 8.1) [634], FR122047
(pIC50 7.5) [510]
celecoxib (pIC50 8.7) [57], SC-236 (pIC50 8–8.3) [236, 539], valdecoxib (pIC50 8.3) [667],
SC-58125 (pIC50 7.4) [236], rofecoxib (pIC50 6.1–6.5) [720], lumiracoxib (pKi 6.5) [60]
Prostaglandin synthases
Enzymes → Eicosanoid turnover → Prostaglandin synthases
Overview: Subsequent to the formation of PGH2, the
cytochrome P450 activities thromboxane synthase (CYP5A1,
TBXAS1, P24557 , EC 5.3.99.5) and prostacyclin synthase
(CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate thromboxane A2
and prostacyclin (PGI2), respectively. Additionally, multiple
enzyme activities are able to generate prostaglandin E2 (PGE2),
prostaglandin D2 (PGD2) and prostaglandin F2α (PGF2α). PGD2
can be metabolised to 9α,11β-prostacyclin F2α through the
multifunctional enzyme activity of AKR1C3. PGE2 can be
metabolised to 9α,11β-prostaglandin F2α through the
9-ketoreductase activity of CBR1. Conversion of the
15-hydroxyecosanoids, including prostaglandins, lipoxins and
leukotrienes to their keto derivatives by the
NAD-dependent enzyme HPGD leads to a reduction in
their biological activity.
Further reading on Prostaglandin synthases
Liu Y et al. (2020) Overview of AKR1C3: Inhibitor Achievements and Disease Insights. J Med Chem
63: 11305-11329 [PMID:32463235]
Searchable database: http://www.guidetopharmacology.org/index.jsp Prostaglandin synthases S356
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Nomenclature CYP5A1 CYP8A1 mPGES1 mPGES2 cPGES
Common abbreviation Thromboxane-A synthase Prostacyclin synthase – – –
HGNC, UniProt TBXAS1, P24557 PTGIS, Q16647 PTGES, O14684 PTGES2, Q9H7Z7 PTGES3, Q15185
EC number 5.3.99.5: PGH2 = thromboxane A2 5.3.99.4 5.3.99.3: PGH2 = PGE2 5.3.99.3: PGH2 = PGE2 5.3.99.3: PGH2 = PGE2
Cofactors – – glutathione dihydrolipoic acid –
Inhibitors dazoxiben (pIC50 8.5) [566], ozagrel
(pIC50 8.4) [303], furegrelate sodium
(pIC50 7.8) [248], picotamide (pIC50
3.8) [255], camonagrel [259]
compound 7p (pIC50 >6)
[190], tranylcypromine [258]
compound 44 (pIC50 9) [238] compound 30 (pIC50 <6)
[579]
–
Selective inhibitors – – compound 39 (pIC50 8.4)
[623], compound III (pIC50
7.1) [396]
– –
Comments – Converts prostaglandin H2
(PGH2) to thromboxane A2
(thromboxane A2) [286].
– – Phosphorylated and activated by casein kinase
2 (CK2) [370].
Appears to regulate steroid hormone function
by interaction with dimeric hsp90 [91, 342].
Nomenclature L-PGDS H-PGDS AKR1C3 CBR1 HPGD
HGNC, UniProt PTGDS, P41222 HPGDS, O60760 AKR1C3, P42330 CBR1, P16152 HPGD, P15428







1.1.1.189: PGE2 + NADP+ =




LXA4 => 15-keto-lipoxin A4
Cofactors – – NADP+ NADP+ –
Inhibitors – TFC007 (pIC50 7.1) [493],
HQL-79 (pIC50 5.3–5.5) [24]
tolfenamic acid (pKi 8.1) [559]
flufenamic acid, indomethacin, flavonoids such as
2’-Hydroxyflavanone (pIC50 6.5) [456, 633]
wedelolactone (pIC50 5.4)
[786]
compound 3 (pIC50 8.1)
[746]
Selective inhibitors AT-56 (pKi 4.1) [325] – – – –
Comments – – AKR1C3 also exhibits an hydroxysteroid dehydrogenase activity. – –
Comments: YS121 has been reported to inhibit mPGES1 and 5-LOX with a pIC50 value of 5.5 [373].
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Lipoxygenases
Enzymes → Eicosanoid turnover → Lipoxygenases
Overview: The lipoxygenases (LOXs) are a structurally related family of non-heme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. For
arachidonic acid as substrate, these products are hydroperoxyeicosatetraenoic acids (HPETEs). In humans there are five lipoxygenases, the 5S-(arachidonate : oxygen 5-oxidoreductase),
12R-(arachidonate 12-lipoxygenase, 12R-type), 12S-(arachidonate : oxygen 12-oxidoreductase), and two distinct 15S-(arachidonate : oxygen 15-oxidoreductase) LOXs that oxygenate arachidonic acid in
different positions along the carbon chain and form the corresponding 5S-, 12S-, 12R-, or 15S-hydroperoxides, respectively.
Nomenclature 5-LOX 12R-LOX 12S-LOX 15-LOX-1 15-LOX-2 E-LOX
HGNC, UniProt ALOX5, P09917 ALOX12B, O75342 ALOX12, P18054 ALOX15, P16050 ALOX15B, O15296 ALOXE3, Q9BYJ1
EC number 1.13.11.34: arachidonic acid + O2 =
LTA4 + H2O
1.13.11.31
arachidonic acid + O2
=> 12R-HPETE
1.13.11.31
arachidonic acid + O2
=> 12S-HPETE
1.13.11.33: arachidonic acid + O2
= 15S-HPETE
linoleic acid + O2 => 13S-HPODE
1.13.11.33:
arachidonic acid + O2
= 15S-HPETE
1.13.11.-
Substrates – methyl arachidonate – – – –
Endogenous substrates arachidonic acid – – – – 12R-HPETE
Endogenous activators 5-LOX activating protein (ALOX5AP,
P20292)
– – – – –
Endogenous inhibitors Protein kinase A-mediated
phosphorylation [438]
– – – – –
Inhibitors BW B70C (pIC50 6.7) [536] – – ML351 (pIC50 6.7) [563],




Selective inhibitors CJ13610 (pIC50 7.2) [195],
PF-04191834 (pIC50 6.6) [454],
zileuton (pIC50 6.4) [86]
– ML355 (pIC50 6.5)
[433]
compound 34 (pKi >8) [564] – –
Comments FLAP activity can be inhibited by
MK-886 [161] and BAY-X1005 [287]
leading to a selective inhibition of
5-LOX activity
– – – Inhibited by
MLS000536924 (pKi
5.6) [335].
E-LOX metabolises the product
from the 12R-lipoxygenase
(12R-HPETE) to a specific
epoxyalcohol compound [770].
Comments: An 8-LOX (EC 1.13.11.40, arachidonate:oxygen
8-oxidoreductase) may be the mouse orthologue of 15-LOX-2
[217]. Some general LOX inhibitors are nordihydroguiaretic acid
and esculetin. Zileuton and caffeic acid are used as
5-lipoxygenase inhibitors, while baicalein and CDC are
12-lipoxygenase inhibitors. The specificity of these inhibitors has
not been rigorously assessed with all LOX forms: baicalein, along
with other flavonoids, such as fisetin and luteolin, also inhibits
15-LOX-1 [591]. 2-TEDC is used as 5-, 12- and 15-LOX
inhibitor [108].
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Leukotriene and lipoxin metabolism
Enzymes → Eicosanoid turnover → Leukotriene and lipoxin metabolism
Overview: Leukotriene A4 (LTA4), produced by 5-LOX activity,
and lipoxins may be subject to further oxidative metabolism;
ω-hydroxylation is mediated by CYP4F2 and CYP4F3, while
β-oxidation in mitochondria and peroxisomes proceeds in a
manner dependent on coenzyme A conjugation. Conjugation of
LTA4 at the 6 position with reduced glutathione to generate
LTC4 occurs under the influence of leukotriene C4 synthase,
with the subsequent formation of LTD4 and LTE4, all three of
which are agonists at CysLT receptors. LTD4 formation is
catalysed by γ-glutamyltransferase, and subsequently dipeptidase
2 removes the terminal glycine from LTD4 to generate LTE4.
Leukotriene A4 hydrolase converts the 5,6-epoxide LTA4 to the
5-hydroxylated LTB4, an agonist for BLT receptors. LTA4 is also
acted upon by 12S-LOX to produce the
trihydroxyeicosatetraenoic acids lipoxins LXA4 and LXB4.
Treatment with a LTA4 hydrolase inhibitor in a murine model of
allergic airway inflammation increased LXA4 levels, in addition
to reducing LTB4, in lung lavage fluid [568].
LTA4 hydrolase is also involved in biosynthesis of resolvin Es.
Aspirin has been reported to increase endogenous formation of
18S-hydroxyeicosapentaenoate (18S-HEPE) compared with
18R-HEPE, a resolvin precursor. Both enantiomers may be
metabolised by human recombinant 5-LOX;
recombinant LTA4 hydrolase converted chiral
5S(6)-epoxide-containing intermediates to resolvin E1
and 18S-resolvin E1 [514].
Nomenclature Leukotriene C4 synthase γ-Glutamyltransferase Dipeptidase 1 Dipeptidase 2 Leukotriene A4 hydrolase
HGNC, UniProt LTC4S, Q16873 GGCT, O75223 DPEP1, P16444 DPEP2, Q9H4A9 LTA4H, P09960
EC number 4.4.1.20: LTC4 = glutathione + LTA4 2.3.2.2: (5-L-glutamyl)-peptide + an amino acid =
a peptide + a 5-L-glutamyl amino acid
LTC4 + H2O => LTD4 + L-glutamate
3.4.13.19: LTD4 + H2O =
LTE4 + glycine
3.4.13.19: LTD4 + H2O =
LTE4 + glycine
3.3.2.6
Inhibitors AZD9898 (pIC50 9.5) [491, 585], example 36
(pIC50 8.1) [585]
acivicin (pIC50 6.2) [18], GGsTop (pKi 3.8) [275] cilastatin (pKi 6) [251] – bestatin (pKi 5.4) [521]
Comments: LTA4H is a member of a family of arginyl
aminopeptidases (ENSFM00250000001675), which also includes
aminopeptidase B (RNPEP, 9H4A4) and aminopeptidase B-like 1
(RNPEPL1, Q9HAU8). Dipeptidase 1 and 2 are members of a
family of membrane dipeptidases, which also includes (DPEP3,
Q9H4B8) for which LTD4 appears not to be a substrate.
GABA turnover
Enzymes → GABA turnover
Overview: The inhibitory neurotransmitter γ-aminobutyrate
(GABA, 4-aminobutyrate) is generated in neurones by glutamic
acid decarboxylase. GAD1 and GAD2 are differentially expressed
during development, where GAD2 is thought to subserve a
trophic role in early life and is distributed throughout the
cytoplasm. GAD1 is expressed in later life and is more associated
with nerve terminals [182] where GABA is principally
accumulated in vesicles through the action of the vesicular
inhibitory amino acid transporter SLC32A1. The role of
γ-aminobutyraldehyde dehydrogenase (ALDH9A1) in
neurotransmitter GABA synthesis is less clear. Following release
from neurons, GABA may interact with either GABAA or GABAB
receptors and may be accumulated in neurones and glia through
the action of members of the SLC6 family of transporters.
Successive metabolism through GABA transaminase and
succinate semialdehyde dehydrogenase generates succinic acid,
which may be further metabolized in the mitochondria in the
tricarboxylic acid cycle.
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Further reading on GABA turnover
Graus F et al. (2020) GAD antibodies in neurological disorders - insights and challenges Nat Rev
Neurol 16: 353-365 [PMID:32457440]
Koenig MK et al. (2017) Phenotype of GABA-transaminase deficiency. Neurology 88: 1919-1924
[PMID:28411234]
Lee H et al. (2015) Ornithine aminotransferase versus GABA aminotransferase: implications for
the design of new anticancer drugs. Med Res Rev 35: 286-305 [PMID:25145640]
Nomenclature Glutamic acid decarboxylase 1 Glutamic acid decarboxylase 2
Common abbreviation GAD1 GAD2
HGNC, UniProt GAD1, Q99259 GAD2, Q05329
EC number 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2
Endogenous substrates L-glutamic acid, L-aspartic acid L-glutamic acid, L-aspartic acid
Products GABA GABA
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate
Selective inhibitors s-allylglycine s-allylglycine
Comments L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid
decarboxylase generating β-alanine [743]. Autoantibodies against GAD1 and GAD2 are
elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).
L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid
decarboxylase generating β-alanine [743]. Autoantibodies against GAD1 and GAD2 are
elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).
Nomenclature aldehyde dehydrogenase 9 family member A1 4-aminobutyrate aminotransferase aldehyde dehydrogenase 5 family member A1
Common abbreviation – GABA-T SSADH
HGNC, UniProt ALDH9A1, P49189 ABAT, P80404 ALDH5A1, P51649
EC number 1.2.1.47: 4-trimethylammoniobutanal + NAD + H2O =
4-trimethylammoniobutanoate + NADPH + 2H+
1.2.1.3: an aldehyde + H2O + NAD = a carboxylate + 2H+ + NADH
1.2.1.19: 4-aminobutanal + NAD + H2O = GABA + NADH + H+
2.6.1.19: GABA + α-ketoglutaric acid = L-glutamic acid
+ 4-oxobutanoate
2.6.1.22: (S)-3-amino-2-methylpropanoate +
α-ketoglutaric acid = 2-methyl-3-oxopropanoate +
L-glutamic acid
1.2.1.24: 4-oxobutanoate + NAD + H2O = succinic
acid + NADH + 2H+
4-hydroxy-trans-2-nonenal + NAD + H2O =
4-hydroxy-trans-2-nonenoate + NADH + 2H+
Cofactors NAD pyridoxal 5-phosphate NAD [618]
Inhibitors – vigabatrin (Irreversible inhibition) (pKi 3.1) [414, 625] 4-acryloylphenol (pIC50 6.5) [673]
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Glycerophospholipid turnover
Enzymes → Glycerophospholipid turnover
Overview: Phospholipids are the basic barrier components of membranes in eukaryotic cells divided into glycerophospholipids (phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine,
phosphatidylserine, phosphatidylinositol and its phosphorylated derivatives) and sphingolipids (ceramide phosphorylcholine and ceramide phosphorylethanolamine).
Further reading on Glycerophospholipid turnover
Cauvin C et al. (2015) Phosphoinositides: Lipids with informative heads and mastermind
functions in cell division. Biochim Biophys Acta 1851: 832-43 [PMID:25449648]
Irvine RF. (2016) A short history of inositol lipids. J Lipid Res 57: 1987-1994 [PMID:27623846]
Poli A et al. (2016) Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol
Phosphate Kinases and Phospholipases C. J Cell Physiol 231: 1645-55 [PMID:26626942]
Phosphoinositide-specific phospholipase C
Enzymes → Glycerophospholipid turnover → Phosphoinositide-specific phospholipase C
Overview: Phosphoinositide-specific phospholipase C (PLC, EC
3.1.4.11), catalyses the hydrolysis of PIP2 to IP3 and
1,2-diacylglycerol, each of which have major second messenger
functions. Two domains, X and Y, essential for catalytic activity,
are conserved in the different forms of PLC. Isoforms of PLC-β
are activated primarily by G protein-coupled receptors through
members of the Gq/11 family of G proteins. The
receptor-mediated activation of PLC-γ involves their
phosphorylation by receptor tyrosine kinases (RTK) in response
to activation of a variety of growth factor receptors and immune
system receptors. PLC-ε1 may represent a point of convergence
of signalling via both G protein-coupled and catalytic receptors.
Ca2+ ions are required for catalytic activity of PLC isoforms and
have been suggested to be the major physiological form of
regulation of PLC-δ activity. PLC has been suggested to be
activated non-selectively by the small molecule m3M3FBS [34],
although this mechanism of action has been questioned [384].
The aminosteroid U73122 has been described as an inhibitor of
phosphoinositide-specific PLC [635], although its selectivity
among the isoforms is untested and it has been reported to
occupy the H1 histamine receptor [318].
Further reading on Phosphoinositide-specific phospholipase C
Filkin SY et al. (2020) Phospholipase Superfamily: Structure, Functions, and Biotechnological
Applications. Biochemistry (Mosc) 85: S177-S195 [PMID:32087059]
Katan M et al. (2020) Phospholipase C families: Common themes and versatility in physiology
and pathology. Prog Lipid Res 80: 101065 [PMID:32966869]
Nakamura Y et al. (2017) Regulation and physiological functions of mammalian phospholipase C.
J Biochem 161: 315-321 [PMID:28130414]
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Nomenclature PLCβ1 PLCβ2 PLCβ3 PLCβ4
HGNC, UniProt PLCB1, Q9NQ66 PLCB2, Q00722 PLCB3, Q01970 PLCB4, Q15147
EC number 3.1.4.11: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H2O = 1D-myo-inositol 1,4,5-trisphosphate + diacylglycerol
Endogenous activators Gαq, Gα11, Gβγ [298, 532, 637] Gα16, Gβγ, Rac2 (RAC2, P15153) [80, 321,
322, 397, 532]
Gαq, Gβγ [85, 397, 532] Gαq [337]
Nomenclature PLCγ1 PLCγ2 PLCδ1 PLCδ3 PLCδ4
HGNC, UniProt PLCG1, P19174 PLCG2, P16885 PLCD1, P51178 PLCD3, Q8N3E9 PLCD4, Q9BRC7
EC number 3.1.4.11: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H2O = 1D-myo-inositol 1,4,5-trisphosphate + diacylglycerol
Endogenous activators PIP3 [33] PIP3, Rac1 (RAC1, P63000), Rac2
(RAC2, P15153), Rac3 (RAC3,
P60763) [33, 545, 710]
Transglutaminase II, p122-RhoGAP
{Rat}, spermine, Gβγ [266, 308, 492,
532]
– –
Endogenous inhibitors – – Sphingomyelin [535] – –
Inhibitors – CCT129957 (pIC50 5.5) [575] – – –
Nomenclature PLCε1 PLCζ1 PLCη1 PLCη2
HGNC, UniProt PLCE1, Q9P212 PLCZ1, Q86YW0 PLCH1, Q4KWH8 PLCH2, O75038
EC number 3.1.4.11: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H2O = 1D-myo-inositol 1,4,5-trisphosphate + diacylglycerol
Endogenous activators Ras, rho [641, 738] – – Gβγ [782]
Comments: A series of PLC-like proteins (PLCL1, Q15111; PLCL2, Q9UPR0 and PLCH1, Q4KWH8) form a family with PLCδ and PLCζ1 isoforms, but appear to lack catalytic activity.
PLC-δ2 has been cloned from bovine sources [468].
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Phospholipase A2
Enzymes → Glycerophospholipid turnover → Phospholipase A2
Overview: Phospholipase A2 (PLA2, EC 3.1.1.4) cleaves the sn-2
fatty acid of phospholipids, primarily phosphatidylcholine, to
generate lysophosphatidylcholine and arachidonic acid. Most
commonly-used inhibitors (e.g. bromoenol lactone, arachidonyl
trifluoromethyl ketone or methyl arachidonyl
fluorophosphonate) are either non-selective within the family of
phospholipase A2 enzymes or have activity against other
eicosanoid-metabolising enzymes.
Secreted or extracellular forms: sPLA2-1B, sPLA2-2A,
sPLA2-2D, sPLA2-2E, sPLA2-2F, sPLA2-3, sPLA2-10 and sPLA2-12A
Cytosolic, calcium-dependent forms: cPLA2-4A, cPLA2-4B,
cPLA2-4C, cPLA2-4D, cPLA2-4E and cPLA2-4F
Other forms: PLA2-G5, iPLA2-G6, PLA2-G7 and PAFAH2
(platelet-activating factor acetylhydrolase 2)
Further reading on Phospholipase A2
Astudillo AM et al. (2019) Selectivity of phospholipid hydrolysis by phospholipase A2 enzymes in
activated cells leading to polyunsaturated fatty acid mobilization. Biochim Biophys Acta Mol
Cell Biol Lipids 1864: 772-783 [PMID:30010011]
Khan MI et al. (2020) Human Secretary Phospholipase A2 Mutations and Their Clinical
Implications J Inflamm Res 13: 551-561 [PMID:32982370]
Kita Y et al. (2019) Cytosolic phospholipase A2 and lysophospholipid acyltransferases. Biochim
Biophys Acta Mol Cell Biol Lipids 1864: 838-845 [PMID:30905348]
Mouchlis VD et al. (2019) Phospholipase A2 catalysis and lipid mediator lipidomics. Biochim
Biophys Acta Mol Cell Biol Lipids 1864: 766-771 [PMID:30905345]
Murakami M et al. (2019) Group IID, IIE, IIF and III secreted phospholipase A2s. Biochim Biophys
Acta Mol Cell Biol Lipids 1864: 803-818 [PMID:30905347]
Samuchiwal SK et al. (2019) Harmful and protective roles of group V phospholipase A2: Current
perspectives and future directions. Biochim Biophys Acta Mol Cell Biol Lipids 1864: 819-826
[PMID:30308324]
Shayman JA et al. (2019) Lysosomal phospholipase A2. Biochim Biophys Acta Mol Cell Biol Lipids
1864: 932-940 [PMID:30077006]
van Hensbergen VP et al. (2020) Type IIA Secreted Phospholipase A2 in Host Defense against
Bacterial Infections Trends Immunol 41: 313-326 [PMID:32151494]
Nomenclature sPLA2-1B sPLA2-2A sPLA2-2D sPLA2-2E sPLA2-2F sPLA2-3
HGNC, UniProt PLA2G1B, P04054 PLA2G2A, P14555 PLA2G2D, Q9UNK4 PLA2G2E, Q9NZK7 PLA2G2F, Q9BZM2 PLA2G3, Q9NZ20
EC number 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4
Inhibitors compound 28xvii (pIC50 8.9) [269] – compound 12e (pIC50 8.1) [523] compound 12e (pIC50 8.1) [523] compound 12e (pIC50 7.3) [523] –
Nomenclature cPLA2-4A cPLA2-4B cPLA2-4C cPLA2-4D cPLA2-4E cPLA2-4F
HGNC, UniProt PLA2G4A, P47712 PLA2G4B, P0C869 PLA2G4C, Q9UP65 PLA2G4D, Q86XP0 PLA2G4E, Q3MJ16 PLA2G4F, Q68DD2
EC number 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4
Inhibitors compound 57 (pIC50 8.4) [434] – – – – –
Comments cPLA2-4A also expresses lysophospholipase (EC 3.1.1.5) activity [621]. – – – – –
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Nomenclature PLA2-G5 iPLA2-G6 sPLA2-10 sPLA2-12A platelet activating factor acetylhydrolase 2
HGNC, UniProt PLA2G5, P39877 PLA2G6, O60733 PLA2G10, O15496 PLA2G12A, Q9BZM1 PAFAH2, Q99487
EC number 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.47
Inhibitors compound 12e (pIC50 7.5) [523] – compound 12e (pIC50 7.7) [523] – –
Comments – – – – PAFAH2 also expresses PAF hydrolase activity (EC 3.1.1.47)
Comments: The sequence of PLA2-2C suggests a lack of catalytic
activity, while PLA2-12B (GXIIB, GXIII sPLA2-like) appears to be
catalytically inactive [590]. A further fragment has been
identified with sequence similarities to Group II PLA2 members.
Otoconin 90 (OC90) shows sequence homology to PLA2-G10.
A binding protein for secretory phospholipase A2 has been
identified which shows modest selectivity for sPLA2-1B over
sPLA2-2A, and also binds snake toxin phospholipase A2 [20].
The binding protein appears to have clearance function for
circulating secretory phospholipase A2, as well as signalling
functions, and is a candidate antigen for idiopathic
membraneous nephropathy [44].
PLA2-G7 and PAFAH2 also express platelet-activating factor
acetylhydrolase activity (EC 3.1.1.47).
Phosphatidylcholine-specific phospholipase D
Enzymes → Glycerophospholipid turnover → Phosphatidylcholine-specific phospholipase D
Overview: Phosphatidylcholine-specific phospholipase D (PLD, EC 3.1.4.4) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols,
such as butanol in a transphosphatidylation reaction [567].
Further reading on Phosphatidylcholine-specific phospholipase D
Brown HA et al. (2017) Targeting phospholipase D in cancer, infection and neurodegenerative
disorders. Nat Rev Drug Discov 16: 351-367 [PMID:28209987]
McDermott MI et al. (2020) Mammalian phospholipase D: Function, and therapeutics. Prog Lipid
Res 78: 101018 [PMID:31830503]
Onono FO et al. (2020) Phospholipase D and Choline Metabolism. Handb Exp Pharmacol 259:
205-218 [PMID:32086667]
Yao Y et al. (2021) Structural insights into phospholipase D function. Prog Lipid Res 81: 101070
[PMID:33181180]
Nomenclature PLD1 PLD2
HGNC, UniProt PLD1, Q13393 PLD2, O14939
EC number 3.1.4.4 3.1.4.4
A phosphatidylcholine + H2O <=> choline + a phosphatidate
Endogenous activators ADP-ribosylation factor 1 (ARF1, P84077), PIP2, RhoA, PKC evoked phosphorylation, RalA [273, 437] ADP-ribosylation factor 1 (ARF1, P84077), PIP2 [428], oleic acid [598]
Endogenous inhibitors Gβγ [555] Gβγ [555]
Inhibitors FIPI (pIC50 8) [610] –
Selective inhibitors compound 69 (pIC50 7.3) [610] VU0364739 (pIC50 7.7) [394]
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Comments: A lysophospholipase D activity (ENPP2, Q13822,
also known as ectonucleotide
pyrophosphatase/phosphodiesterase 2, phosphodiesterase I,
nucleotide pyrophosphatase 2, autotaxin) has been described,
which not only catalyses the production of lysophosphatidic
acid (LPA) from lysophosphatidylcholine, but also cleaves ATP
(see Goding et al., 2003 [241]). Additionally, an
N-acylethanolamine-specific phospholipase D (NAPEPLD,
Q6IQ20) has been characterized, which appears to have a role in
the generation of endocannabinoids/endovanilloids, including
anandamide [519]. This enzyme activity appears to be enhanced
by polyamines in the physiological range [420] and fails to
transphosphatidylate with alcohols [542].
Three further, less well-characterised isoforms are PLD3 (PLD3,
Q8IV08, other names Choline phosphatase 3, HindIII K4L
homolog, Hu-K4), PLD4 (PLD4, Q96BZ4, other names Choline
phosphatase 4, Phosphatidylcholine-hydrolyzing phospholipase,
D4C14orf175 UNQ2488/PRO5775) and PLD5 (PLD5, Q8N7P1).
PLD3 has been reported to be involved in myogenesis [522].
PLD4 is described not to have phospholipase D catalytic activity
[765], but has been associated with inflammatory disorders [518,
659, 679]. Sequence analysis suggests that PLD5 is catalytically
inactive.
Lipid phosphate phosphatases
Enzymes → Glycerophospholipid turnover → Lipid phosphate phosphatases
Overview: Lipid phosphate phosphatases, divided into phosphatidic acid phosphatases or lipins catalyse the dephosphorylation of phosphatidic acid (and other phosphorylated lipid derivatives) to
generate inorganic phosphate and diacylglycerol. PTEN, a phosphatase and tensin homolog (BZS, MHAM, MMAC1, PTEN1, TEP1) is a phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase which acts
as a tumour suppressor by reducing cellular levels of PI 3,4,5-P, thereby toning down activity of PDK1 and PKB. Loss-of-function mutations are frequently identified as somatic mutations in cancers.
Further reading on Lipid phosphate phosphatases
Csolle MP et al. (2020) PTEN and Other PtdIns(3,4,5)P_3 Lipid Phosphatases in Breast Cancer. Int J
Mol Sci 21: [PMID:33276499]
Dey P et al. (2020) A review of phosphatidate phosphatase assays. J Lipid Res 61: 1556-1564
[PMID:32963036]
Knafo S et al. (2017) PTEN: Local and Global Modulation of Neuronal Function in Health and
Disease. Trends Neurosci 40: 83-91 [PMID:28081942]
Lee YR et al. (2018) The functions and regulation of the PTEN tumour suppressor: new modes and
prospects. Nat Rev Mol Cell Biol 19: 547-562 [PMID:29858604]
Yehia L et al. (2020) The Clinical Spectrum of PTEN Mutations. Annu Rev Med 71: 103-116
[PMID:31433956]
Yehia L et al. (2019) PTEN-opathies: from biological insights to evidence-based precision
medicine. J Clin Invest 129: 452-464 [PMID:30614812]
Nomenclature Lipin1 Lipin2 Lipin3 PPA2A PPA2B PPA3A phosphatase and tensin homolog
Common abbreviation – – – – – – PTEN
HGNC, UniProt LPIN1, Q14693 LPIN2, Q92539 LPIN3, Q9BQK8 PLPP1, O14494 PLPP3, O14495 PLPP2, O43688 PTEN, P60484
EC number 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.16
3.1.3.48
3.1.3.67
Substrates – phosphatidic acid – – phosphatidic acid – phosphatidylinositol (3,4,5)-trisphosphate
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Phosphatidylinositol kinases
Enzymes → Glycerophospholipid turnover → Phosphatidylinositol kinases
Overview:
Phosphatidylinositol may be phosphorylated at either 3- or 4-
positions on the inositol ring by PI 3-kinases or PI 4-kinases,
respectively.
Phosphatidylinositol 3-kinases
Phosphatidylinositol 3-kinases (PI3K, provisional nomenclature)
catalyse the introduction of a phosphate into the 3-position of
phosphatidylinositol (PI), phosphatidylinositol 4-phosphate
(PIP) or phosphatidylinositol 4,5-bisphosphate (PIP2). There is
evidence that PI3K can also phosphorylate serine/threonine
residues on proteins. In addition to the classes described below,
further serine/threonine protein kinases, including ATM
(Q13315) and mTOR (P42345), have been described to
phosphorylate phosphatidylinositol and have been termed
PI3K-related kinases. Structurally, PI3Ks have common motifs of
at least one C2, calcium-binding domain and helical domains,
alongside structurally-conserved catalytic domains. Wortmannin
and LY 294002 are widely-used inhibitors of PI3K activities.
Wortmannin is irreversible and shows modest selectivity
between Class I and Class II PI3K, while LY294002 is reversible
and selective for Class I compared to Class II PI3K.
Class I PI3Ks (EC 2.7.1.153) phosphorylate
phosphatidylinositol 4,5-bisphosphate to generate
phosphatidylinositol 3,4,5-trisphosphate and are heterodimeric,
matching catalytic and regulatory subunits. Class IA PI3Ks
include p110α, p110β and p110δ catalytic subunits, with
predominantly p85 and p55 regulatory subunits. The single
catalytic subunit that forms Class IB PI3K is p110γ. Class IA PI3Ks
are more associated with receptor tyrosine kinase pathways,
while the Class IB PI3K is linked more with GPCR signalling.
Class II PI3Ks (EC 2.7.1.154) phosphorylate
phosphatidylinositol to generate phosphatidylinositol
3-phosphate (and possibly phosphatidylinositol 4-phosphate to
generate phosphatidylinositol 3,4-bisphosphate). Three
monomeric members exist, PI3K-C2α, β and β, and include
Ras-binding, Phox homology and two C2 domains.
The only class III PI3K isoform (EC 2.7.1.137) is a heterodimer
formed of a catalytic subunit (VPS34) and regulatory subunit
(VPS15).
Phosphatidylinositol 4-kinases
Phosphatidylinositol 4-kinases (EC 2.7.1.67) generate
phosphatidylinositol 4-phosphate and may be divided into
higher molecular weight type III and lower molecular weight
type II forms.
Further reading on Phosphatidylinositol kinases
Goncalves MD et al. (2018) Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J
Med 379: 2052-2062 [PMID:30462943]
Raphael J et al. (2018) Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A
systematic review and meta-analysis. Eur J Cancer 91: 38-46 [PMID:29331750]
Wang D et al. (2019) Upstream regulators of phosphoinositide 3-kinase and their role in diseases. J
Cell Physiol [PMID:30710358]
Nomenclature phosphatidylinositol 4-kinase alpha phosphatidylinositol 4-kinase beta phosphatidylinositol 4-kinase type 2 alpha phosphatidylinositol 4-kinase type 2 beta
Common abbreviation PI4KIIIα/PIK4CA PI4KIIIβ/PIK4CB PI4KIIα/PI4K2A PI4KIIβ/PI4K2B
HGNC, UniProt PI4KA, P42356 PI4KB, Q9UBF8 PI4K2A, Q9BTU6 PI4K2B, Q8TCG2
EC number 2.7.1.67 2.7.1.67 2.7.1.67 2.7.1.67
Endogenous activation – PKD-mediated phosphorylation [289] – –
Sub/family-selective inhibitors wortmannin (pIC50 6.7–6.8) [233, 469] wortmannin (pIC50 6.7–6.8) [233, 469] adenosine (pIC50 4.5–5) [662] adenosine (pIC50 4.5–5) [662]
Selective inhibitors – PIK-93 (pIC50 7.7) [39, 369] – –
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Nomenclature phosphatidylinositol-4-phosphate 3-kinase catalytic subunit
type 2 alpha
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit
type 2 beta
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit
type 2 gamma
Common abbreviation C2α/PIK3C2A C2β/PIK3C2B C2γ/PIK3C2G
HGNC, UniProt PIK3C2A, O00443 PIK3C2B, O00750 PIK3C2G, O75747
EC number 2.7.1.154 2.7.1.154 2.7.1.154
Inhibitors torin 2 (pIC50 7.6) [421] PI-103 (pIC50 8) [290] –
Nomenclature phosphatidylinositol 3-kinase catalytic subunit type 3
Common abbreviation VPS34
HGNC, UniProt PIK3C3, Q8NEB9
EC number 2.7.1.137
Nomenclature phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit alpha
phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit beta
phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit gamma
phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit delta
Common abbreviation PI3Kα PI3Kβ PI3Kγ PI3Kδ




Inhibitors PIK-75 (pIC50 9.5) [290], gedatolisib
(pIC50 9.4) [703], PF-04691502 (pKi 9.2)
[418], PI-103 (pIC50 8.7) [574], BGT-226
(pIC50 8.4) [450], KU-0060648 (pIC50 8.4)
[81], dactolisib (pIC50 8.4) [445], apitolisib
(pIC50 8.3) [658], PIK-75 (pIC50 8.2) [369]
KU-0060648 (pIC50 9.3) [81], PI-103
(pIC50 8.5) [574], AZD6482 (pIC50 8)
[508], ZSTK474 (pIC50 7.4–7.8) [744,
754], apitolisib (pIC50 7.6) [658], BGT-226
(pIC50 7.2) [450]
dactolisib (pIC50 8.3) [445], apitolisib
(pIC50 7.8) [658], PI-103 (pIC50 7.8) [574],
BGT-226 (pIC50 7.4) [450], ZSTK474
(pIC50 7.3–7.3) [744, 754], TG-100-115
(pIC50 7.1) [527], alpelisib (pIC50 6.6)
[215], KU-0060648 (pIC50 6.2) [81]
KU-0060648 (pIC50 >10) [81], idelalisib
(in vitro activity against recombinant
enzyme) (pIC50 8.6) [391], PI-103 (pIC50
8.5) [574], ZSTK474 (pIC50 8.2–8.3) [744,
754], apitolisib (pIC50 8.2) [658],
dactolisib (pIC50 8.1) [445], alpelisib
(pIC50 6.5) [215]
Sub/family-selective inhibitors pictilisib (pIC50 8.5) [200] pictilisib (pIC50 7.5) [200] pictilisib (pIC50 7.1) [200] pictilisib (pIC50 8.5) [200]
Selective inhibitors GSK1059615 (pIC50 8.7) [368] – CZC 24832 (pIC50 7.6) [48] –
Comments: Wortmannin also inhibits type III phosphatidylinositol 4-kinases and polo-like kinase [422]. PIK93 also inhibits PI 3-kinases [369]. Adenosine activates adenosine receptors.
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Phosphatidylinositol phosphate kinases
Enzymes → Glycerophospholipid turnover → Phosphatidylinositol phosphate kinases
Overview: PIP2 is generated by phosphorylation of PI 4-phosphate or PI 5-phosphate by type I PI 4-phosphate 5-kinases or type II PI 5-phosphate 4-kinases.
Nomenclature phosphatidylinositol-4-phosphate 5-kinase type 1 alpha phosphatidylinositol-4-phosphate 5-kinase type 1 beta phosphatidylinositol-4-phosphate 5-kinase type 1 gamma
Common abbreviation PIP5K1A PIP5K1B PIP5K1C
HGNC, UniProt PIP5K1A, Q99755 PIP5K1B, O14986 PIP5K1C, O60331
EC number 2.7.1.68 2.7.1.68 2.7.1.68
Inhibitors ISA-2011B [613] – –
Nomenclature phosphatidylinositol-5-phosphate 4-kinase type 2 alpha phosphatidylinositol-5-phosphate 4-kinase type 2 beta phosphatidylinositol-5-phosphate 4-kinase type 2 gamma
Common abbreviation PIP4K2A PIP4K2B PIP4K2C
HGNC, UniProt PIP4K2A, P48426 PIP4K2B, P78356 PIP4K2C, Q8TBX8
EC number 2.7.1.149
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate <=>
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
2.7.1.149 2.7.1.149
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Haem oxygenase
Enzymes → Haem oxygenase
Overview: Haem oxygenase (heme,hydrogen-donor:oxygen oxidoreductase (α-methene-oxidizing, hydroxylating)), E.C. 1.14.99.3, converts heme into biliverdin and carbon monoxide, utilizing
NADPH as cofactor.
Further reading on Haem oxygenase
Campbell NK et al. (2021) Regulation of inflammation by the antioxidant haem oxygenase 1. Nat
Rev Immunol [PMID:33514947]
Drummond GS et al. (2019) HO-1 overexpression and underexpression: Clinical implications.
Arch Biochem Biophys 673: 108073 [PMID:31425676]
Ryter SW. (2019) Heme oxygenase-1/carbon monoxide as modulators of autophagy and
inflammation. Arch Biochem Biophys 678: 108186 [PMID:31704095]
Sasson A et al. (2021) The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and
systemic complications of NAFLD. Arch Biochem Biophys 697: 108679 [PMID:33248947]
Szade A et al. (2021) The role of heme oxygenase-1 in hematopoietic system and its
microenvironment. Cell Mol Life Sci [PMID:33787980]
Nomenclature Haem oxygenase 1 Haem oxygenase 2
Common abbreviation HO1 HO2
HGNC, UniProt HMOX1, P09601 HMOX2, P30519
EC number 1.14.14.18
Protoheme + 3 [reduced NADPH-hemoprotein reductase] + 3 O(2) <=> biliverdin +
Fe(2+) + CO + 3 [oxidized NADPH-hemoprotein reductase] + 3 H(2)O
1.14.14.18
Protoheme + 3 [reduced NADPH–hemoprotein reductase] + 3 O(2) <=> biliverdin +
Fe(2+) + CO + 3 [oxidized NADPH–hemoprotein reductase] + 3 H(2)O
Inhibitors – compound 1 (pIC50 3.5) [707] – Rat
Comments: The existence of a third non-catalytic version of haem oxygenase, HO3, has been proposed, although this has been suggested to be a pseudogene [293]. The chemical tin protoporphyrin IX
acts as a haem oxygenase inhibitor in rat liver with an IC50 value of 11 nM [167].
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Hydrogen sulphide synthesis
Enzymes → Hydrogen sulphide synthesis
Overview: Hydrogen sulfide is a gasotransmitter, with
similarities to nitric oxide and carbon monoxide. Although the
enzymes indicated below have multiple enzymatic activities, the
focus here is the generation of hydrogen sulphide (H2S) and the
enzymatic characteristics are described accordingly.
Cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE)
are pyridoxal phosphate (PLP)-dependent enzymes.
3-mercaptopyruvate sulfurtransferase (3-MPST) functions to
generate H2S; only CAT is PLP-dependent, while 3-MPST is not.
Thus, this third pathway is sometimes referred to as
PLP-independent. CBS and CSE are predominantly cytosolic
enzymes, while 3-MPST is found both in the cytosol and the
mitochondria. For an authoritative review on the
pharmacological modulation of H2S levels, see Szabo and
Papapetropoulos, 2017 [661].
Further reading on Hydrogen sulphide synthesis
Asimakopoulou A et al. (2013) Selectivity of commonly used pharmacological inhibitors for
cystathionine β synthase (CBS) and cystathionine γ lyase (CSE). Br J Pharmacol 169: 922-32
[PMID:23488457]
Szabo C et al. (2017) International Union of Basic and Clinical Pharmacology. CII:
Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors.
Pharmacol Rev 69: 497-564 [PMID:28978633]
Nomenclature Cystathionine β-synthase Cystathionine γ-lyase L-Cysteine:2-oxoglutarate aminotransferase 3-Mercaptopyruvate sulfurtransferase
Common abbreviation CBS CSE CAT MPST
HGNC, UniProt CBS, P35520 CTH, P32929 KYAT1, Q16773 MPST, P25325
EC number 4.2.1.22 4.4.1.1 4.4.1.13 2.8.1.2
Endogenous substrates L-homocysteine [98], L-cysteine (Km
6×10−3M) [98]
L-cysteine L-cysteine 3-mercaptopyruvic acid (Km 1.2×10−3M) [494]
Products cystathionine pyruvic acid, NH3 pyruvic acid, NH3 pyruvic acid
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate pyridoxal 5-phosphate Zn2+
Inhibitors aminooxyacetic acid (pIC50 5.1) [25],
benserazide (pIC50 ∼4.5) [168]
aminoethoxyvinylglycine (pIC50 6)
[25], aminooxyacetic acid (pIC50 6)
[25], β-Cyano-L-alanine (pIC50 5.8)
[25], propargylglycine (pIC50 4.4) [25]
– I3MT-3 (pIC50 5.6) [277]
Comments A copper-containing metabolite of
disulfiram acts as a direct inhibitor of
CBS and H2S scavenger [788].
– – Pioglitazone and rosiglitazone inhibit bacterial 3-MST
[129], but have not been shown to inhibit the
mammalian orthologue.
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Hydrolases
Enzymes → Hydrolases
Overview: Listed in this section are hydrolases not accumulated
in other parts of the Concise Guide, such as monoacylglycerol
lipase and acetylcholinesterase. Pancreatic lipase is the
predominant mechanism of fat digestion in the alimentary
system; its inhibition is associated with decreased fat absorption.
CES1 is present at lower levels in the gut than CES2 (P23141),
but predominates in the liver, where it is responsible for the
hydrolysis of many aliphatic, aromatic and steroid esters.
Hormone-sensitive lipase is also a relatively non-selective
esterase associated with steroid ester hydrolysis and triglyceride
metabolism, particularly in adipose tissue. Endothelial lipase is
secreted from endothelial cells and regulates circulating
cholesterol in high density lipoproteins.
Further reading on Hydrolases
Coleman RA. (2020) The "discovery" of lipid droplets: A brief history of organelles hidden in plain
sight Biochim Biophys Acta Mol Cell Biol Lipids 1865: 158762 [PMID:32622088]
Haas CB et al. (2021) Ectonucleotidases in Inflammation, Immunity, and Cancer. J Immunol 206:
1983-1990 [PMID:33879578]
Kishore BK et al. (2018) CD39-adenosinergic axis in renal pathophysiology and therapeutics.
Purinergic Signal 14: 109-120 [PMID:29332180]
Lan L et al. (2020) Detection techniques of carboxylesterase activity: An update review. Bioorg
Chem 94: 103388 [PMID:31676115]
Zimmermann H. (2021) Ectonucleoside triphosphate diphosphohydrolases and
ecto-5’-nucleotidase in purinergic signaling: how the field developed and where we are now.
Purinergic Signal 17: 117-125 [PMID:33336318]
Zou LW et al. (2018) Carboxylesterase Inhibitors: An Update. Curr Med Chem 25: 1627-1649
[PMID:29210644]
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pancreatic lipase lipase E, hormone
sensitive type
lipase G, endothelial type
Systematic nomenclature – CD39 CD39L1 – – –
Common abbreviation CES1 NTPDase-1 NTPDase-2 PNLIP LIPE LIPG
HGNC, UniProt CES1, P23141 ENTPD1, P49961 ENTPD2, Q9Y5L3 PNLIP, P16233 LIPE, Q05469 LIPG, Q9Y5X9
EC number 3.1.1.1 3.6.1.5
Hydrolyzes NTPs to nucleotide
monophosphates (NMPs): A nucleoside
5’-triphosphate + 2 H2O <=> a




NTP>NMP + 2 phosphate
3.1.1.3 3.1.1.79 3.1.1.3
Inhibitors – – – orlistat (pIC50 8.9) [72],
cetilistat (pIC50 8.2) [755]
– –
Selective inhibitors – – PSB-6426 (pKi 5.1) [69] – – –
Comments – ENTPD1 sequentially converts
extracellular purine nucleotides (ATP
and ADP) to the monophosphate form.
Adenosine is then generated by the
action of Ecto-5’-Nucleotidase (CD73).
ENTPD1 is the rate-limiting step.
Extracellular ATP acts as a
damage-associated molecular pattern
(DAMP) that activates innate immune
cells through adenosine-induced
activation of P2X and P2Y purinogenic
receptors.
– – – Endothelial lipase (EL) activity is
implicated in HDL metabolism
and in atherosclerotic plaque
development. Small molecule
EL inhibitors are being
investigated as a potential
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Inositol phosphate turnover
Enzymes → Inositol phosphate turnover
Overview: The sugar alcohol D-myo-inositol is a component of
the phosphatidylinositol signalling cycle, where the principal
second messenger is inositol 1,4,5-trisphosphate, IP3, which acts
at intracellular ligand-gated ion channels, IP3 receptors to
elevate intracellular calcium. IP3 is recycled to inositol by
phosphatases or phosphorylated to form other active inositol
polyphosphates. Inositol produced from dephosphorylation of
IP3 is recycled into membrane phospholipid under the influence
of phosphatidyinositol synthase activity
(CDP-diacylglycerol-inositol 3-phosphatidyltransferase [EC
2.7.8.11]).
Further reading on Inositol phosphate turnover
Irvine R. (2016) A tale of two inositol trisphosphates. Biochem Soc Trans 44: 202-11
[PMID:26862207]
Livermore TM et al. (2016) Phosphate, inositol and polyphosphates. Biochem Soc Trans 44: 253-9
[PMID:26862212]
Miyamoto A et al. (2017) Probes for manipulating and monitoring IP_3. Cell Calcium 64: 57-64
[PMID:27887748]
Windhorst S et al. (2017) Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) is frequently
over-expressed and functions as an oncogene in several tumor types. Biochem Pharmacol 137:
1-9 [PMID:28377279]
Inositol 1,4,5-trisphosphate 3-kinases
Enzymes → Inositol phosphate turnover → Inositol 1,4,5-trisphosphate 3-kinases
Overview: Inositol 1,4,5-trisphosphate 3-kinases (E.C. 2.7.1.127, ENSFM00250000001260) catalyse the generation of inositol 1,3,4,5-tetrakisphosphate (IP4) from IP3. IP3 kinase activity is enhanced in
the presence of calcium/calmodulin (CALM1 CALM2 CALM3, P62158) [121].
Information on members of this family may be found in the online database.
Inositol polyphosphate phosphatases
Enzymes → Inositol phosphate turnover → Inositol polyphosphate phosphatases
Overview: Members of this family exhibit phosphatase activity
towards IP3, as well as towards other inositol derivatives,
including the phospholipids PIP2 and PIP3. With IP3 as substrate,
1-phosphatase (EC 3.1.3.57) generates 4,5,-IP2, 4-phosphatases
(EC 3.1.3.66, ENSFM00250000001432) generate 1,5,-IP2 and
5-phosphatases (E.C. 3.1.3.36 or 3.1.3.56) generate 1,4,-IP2.
Information on members of this family may be found in the online database.
Comments: In vitro analysis suggested IP3 and IP4 were poor substrates for SKIP, synaptojanin 1 and synaptojanin 2, but suggested that PIP2 and PIP3 were more efficiently hydrolysed [602].
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Inositol monophosphatase
Enzymes → Inositol phosphate turnover → Inositol monophosphatase
Overview: Inositol monophosphatase (E.C. 3.1.3.25, IMPase,
myo-inositol-1(or 4)-phosphate phosphohydrolase) is a
magnesium-dependent homodimer which hydrolyses
myo-inositol monophosphate to generate myo-inositol and
phosphate. Glycerol may be a physiological phosphate
acceptor. Li+ is a nonselective un-competitive inhibitor more
potent at IMPase 1 (pKi ca. 3.5, [460]; pIC50 3.2, [515]) than
IMPase 2 (pIC50 1.8-2.1, [515]). IMPase activity may be
inhibited competitively by L690330
(pKi 5.5, [460]), although the enzyme selectivity is not
yet established.
Nomenclature IMPase 1 IMPase 2
HGNC, UniProt IMPA1, P29218 IMPA2, O14732
EC number 3.1.3.25 3.1.3.25
Rank order of affinity inositol 4-phosphate > inositol 3-phosphate > inositol 1-phosphate [460] –
Inhibitors Li+ (pKi 3.5) [460] –
Comments: Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder [631, 632, 766]. Disruption of the gene encoding IMPase 1, but not IMPase 2, appears
to mimic the effects of Li+ in mice [131, 132].
Kinases (EC 2.7.x.x)
Enzymes → Kinases (EC 2.7.x.x)
Overview: Protein kinases (E.C. 2.7.11.-) use the co-substrate
ATP to phosphorylate serine and/or threonine residues on target
proteins. Analysis of the human genome suggests the presence of
518 protein kinases in man (divided into 15 subfamilies), with
over 100 protein kinase-like pseudogenes [447]. It is beyond the
scope of the Concise Guide to list all these protein kinase
activities, but full listings are available on the ’Detailed page’
provided for each enzyme.
Most inhibitors of these enzymes have been assessed in cell-free
investigations and so may appear to ’lose’ potency and selectivity
in intact cell assays. In particular, ambient ATP concentrations
may be influential in responses to inhibitors, since the majority
are directed at the ATP binding site [140].
Further reading on Kinases (EC 2.7.x.x)
Graves LM et al. (2013) The dynamic nature of the kinome. Biochem J 450: 1-8 [PMID:23343193]
Martin KJ et al. (2012) Selective kinase inhibitors as tools for neuroscience research.
Neuropharmacology 63: 1227-37 [PMID:22846224]
Saha D et al. (2020) The Exploration of Chirality for Improved Druggability within the Human
Kinome. J Med Chem 63: 441-469 [PMID:31550151]
Zarrin AA et al. (2021) Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov
20: 39-63 [PMID:33077936]
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Rho kinase
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → DMPK family → Rho kinase
Overview: Rho kinase (also known as P160ROCK, Rho-activated kinase) is activated by members of the Rho small G protein family, which are activated by GTP exchange factors, such as ARHGEF1
(Q92888, p115-RhoGEF), which in turn may be activated by Gα12/13 subunits [381].
Nomenclature Rho associated coiled-coil containing protein kinase 1 Rho associated coiled-coil containing protein kinase 2
Systematic nomenclature ROCK1 ROCK2
Common abbreviation Rho kinase 1 Rho kinase 2
HGNC, UniProt ROCK1, Q13464 ROCK2, O75116
EC number 2.7.11.1 2.7.11.1
Inhibitors RKI-1447 (pIC50 >9) [548], Y27632 (pIC50 5.9–7.3)
[425, 741], fasudil (pKi 7) [573], Y27632 (pKi 6.8)
[695], fasudil (pIC50 5.5–5.6) [425, 573]
RKI-1447 (pIC50 >9) [548], compound 11d [DOI: 10.1039/c0md00194e] (pIC50 >9) [101], GSK269962A (pIC50 8.4) [163],
compound 32 (pIC50 8.4) [64], compound 22 (pIC50 7.7) [741], Y27632 (pIC50 6.3–7.2) [425, 741], Y27632 (pKi 6.8–6.9)
[425, 695], fasudil (pIC50 5.9–5.9) [425, 573]
Selective inhibitors GSK269962A (pIC50 8.8) [163] –
Protein kinase C (PKC) family
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family
Overview: Protein kinase C is the target for the tumour-promoting phorbol esters, such as tetradecanoyl-β-phorbol acetate (TPA, also known as phorbol 12-myristate 13-acetate). Subfamilies of protein
kinase C are identified on the basis of sequence similarities, although functional division groups classical protein kinase C isoforms (PKCα, PKCβ, and PKCγ) activated by Ca2+ and diacylglycerol, novel
protein kinase C isoforms (PKCδ, PKCε, PKCη, and PKCθ) activated by diacylglycerol and atypical protein kinase C isoforms (PKCι and PKCζ) are useful.
Further reading on Protein kinase C (PKC) family
Igumenova TI. (2015) Dynamics and Membrane Interactions of Protein Kinase C. Biochemistry 54:
4953-68 [PMID:26214365]
Newton AC et al. (2017) Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. Trends
Pharmacol Sci 38: 438-447 [PMID:28283201]
Reina-Campos M et al. (2019) The Dual Roles of the Atypical Protein Kinase Cs in Cancer Cancer
Cell 36: 218-235 [PMID:31474570]
Salzer E et al. (2016) Protein Kinase C δ: a Gatekeeper of Immune Homeostasis. J Clin Immunol 36:
631-40 [PMID:27541826]
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Alpha subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family → Alpha subfamily
Overview: These two classical PKC isoforms are Ser/Thr kinases. They are activated by Ca2+ and diacylglycerol, and may be inhibited by GF109203X, calphostin C, Gö 6983, chelerythrine and
Ro31-8220.
Nomenclature protein kinase C beta protein kinase C gamma
Common abbreviation PKCβ PKCγ
HGNC, UniProt PRKCB, P05771 PRKCG, P05129
EC number 2.7.11.13 2.7.11.13
Inhibitors sotrastaurin (pIC50 8.7) [708], Gö 6983 (pIC50 8.1) [260], GF109203X (pIC50 7.8) [688] – Bovine, 7-hydroxystaurosporine (pIC50 7.5)
[617]
Gö 6983 (pIC50 8.2) [260],
7-hydroxystaurosporine (pIC50 7.5) [617]
Selective inhibitors ruboxistaurin (pIC50 8.2) [339], enzastaurin (pIC50 7.5) [189], CGP53353 (pIC50 6.4) [92] –
Delta subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family → Delta subfamily
Overview: PKCδ and PKCθ are PKC isoforms that are activated by diacylglycerol and may be inhibited by calphostin C, Gö 6983 and chelerythrine.
Nomenclature protein kinase C alpha protein kinase C delta protein kinase C theta
Common abbreviation PKCα PKCδ PKCθ
HGNC, UniProt PRKCA, P17252 PRKCD, Q05655 PRKCQ, Q04759
EC number 2.7.11.13 2.7.11.13 2.7.11.13
Activators – ingenol mebutate (pKi 9.4) [359] –
Inhibitors sotrastaurin (pIC50 8.7) [708], Gö 6983 (pIC50 8.1) [260], 7-hydroxystaurosporine (pIC50 7.5) [617] sotrastaurin (pIC50 8.9) [708], Gö 6983 (pIC50 8) [260] sotrastaurin (pIC50 9) [708]
Searchable database: http://www.guidetopharmacology.org/index.jsp Delta subfamily S376
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Eta subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family → Eta subfamily
Overview: PKCε and PKCη are PKC isoforms that are activated by diacylglycerol and may be inhibited by calphostin C, Gö 6983 and chelerythrine.
Nomenclature protein kinase C epsilon protein kinase C eta
Common abbreviation PKCε PKCη
HGNC, UniProt PRKCE, Q02156 PRKCH, P24723
EC number 2.7.11.13 2.7.11.13
Inhibitors sotrastaurin (pIC50 8.2) [708] balanol (pIC50 8.5) [143], sotrastaurin (pIC50 8.2) [708]
Iota subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family → Iota subfamily
Overview: PKCι, PKCζ are atypical serine/threonine protein kinase C isoforms. In contrast to other PKC enzymes these are not activated by phorbolesters or diacylglycerol.
Nomenclature protein kinase C iota protein kinase C zeta
Common abbreviation PKCι PKCζ
HGNC, UniProt PRKCI, P41743 PRKCZ, Q05513
EC number 2.7.11.13 2.7.11.13
Endogenous activators – arachidonic acid [490]
Inhibitors – Gö 6983 (pIC50 7.2) [260]
Comments Known as PKCλ in rodents –
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FRAP subfamily
Enzymes → Kinases (EC 2.7.x.x) → Atypical → Phosphatidyl inositol 3’ kinase-related kinases (PIKK) family → FRAP subfamily
Overview: The protein product of the MTOR gene (previously been known as FK506-binding protein 12-rapamycin-associated protein 1; FRAP1) is the only member of this kinase subfamily. mTOR is
the key enzymatic component of the TORC1 and TORC2 protein complexes. It can act as a Ser/Thr kinase (in both complexes) or a Tyr kinase (in TORC2). The clinically used drugs temsirolimus and
everolimus inhibit mTOR kinase activity.
Further reading on FRAP subfamily
Chen Y et al. (2020) Research progress of mTOR inhibitors. Eur J Med Chem 208: 112820
[PMID:32966896]
Liu GY et al. (2020) mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell
Biol 21: 183-203 [PMID:31937935]
Saxton RA et al. (2017) mTOR Signaling in Growth, Metabolism, and Disease. Cell 169: 361-371
[PMID:28388417]
Xu T et al. (2020) Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors. Eur
J Med Chem 199: 112391 [PMID:32416459]
Nomenclature mechanistic target of rapamycin kinase
Common abbreviation mTOR
HGNC, UniProt MTOR, P42345
EC number 2.7.11.1
Inhibitors ridaforolimus (pIC50 9.7) [582], torin 1 (pIC50 9.5) [419], sapanisertib (pIC50 9) [313], sapanisertib (pKi 8.9) [313], gedatolisib (pIC50 8.8) [703], dactolisib (pIC50 8.2) [445], PP121
(pIC50 8) [23], XL388 (pIC50 8) [666], PF-04691502 (pKi 7.8) [418], apitolisib (pKi 7.8) [658]
Selective inhibitors everolimus (pIC50 8.7) [611], PP-242 (pIC50 8.1) [23], temsirolimus (pIC50 5.8) [376]
Cyclin-dependent kinase (CDK) family
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Cyclin-dependent kinase (CDK) family
Overview: Five of the cyclin-dependent kinases (CDKs: 7, 8, 9, 12, and 13) are involved in the phosphorylation of serine residues in the C-terminal domain of RNA polymerase II, the enzyme that is
responsible for the transcription of protein-coding genes into mRNA in eukaryotes. Phosphorylation of RNA polymerase II at Ser5 is essential for transcriptional initiation, and phosphorylation of Ser 2
contributes to transcriptional elongation and termination. All five of the C-terminal domain kinases can phosphorylate Ser5, but only CDK9, CDK12, and CDK13 can phosphorylate at Ser2
[65, 374, 410].
Searchable database: http://www.guidetopharmacology.org/index.jsp Cyclin-dependent kinase (CDK) family S378
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CDK4 subfamily
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Cyclin-dependent kinase (CDK) family → CDK4 subfamily
Overview: CDK4 and CDK6 are Ser/Thr protein kinases that are components of protein complexes that regulate progression through the G1 phase of the cell cycle. These kinases are important
integrators of mitogenic and antimitogenic signals, and are oncology drug targets. CDK4/6 inhibitors are in clinical use (e.g. abemaciclib, ribociclib and palbociclib).
Nomenclature cyclin dependent kinase 4 cyclin dependent kinase 6
Common abbreviation CDK4 CDK6
HGNC, UniProt CDK4, P11802 CDK6, Q00534
EC number 2.7.11.22 2.7.11.22
Inhibitors R547 (pKi 9) [147], palbociclib (pIC50 8) [211], Ro-0505124 (pIC50 7.7) [158], riviciclib (pIC50 7.2) [347], alvocidib (pKi 7.2) [84] palbociclib (pIC50 7.8) [211]
Comments on Cyclin-dependent kinase (CDK) family: The development of CDK inhibitors as anticancer drugs is reviewed in [596], with detailed content covering CDK4 and CDK6 inhibitors
that are under clinical evaluation. Data produced by Jorda et al. (2018) highlights the caution that must be used when deploying commercially available CDK inhibitors as pharmacological probes [346],
as most of them are more promiscuous in their selectivity than indicated. To make their findings easily accessible the Jorda data is hosted on the cyclin-dependent kinase inhibitor database (CDKiDB).
GSK subfamily
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Glycogen synthase kinase (GSK) family → GSK subfamily
Overview: GSK3A and GSK3B are protein Ser/Thr kinases that are involved in the regulation of glycogen synthesis. GSK3B (GSK-3β) has been associated with the pathogenesis and progression of
diseases including obesity, diabetes, cancer and Alzheimer’s, and as a result pharmacological inhibition of this enzyme is an attractive therapeutic mechanism.
Further reading on GSK subfamily
Beurel E et al. (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.
Pharmacol Ther 148: 114-31 [PMID:25435019]
Domoto T et al. (2016) Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and
resistance to therapy. Cancer Sci 107: 1363-1372 [PMID:27486911]
Khan I et al. (2017) Natural and synthetic bioactive inhibitors of glycogen synthase kinase. Eur J
Med Chem 125: 464-477 [PMID:27689729]
Lauretti E et al. (2020) Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim
Biophys Acta Mol Cell Res 1867: 118664 [PMID:32006534]
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Nomenclature glycogen synthase kinase 3 beta
Common abbreviation GSK3B
HGNC, UniProt GSK3B, P49841
EC number 2.7.11.26
Inhibitors CHIR-98014 (pIC50 9.2) [580], LY2090314 (pIC50 9) [177], laduviglusib (pIC50 8.2) [580], SB 216763 (pIC50 ∼8.1) [117], 1-azakenpaullone (pIC50 7.7) [386], SB-415286 (pIC50
∼7.4) [117], IM-12 (pIC50 7.3) [604]
Selective inhibitors AZD2858 (pKi 8.3) [47]
Comments Due to its Tau phosphorylating activity, small molecule inhibitors of GSK-3β are being investigated as potential treatments for Alzheimer’s disease (AD) [47]. GSK-3β also plays a role in
canonical Wnt pathway signalling, the normal activity of which is crucial for the maintenance of normal bone mass. It is hypothesised that small molecule inhibitors of GSK-3β may
provide effective therapeutics for the treatment of diseases characterised by low bone mass [451].
Polo-like kinase (PLK) family
Enzymes → Kinases (EC 2.7.x.x) → Other protein kinases → Polo-like kinase (PLK) family
Overview: The Polo-like kinases (PLK) are Ser/Thr kinases of the cell cycle that are involved in regulating mitotic entry, mitotic exit, spindle formation, cytokinesis, and meiosis [40, 595]. PLK
inhibitors are predicted to offer anti-proliferative potential for application in oncology [607, 779].
Nomenclature polo like kinase 4
Common abbreviation PLK4
HGNC, UniProt PLK4, O00444
EC number 2.7.11.21
Inhibitors CFI-400945 (pIC50 8.6) [455]
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STE7 family
Enzymes → Kinases (EC 2.7.x.x) → STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases → STE7 family
Overview: STE7 (also known as MAPKK, MAP2K or MEK) kinases are part of the MAPK signalling cascades. They are activated by phosphorylation by upstream STE11 (MAP3K, MAPKKK) kinases and
phosphorylate downstream MAPK kinases. Small molecule pharmacological inhibitors, including negative allosteric modulators, of MEKs are used to disrupt signalling via the RAS-RAF-MEK-ERK
pathway that drives proliferation in certain cancers.
Further reading on STE7 family
Wang C et al. (2021) Research progress of MEK1/2 inhibitors and degraders in the treatment of
cancer J Neurochem [PMID:33774345]
Nomenclature mitogen-activated protein kinase kinase 1 mitogen-activated protein kinase kinase 2
Common abbreviation MEK1 MEK2
HGNC, UniProt MAP2K1, Q02750 MAP2K2, P36507
EC number 2.7.12.2 2.7.12.2
Inhibitors trametinib (pIC50 9–9.1) [237, 756], mirdametinib (pIC50 8.1) [285] trametinib (pIC50 8.7) [756]
Allosteric modulators binimetinib (Negative) (pIC50 7.9) [543], refametinib (Negative) (pIC50 7.7) [330], CI-1040
(Negative) (pKd 6.9) [142]
binimetinib (Negative) (pIC50 7.9) [543], refametinib (Negative) (pIC50 7.3) [330]
Selective allosteric modulators cobimetinib (Negative) (pIC50 9.1) [577] –
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Abl family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Abl family
Overview: ABL1 is a tyrosine kinase. Deletion of the kinase’s inhibitory SH3 domain converts it into an oncogene. A fusion protein caused by a gene translocation, t(9;22), that generates a BCR-ABL
fusion is present in many cases of chronic myelogenous leukemia (CML). The clinically approved drug imatinib, was the first kinase inhibitor to target ABL1 activity to treat CML.
Nomenclature ABL proto-oncogene 1, non-receptor tyrosine kinase
Common abbreviation Abl
HGNC, UniProt ABL1, P00519
EC number 2.7.10.2
Inhibitors compound 8h (pIC50 9.7) [684], dasatinib (pIC50 9.6) [367], compound 24 (pIC50 9.3) [148], PD-173955 (pKd 9.2) [142], bosutinib (pIC50 9) [242], PD-173955 (pIC50 ∼8.3) [495],
bafetinib (pIC50 7.6–8.2) [310, 366], ponatinib (pIC50 8.1) [315], nilotinib (pIC50 7.8) [509], PP121 (pIC50 7.7) [23], imatinib (pIC50 6.7) [310], GNF-5 (pIC50 6.7) [775]
Ack family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Ack family
Overview: TNK2 (ACK1) is a tyrosine kinase that induces cell survival mechanisms. Substrates include receptor tyrosine kinases (EGFR, MERTK, AXL, HER2 and insulin receptor), AKT, FYN, the
androgen receptor and the GTPase Cdc42Hs. TNK2 is associated with tumour cell survival, proliferation and hormone-resistance, and hence TNK2 is considered to be a novel cancer target, although no
inhibitors have entered clinical trials.
Nomenclature tyrosine kinase non receptor 2
Common abbreviation Ack
HGNC, UniProt TNK2, Q07912
EC number 2.7.10.2
Inhibitors compound 30 (pIC50 9) [157]
Searchable database: http://www.guidetopharmacology.org/index.jsp Ack family S382
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Janus kinase (JakA) family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Janus kinase (JakA) family
Overview: Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). They are essential for cytokine signalling and are strongly linked to both cancer and
inflammatory diseases.
Further reading on Janus kinase (JakA) family
Bharadwaj U et al. (2020) Targeting Janus Kinases and Signal Transducer and Activator of
Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Pharmacol Rev 72: 486-526 [PMID:32198236]
Nomenclature Janus kinase 1 Janus kinase 2 Janus kinase 3 tyrosine kinase 2
Common abbreviation JAK1 JAK2 JAK3 Tyk2
HGNC, UniProt JAK1, P23458 JAK2, O60674 JAK3, P52333 TYK2, P29597
EC number 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2
Inhibitors ruxolitinib (pIC50 8.5–10.1) [276,
561], filgotinib (pIC50 8) [698]
ilginatinib (pIC50 9.1) [500], BMS-911543 (pIC50 9) [557], AT-9283 (pIC50 8.9) [312], XL019 (pIC50
8.7) [202], fedratinib (pIC50 8.5) [446, 731], gandotinib (pIC50 8.4) [442]
AT-9283 (pIC50 9) [312] –
Selective inhibitors – compound 1d (pIC50 >9) [716] – –
Comments – The JAK2V617F mutation, which causes constitutive activation, plays an oncogenic role in the
pathogenesis of the myeloproliferative disorders, polycythemia vera, essential thrombocythemia, and
idiopathic myelofibrosis [79, 145]. Small molecule compounds which inhibit aberrant JAK2 activity are
being developed as novel anti-cancer pharmaceuticals.
– –
Src family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Src family
Overview: Activation of Src-family kinases leads to both
stimulatory and inhibitory signaling responses, with cell-specific
and signaling pathway-specific outcomes and redundancy of
kinase function.
Immune system:
In immune cells Src kinases are involved in many signalling
pathways, including ITAM- and ITIM-domain-containing
receptor signaling, integrin signaling, and responses to
chemokines/chemoattractants, cytokines, innate immune
stimuli and a large variety of non-immune cell specific stimuli
(UV irradiation, heat, osmotic shock etc.). In many cases Src
kinases signal to MAP kinase or NF-κB pathways, but they can
also modulate other pathways through less well characterized
mechanisms.
The primary T cell Src kinases are Lck and Fyn; the main B cell
Srcs are Lyn, Fyn and Blk. Mast cells express Fyn and Lyn, with
low expression of Src.
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Nomenclature BLK proto-oncogene, Src family
tyrosine kinase
fyn related Src family tyrosine
kinase
FYN proto-oncogene, Src family
tyrosine kinase
LYN proto-oncogene, Src family
tyrosine kinase
SRC proto-oncogene, non-receptor tyrosine
kinase
Common abbreviation Blk FRK Fyn Lyn Src
HGNC, UniProt BLK, P51451 FRK, P42685 FYN, P06241 LYN, P07948 SRC, P12931
EC number 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2
Inhibitors – – PP1 (pIC50 8.2) [279] bafetinib (pIC50 8) [310] WH-4-023 (pIC50 8.2) [452], PD166285
(pKi 8.1) [530], PP121 (pIC50 7.8) [23],
ENMD-2076 (pIC50 7.7) [551]
Tec family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Tec family
Nomenclature BMX non-receptor tyrosine kinase Bruton tyrosine kinase TXK tyrosine kinase
Common abbreviation Etk Btk TXK
HGNC, UniProt BMX, P51813 BTK, Q06187 TXK, P42681
EC number 2.7.10.2 2.7.10.2 2.7.10.2
Inhibitors compound 38 (pIC50 9.1) [405], ibrutinib (pIC50 9.1) [430], compound 31
(pIC50 8.7) [405]
ibrutinib (pIC50 9.3) [529], compound 31 (pIC50 8.4) [405], compound 38 (pIC50
>8.4) [405]
–
Selective inhibitors BMX-IN-1 (pIC50 8.1) [416] CGI1746 (pIC50 8.7) [153], CHMFL-BTK-11 (Irreversible inhibition) (pIC50 7.6) [742] –
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RAF family
Enzymes → Kinases (EC 2.7.x.x) → TKL: Tyrosine kinase-like → RAF family
Overview: The RAF (acronym for rapidly accelerated fibrosarcoma) kinases are a family of related Ser/Thr kinases that are important for normal cellular and physiological processes, but are also
associated with oncogenesis [400]. They are components of the Ras-Raf-MAPK signalling pathway.
Nomenclature B-Raf proto-oncogene, serine/threonine kinase Raf-1 proto-oncogene, serine/threonine kinase
Common abbreviation B-Raf c-Raf
HGNC, UniProt BRAF, P15056 RAF1, P04049
EC number 2.7.11.1 2.7.11.1
Inhibitors GDC-0879 (pIC50 9.7–9.9) [142, 280], dabrafenib (pIC50 8.5) [392], regorafenib (pIC50 7.6) [771], vemurafenib (pIC50 7) [717],
PLX-4720 (pKd 6.5) [142], compound 2 (pKd 6.3) [309], CHIR-265 (pKd 5.9) [142]
–
Selective inhibitors – GW5074 (pIC50 8.1) [107]
Lanosterol biosynthesis pathway
Enzymes → Lanosterol biosynthesis pathway
Overview: Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described as the mevalonate or HMG-CoA reductase pathway. The first two steps
(formation of acetoacetyl CoA and the mitochondrial generation of (S)-3-hydroxy-3-methylglutaryl-CoA) are also associated with oxidation of fatty acids.
Further reading on Lanosterol biosynthesis pathway
Göbel A et al. (2020) Cholesterol and beyond - The role of the mevalonate pathway in cancer
biology. Biochim Biophys Acta Rev Cancer 1873: 188351 [PMID:32007596]
Juarez D et al. (2021) Targeting the Mevalonate Pathway in Cancer. Trends Cancer 7: 525-540
[PMID:33358111]
Moutinho M et al. (2017) The mevalonate pathway in neurons: It’s not just about cholesterol. Exp
Cell Res 360: 55-60 [PMID:28232115]
Mullen PJ et al. (2016) The interplay between cell signalling and the mevalonate pathway in
cancer. Nat Rev Cancer 16: 718-731 [PMID:27562463]
Proto MC et al. (2021) Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts
and potential therapeutic targets. Prog Lipid Res 82: 101099 [PMID:33915202]
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Nomenclature acetyl-CoA acetyltransferase 1 acetyl-CoA acetyltransferase 2
HGNC, UniProt ACAT1, P24752 ACAT2, Q9BWD1
EC number 2.3.1.9: 2acetyl CoA = acetoacetyl CoA + coenzyme A 2.3.1.9: 2acetyl CoA = acetoacetyl CoA + coenzyme A
Nomenclature hydroxymethylglutaryl-CoA synthase 1 hydroxymethylglutaryl-CoA synthase 2
HGNC, UniProt HMGCS1, Q01581 HMGCS2, P54868
EC number 2.3.3.10: acetyl CoA + H2O + acetoacetyl CoA -> (S)-3-hydroxy-3-methylglutaryl-CoA +
coenzyme A
2.3.3.10: acetyl CoA + H2O + acetoacetyl CoA -> (S)-3-hydroxy-3-methylglutaryl-CoA +
coenzyme A
Comments HMGCoA synthase is found in cytosolic (HMGCoA synthase 1) and mitochondrial (HMGCoA
synthase 2) versions; the former associated with (R)-mevalonate synthesis and the latter with
ketogenesis.
HMGCoA synthase is found in cytosolic (HMGCoA synthase 1) and mitochondrial (HMGCoA
synthase 2) versions; the former associated with (R)-mevalonate synthesis and the latter with
ketogenesis.
Nomenclature hydroxymethylglutaryl-CoA reductase
HGNC, UniProt HMGCR, P04035
EC number 1.1.1.34: (S)-3-hydroxy-3-methylglutaryl-CoA + NADPH -> (R)-mevalonate + coenzyme A + NADP+
Reaction mechanism:: First step: (S)-3-hydroxy-3-methylglutaryl-CoA + NADPH -> mevaldyl-CoA + NADP+
Second step: mevaldyl-CoA + H2O -> (R)-mevalonate + NADP+
Inhibitors lovastatin (Competitive) (pKi 9.2) [15], rosuvastatin (Competitive) (pIC50 8.3) [328], cerivastatin (Competitive) (pKi 8.2) [82], atorvastatin (Competitive) (pIC50 8.1) [328], cerivastatin
(Competitive) (pIC50 8) [683], simvastatin (Competitive) (pIC50 8) [328], fluvastatin (Competitive) (pIC50 7.6) [328]
Comments HMGCoA reductase is associated with intracellular membranes; enzymatic activity is inhibited by phosphorylation by AMP-activated kinase. The enzymatic reaction is a three-step reaction
involving the intermediate generation of mevaldehyde-CoA and mevaldehyde.
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Nomenclature mevalonate kinase phosphomevalonate kinase diphosphomevalonate decarboxylase
HGNC, UniProt MVK, Q03426 PMVK, Q15126 MVD, P53602
EC number 2.7.1.36: ATP + (R)-mevalonate -> ADP + (R)-5-phosphomevalonate 2.7.4.2: ATP + (R)-5-phosphomevalonate = ADP
+ (R)-5-diphosphomevalonate
4.1.1.33: ATP + (R)-5-diphosphomevalonate ->
ADP + isopentenyl diphosphate + CO2 + PO34-
Comments Mevalonate kinase activity is regulated by the downstream products farnesyl







HGNC, UniProt IDI1, Q13907 IDI2, Q9BXS1 GGPS1, O95749
EC number 5.3.3.2: isopentenyl diphosphate =
dimethylallyl diphosphate
5.3.3.2: isopentenyl diphosphate =
dimethylallyl diphosphate
2.5.1.1: dimethylallyl diphosphate + isopentenyl diphosphate = geranyl diphosphate + diphosphate
2.5.1.10: geranyl diphosphate + isopentenyl diphosphate -> trans,trans-farnesyl diphosphate + diphosphate
2.5.1.29: trans,trans-farnesyl diphosphate + isopentenyl diphosphate -> geranylgeranyl diphosphate + diphosphate
Nomenclature farnesyl diphosphate synthase squalene synthase squalene monooxygenase lanosterol synthase
HGNC, UniProt FDPS, P14324 FDFT1, P37268 SQLE, Q14534 LSS, P48449
EC number 2.5.1.1: dimethylallyl diphosphate + isopentenyl diphosphate =
geranyl diphosphate + diphosphate
2.5.1.10: geranyl diphosphate + isopentenyl diphosphate ->
trans,trans-farnesyl diphosphate + diphosphate
2.5.1.21: 2trans,trans-farnesyl diphosphate
-> presqualene diphosphate + diphosphate
presqualene diphosphate + NAD(P)H + H+ ->
squalene + diphosphate + NAD(P)+
1.14.13.132: H+ + NADPH + O2 + squalene




Cofactors – NADPH – –
Inhibitors risedronate (pIC50 8.4) [49], zoledronic acid (pKi 7.1) [170],
alendronate (pIC50 6.3) [49]
zaragozic acid A (pKi 10.1) [50] – Rat,
zaragozic acid A (pIC50 9.2) [685]
– –
Selective inhibitors ibandronic acid (pKi 6.7) [170], pamidronic acid (pIC50 6.7) [170] – – –
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Nucleoside synthesis and metabolism
Enzymes → Nucleoside synthesis and metabolism
Overview: The de novo synthesis and salvage of nucleosides have been targetted for therapeutic advantage in the treatment of particular cancers and gout. Dihydrofolate reductase produces
tetrahydrofolate, a cofactor required for synthesis of purines, pyrimidines and amino acids. GART allows formylation of phosphoribosylglycinamide, an early step in purine biosynthesis. Dihydroorotate
dehydrogenase produces orotate, a key intermediate in pyrimidine synthesis. IMP dehydrogenase generates xanthosine monophosphate, an intermediate in GTP synthesis.
Further reading on Nucleoside synthesis and metabolism
Furuhashi M. (2020) New insights into purine metabolism in metabolic diseases: role of xanthine
oxidoreductase activity. Am J Physiol Endocrinol Metab 319: E827-E834 [PMID:32893671]
Okafor ON et al. (2017) Allopurinol as a therapeutic option in cardiovascular disease. Pharmacol
Ther 172: 139-150 [PMID:27916655]













Common abbreviation DHFR GART DHODH IMPDH1 IMPDH2 TYMS
HGNC, UniProt DHFR, P00374 GART, P22102 DHODH, Q02127 IMPDH1, P20839 IMPDH2, P12268 TYMS, P04818
EC number 1.5.1.3 2.1.2.2
6.3.3.1
6.3.4.13
1.3.5.2 1.1.1.205 1.1.1.205 2.1.1.45







Selective inhibitors methotrexate (pKi 8.9) [588] – – – – raltitrexed (pIC50 6.5) [222]





TP53 inducible subunit M2B






HGNC, UniProt PNP, P00491 XDH, P47989 RRM1, P23921 RRM2, P31350 RRM2B, Q7LG56
EC number 1.4.2.1
Purine-nucleoside phosphorylase: Purine
nucleoside + phosphate <=> purine +
alpha-D-ribose 1-phosphate
Purine deoxynucleoside + phosphate <=>
purine + 2’-deoxy-alpha-D-ribose 1-phosphate
1.17.1.4 1.17.14.1 1.17.4.1 1.17.1.4
Inhibitors – febuxostat (pIC50 8.9) [186], topiroxostat – – –
Searchable database: http://www.guidetopharmacology.org/index.jsp Nucleoside synthesis and metabolism S388
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Comments: TYMS allows the interconversion of dUMP and dTMP, thereby acting as a crucial step in DNA synthesis. PNP allows separation of a nucleoside into the nucleobase and ribose phosphate for
nucleotide salvage. XDH generates urate in the purine degradation pathway. Post-translational modifications of XDH convert the enzymatic reaction to a xanthine oxidase, allowing the interconversion
of hypoxanthine and xanthine, with the production (or consumption) of reactive oxygen species.
Paraoxonase (PON) family
Enzymes → Paraoxonase (PON) family
Overview: Paraoxonases (PON) are calcium-dependent esterases, which may be involved in lipoprotein turnover and the conversion of lactone statin prodrugs, as well as being targets of
organophosphates, such as the insecticide paraoxon.
Further reading on Paraoxonase (PON) family
Dardiotis E et al. (2019) Paraoxonase-1 genetic polymorphisms in organophosphate metabolism.
Toxicology 411: 24-31 [PMID:30359673]
Lioudaki S et al. (2019) Paraoxonase-1: Characteristics and Role in Atherosclerosis and Carotid
Artery Disease. Curr Vasc Pharmacol 17: 141-146 [PMID:29189170]
Taler-Vercic A et al. (2020) The Structure and Function of Paraoxonase-1 and Its Comparison to
Paraoxonase-2 and -3 Molecules 25: 5980 [PMID:33348669]
Nomenclature paraoxonase 1 paraoxonase 2 paraoxonase 3
Common abbreviation PON1 PON2 PON3
HGNC, UniProt PON1, P27169 PON2, Q15165 PON3, Q15166
EC number 3.1.1.2
A phenyl acetate + H(2)O <=> a phenol + acetate
3.1.1.81
An N-acyl-L-homoserine lactone + H(2)O <=> an N-acyl-L-homoserine
3.1.8.1
An aryl dialkyl phosphate + H(2)O <=> dialkyl phosphate + an aryl
alcohol
3.1.1.2
A phenyl acetate + H(2)O <=> a
phenol + acetate
3.1.1.81
A N-acyl-L-homoserine lactone + H(2)O
<=> a N-acyl-L-homoserine
3.1.1.2
A phenyl acetate + H(2)O <=> a phenol + acetate
3.1.1.81
A N-acyl-L-homoserine lactone + H(2)O <=> a N-acyl-L-homoserine
3.1.8.1
An aryl dialkyl phosphate + H(2)O <=> dialkyl phosphate + an aryl
alcohol
Comments PON1 forms homodimers. Loss-of-function mutations in PON1 are
associated with microvascular complications of diabetes [354, 355].
PON2 forms heterotrimers [165]. PON3 likely forms heterodimers in vivo [165].
Searchable database: http://www.guidetopharmacology.org/index.jsp Paraoxonase (PON) family S389
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Peptidases and proteinases
Enzymes → Peptidases and proteinases
Overview: Peptidases and proteinases hydrolyse peptide bonds,
and can be simply divided on the basis of whether terminal
peptide bonds are cleaved (exopeptidases and exoproteinases) at
the amino terminus (aminopeptidases) or carboxy terminus
(carboxypeptidases). Non-terminal peptide bonds are cleaved by
endopeptidases and endoproteinases, which are divided into
serine endopeptidases (EC 3.4.21.-), cysteine endopeptidases (EC
3.4.22.-), aspartate endopeptidases (EC 3.4.23.-),
metalloendopeptidases (EC 3.4.24.-) and threonine
endopeptidases (EC 3.4.25.-).
Since it is beyond the scope of the Guide to list all peptidase
and proteinase activities, this summary focuses on selected
enzymes of significant pharmacological interest that have
ligands (mostly small-molecules) directed against them.
For those interested in detailed background we
recommend the MEROPS database [570] (with whom we
collaborate) as an information resource [571].
Blood coagulation components
Enzymes → Peptidases and proteinases → Blood coagulation components
Overview: Coagulation as a process is interpreted as a
mechanism for reducing excessive blood loss through the
generation of a gel-like clot local to the site of injury. The process
involves the activation, adhesion (see Integrins), degranulation
and aggregation of platelets, as well as proteins circulating in the
plasma. The coagulation cascade involves multiple proteins
being converted to more active forms from less active precursors
(for example, prothrombin [Factor II] is converted to thrombin
[Factor IIa]), typically through proteolysis (see Proteases). Listed
here are the components of the coagulation cascade targeted by
agents in current clinical usage or at an advanced level of
development.
Further reading on Blood coagulation components
Astermark J. (2015) FVIII inhibitors: pathogenesis and avoidance. Blood 125: 2045-51
[PMID:25712994]
Beavers CJ et al. (2020) Osocimab: A Novel Agent in Preventing Venous Thromboembolism. J
Cardiovasc Pharmacol 76: 645-649 [PMID:33105325]
Girolami A et al. (2017) New clotting disorders that cast new light on blood coagulation and may
play a role in clinical practice. J Thromb Thrombolysis 44: 71-75 [PMID:28251495]
Lin L et al. (2020) From multi-target anticoagulants to DOACs, and intrinsic coagulation factor
inhibitors. Blood Rev 39: 100615 [PMID:31492462]
Rana K et al. (2016) Blood flow and mass transfer regulation of coagulation. Blood Rev 30: 357-68
[PMID:27133256]
Wheeler AP et al. (2016) The Intrinsic Pathway of Coagulation as a Target for Antithrombotic
Therapy. Hematol Oncol Clin North Am 30: 1099-114 [PMID:27637310]
Nomenclature coagulation factor II, thrombin coagulation factor V coagulation factor VIII
Systematic nomenclature prothrombin – –
HGNC, UniProt F2, P00734 F5, P12259 F8, P00451
EC number 3.4.21.5 – –
Inhibitors lepirudin (pKi 13) [612, 719], desirudin (pKi 12.7) [181, 343],
bivalirudin (pKi 8.6) [653, 739], dabigatran (Antithrombotic effects
occur via inhibition of the activated form, factor IIa) (pKi 8.3)
[288, 733], argatroban (pKi 7.7) [324, 612]
– –
Selective inhibitors – drotrecogin alfa (Antithrombotic effect thought to
occur via inhibition of factors Va and VIIIa) [353, 356]
drotrecogin alfa (Antithrombotic effect thought to
occur via inhibition of factors Va and VIIIa) [353, 356]
Searchable database: http://www.guidetopharmacology.org/index.jsp Blood coagulation components S390
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Nomenclature coagulation factor X serpin family C member 1
Common abbreviation – antithrombin, antithrombin III
HGNC, UniProt F10, P00742 SERPINC1, P01008
EC number 3.4.21.6 –
Selective activators – heparin (pKd 7.8) [249], fondaparinux (pKd 7.5) [531], dalteparin
[307], danaparoid [135, 498], enoxaparin [180], tinzaparin [208]
Selective inhibitors apixaban (pKi 10.1) [740], rivaroxaban (pKi 9.4) [541], edoxaban (pKi 9.2) [219, 547], JTV-803 (Antithrombotic
effect occurs via the inhibition of the activated form, Xa) (pKi 7.7) [291, 320], DX-9065a (Antithrombotic effect
occurs via the inhibition of the activated form, Xa) (pKi 7.4) [281, 320]
–
Comments: Antithrombin is an inhibitor of thrombin, Factor Xa and multiple other proteinases. Lepirudin has been withdrawn from market.
A1: Pepsin
Enzymes → Peptidases and proteinases → AA: Aspartic (A) Peptidases → A1: Pepsin
Nomenclature renin
HGNC, UniProt REN, P00797
EC number 3.4.23.15
Inhibitors aliskiren (pIC50 9.2) [749]
A22: Presenilin
Enzymes → Peptidases and proteinases → AD: Aspartic (A) Peptidases → A22: Presenilin
Overview: Presenilin (PS)-1 or -2 act as the catalytic
component/essential co-factor of the γ-secretase complex
responsible for the final carboxy-terminal cleavage of amyloid
precursor protein (APP) [352] in the generation of amyloid beta
(Aβ) [12, 665]. Given that the accumulation and aggregation of
Aβ in the brain is pivotal in the development of Alzheimer’s
disease (AD), inhibition of PS activity is one mechanism being
investigated as a therapeutic option for AD [244]. Several small
molecule inhibitors of PS-1 have been investigated, with some
reaching early clinical trials, but none have been formally
approved. Dewji et al. (2015) have reported that small peptide
fragments of human PS-1 can significantly inhibit Aβ production
(total Aβ, Aβ40 and Aβ42) both in vitro and when infused in to
the brains of APP transgenic mice [151]. The most active small
peptides in this report were P4 and P8, from the amino-terminal
domain of PS-1.
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp A22: Presenilin S391
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C14: Caspase
Enzymes → Peptidases and proteinases → CD: Cysteine (C) Peptidases → C14: Caspase
Overview: Caspases, (E.C. 3.4.22.-) which derive their name
from Cysteine ASPartate-specific proteASES, include at least two
families; initiator caspases (caspases 2, 8, 9 and 10), which are
able to hydrolyse and activate a second family of effector
caspases (caspases 3, 6 and 7), which themselves are able to
hydrolyse further cellular proteins to bring about programmed
cell death. Caspases are heterotetrameric, being made up of two
pairs of subunits, generated by a single gene product, which is
proteolysed to form the mature protein. Members of the
mammalian inhibitors of apoptosis proteins (IAP) are able to
bind the procaspases, thereby preventing maturation to active
proteinases.
Information on members of this family may be found in the online database.
Comments: CARD16 (Caspase recruitment domain-containing protein 16, caspase-1 inhibitor COP, CARD only domain-containing protein 1, pseudo interleukin-1β converting enzyme, pseudo-ICE,
ENSG00000204397) shares sequence similarity with some of the caspases.
M1: Aminopeptidase N
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M1: Aminopeptidase N
Overview: Aminopeptidases catalyze the cleavage of amino acids from the amino (N) terminus of protein or peptide substrates, and are involved in many essential cellular functions. Members of this
enzyme family may be monomeric or multi-subunit complexes, and many are zinc metalloenzymes [676].
Nomenclature Leukotriene A4 hydrolase
HGNC, UniProt LTA4H, P09960
EC number 3.3.2.6
Inhibitors bestatin (pKi 5.4) [521]
Searchable database: http://www.guidetopharmacology.org/index.jsp M1: Aminopeptidase N S392
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M2: Angiotensin-converting enzymes (ACE and ACE2)
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M2: Angiotensin-converting enzymes (ACE and ACE2)
Nomenclature Angiotensin-converting enzyme Angiotensin-converting enzyme 2
Common abbreviation ACE ACE2
HGNC, UniProt ACE, P12821 ACE2, Q9BYF1
EC number 3.4.15.1 3.4.15.1
Binding dissociation
constants for SARS-CoVs (Kd)
– SARS-CoV-2 (1.2 nM); SARS-CoV (5 nM); Binding of hACE2 ectodomain to
immobilised SB domains of the viral strains in a biolayer interferometry assay. [711]
Substrates Ac-SDKP –
Endogenous substrates angiotensin I (AGT, P01019) > angiotensin II (AGT, P01019) angiotensin I (AGT, P01019) > angiotensin-(1-9) (AGT, P01019) [164]
Activators – XNT (pEC50 4.7) [299]
Inhibitors zofenoprilat (pKi 9.4) [383] – Rabbit, captopril (pKi 8.4) [471], zofenopril compound 28 (pKi 9.9) [485]
Selective inhibitors perindoprilat (pIC50 9) [89], cilazaprilat (pIC50 8.7) [723] – Rabbit, imidaprilat (pIC50 8.7)
[584], lisinopril-tryptophan (C-domain assay) (pIC50 8.2) [724], RXP-407 (N-domain selective
inhibition) (pIC50 8.1) [620], fosinoprilat (pIC50 8) [144] – Rabbit, enalaprilat (pIC50 7.5)
[104], benazeprilat (pIC50 6.6) [398]
MLN-4760 (pIC50 9.4) [485]
Comments Reports of ACE GPI hydrolase activity [375] have been refuted [401] –
M10: Matrix metallopeptidase
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M10: Matrix metallopeptidase
Overview: Matrix metalloproteinases (MMP) are calcium- and zinc-dependent proteinases regulating the extracellular matrix and are often divided (e.g. [705]) on functional and structural bases into
gelatinases, collagenases, stromyelinases and matrilysins, as well as membrane type-MMP (MT-MMP).
Nomenclature MMP2 MMP8
HGNC, UniProt MMP2, P08253 MMP8, P22894
EC number 3.4.24.24 3.4.24.34
Selective inhibitors ARP100 [691] –
Comments MMP2 is categorised as a gelatinase with substrate specificity for gelatinase A. MMP8 is categorised as a collagenase.
Comments: A number of small molecule ‘broad spectrum’ inhibitors of MMP have been described, including marimastat and batimastat.
Tissue inhibitors of metalloproteinase (TIMP) proteins are endogenous inhibitors acting to chelate MMP proteins: TIMP1 (TIMP1, P01033), TIMP2 (TIMP2, P16035), TIMP3 (TIMP3, P35625),
TIMP4 (TIMP4, Q99727)
Searchable database: http://www.guidetopharmacology.org/index.jsp M10: Matrix metallopeptidase S393
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M12: Astacin/Adamalysin
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M12: Astacin/Adamalysin
Overview: ADAM (A Disintegrin And Metalloproteinase domain containing proteins) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited
products.
ADAMTS (with thrombospondin motifs) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited products.
Information on members of this family may be found in the online database.
Comments: Additional ADAM family members include AC123767.2 (cDNA FLJ58962, moderately similar to mouse ADAM3, ENSG00000231168), AL160191.3 (ADAM21-like protein,
ENSG00000235812), AC136428.3-2 (ENSG00000185520) and ADAMDEC1 (decysin 1, ENSG00000134028).
Other ADAMTS family members include AC104758.12-5 (FLJ00317 protein Fragment ENSG00000231463), AC139425.3-1 (ENSG00000225577), and AC126339.6-1 (ENSG00000225734).
M28: Aminopeptidase Y
Enzymes → Peptidases and proteinases → MH: Metallo (M) Peptidases → M28: Aminopeptidase Y
Nomenclature Folate hydrolase (prostate-specific membrane antigen) 1
HGNC, UniProt FOLH1, Q04609
EC number 3.4.17.21
Antibodies capromab (Binding)
Comments Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N-acetaspartylglutamate to form N-acetylaspartate and L-glutamate (L-glutamic acid). In the gut, the
enzyme assists in the assimilation of folate by hydrolysing dietary poly-gamma-glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up-regulated in cancerous
tissue. A tagged version of the antibody capromab has been used for imaging purposes.
Comments: Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N-acetaspartylglutamate to form N-acetylaspartate and L-glutamate. In the gut, the enzyme assists in
the assimilation of folate by hydrolysing dietary poly-gamma-glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up-regulated in cancerous tissue. A tagged version of
the antibody capromab has been used for imaging purposes.
Searchable database: http://www.guidetopharmacology.org/index.jsp M28: Aminopeptidase Y S394
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M19: Membrane dipeptidase
Enzymes → Peptidases and proteinases → MJ: Metallo (M) Peptidases → M19: Membrane dipeptidase
Nomenclature Dipeptidase 1
HGNC, UniProt DPEP1, P16444
EC number 3.4.13.19: LTD4 + H2O = LTE4 + glycine
Inhibitors cilastatin (pKi 6) [251]
S1: Chymotrypsin
Enzymes → Peptidases and proteinases → PA: Serine (S) Peptidases → S1: Chymotrypsin
Nomenclature complement C1r coagulation factor II, thrombin coagulation factor X
Systematic nomenclature – prothrombin –
HGNC, UniProt C1R, P00736 F2, P00734 F10, P00742
EC number 3.4.21.41 3.4.21.5 3.4.21.6
Inhibitors nafamostat (pIC50
4.9) [294]
lepirudin (pKi 13) [612, 719], desirudin (pKi 12.7) [181, 343], bivalirudin (pKi
8.6) [653, 739], dabigatran (Antithrombotic effects occur via inhibition of the
activated form, factor IIa) (pKi 8.3) [288, 733], argatroban (pKi 7.7) [324, 612]
–
Selective inhibitors – – apixaban (pKi 10.1) [740], rivaroxaban (pKi 9.4) [541], edoxaban (pKi 9.2)
[219, 547], JTV-803 (Antithrombotic effect occurs via the inhibition of the
activated form, Xa) (pKi 7.7) [291, 320], DX-9065a (Antithrombotic effect
occurs via the inhibition of the activated form, Xa) (pKi 7.4) [281, 320]
Searchable database: http://www.guidetopharmacology.org/index.jsp S1: Chymotrypsin S395
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Nomenclature elastase, neutrophil expressed plasminogen plasminogen activator, tissue type
HGNC, UniProt ELANE, P08246 PLG, P00747 PLAT, P00750
EC number 3.4.21.37 3.4.21.7 3.4.21.68
Inhibitors alvelestat (pKi 8) [652], sivelestat (pIC50 7.4) [128] aprotinin {Bovine} (Binding) (pIC50 6.8) [644],
tranexamic acid (Binding) (pIC50 3.6) [644]
–
Selective inhibitors – 6-aminocaproic acid (Binding) (pIC50 4.4) [103] –
Comments Neutrophil elastase (NE) is a destructive serine protease. It is stored in the primary granules of
neutrophils and is endogenously inhibited by alpha1-proteinase inhibitor (a.k.a. alpha-1
antitrypsin). NE is a molecular target for neutrophil-mediated inflammatory lung diseases.
– –
Nomenclature serine protease 1 transmembrane serine protease 2 tryptase alpha/beta 1
HGNC, UniProt PRSS1, P07477 TMPRSS2, O15393 TPSAB1, Q15661
EC number 3.4.21.4 3.4.21.- 3.4.21.59
Inhibitors nafamostat (pIC50 7.8) [294] – nafamostat (pIC50 10) [486]
Selective inhibitors – – gabexate (pIC50 8.5) [179]
T1: Proteasome
Enzymes → Peptidases and proteinases → PB: Threonine (T) Peptidases → T1: Proteasome
Overview: The T1 macropain beta subunits form the catalytic proteinase core of the 20S proteasome complex [114]. This catalytic core enables the degradation of peptides with Arg, Phe, Tyr, Leu, and
Glu adjacent to the cleavage site. The β5 subunit is the principal target of the approved drug proteasome inhibitor bortezomib.
Nomenclature proteasome 20S subunit beta 5
HGNC, UniProt PSMB5, P28074
EC number 3.4.25.1
Inhibitors bortezomib (pIC50 7.7) [496]
Selective inhibitors ixazomib (pKi 9) [387]
Searchable database: http://www.guidetopharmacology.org/index.jsp T1: Proteasome S396
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S8: Subtilisin
Enzymes → Peptidases and proteinases → SB: Serine (S) Peptidases → S8: Subtilisin
Overview: One member of this family has garnered intense
interest as a clinical drug target. As liver PCSK9 acts to maintain
cholesterol homeostasis, it has become a target of intense
interest for clinical drug development. Inhibition of PCSK9 can
lower low-density cholesterol (LDL-C) by clearing LDLR-bound
LDL particles, thereby lowering circulating cholesterol levels. It is
hypothesised that this action may improve outcomes in patients
with atherosclerotic cardiovascular disease [427, 593, 651].
Therapeutics which inhibit PCSK9 are viewed as potentially
lucrative replacements for statins, upon statin patent expiry.
Several monoclonal antibodies including alirocumab,
evolocumab, bococizumab, RG-7652 and LY3015014 are under
development. One RNAi therapeutic, code named ALN-PCS02, is
also in development [133, 199, 206].
Information on members of this family may be found in the online database.
S9: Prolyl oligopeptidase
Enzymes → Peptidases and proteinases → SC: Serine (S) Peptidases → S9: Prolyl oligopeptidase
Nomenclature dipeptidyl peptidase 4
HGNC, UniProt DPP4, P27487
EC number 3.4.14.5
Endogenous substrates glucagon-like peptide 1 (GCG, P01275)
Inhibitors saxagliptin (pKi 9.2) [264], linagliptin (pKi 9) [173], sitagliptin (pIC50 8.1) [141], vildagliptin (pKi 7.8) [264]
Selective inhibitors ZY15557 (Competitive) (pKi 8.3) [334]
Peptidyl-prolyl cis/trans isomerases
Enzymes → Peptidyl-prolyl cis/trans isomerases
Overview: Peptidyl-prolyl cis/trans isomerases (PPIases) are an enzyme family which catalyse the cis/trans isomerisation of proline peptide bonds to promote the folding and re-folding of peptides and
proteins. Three subfamilies have been identified: cyclophilins, FK506-binding proteins and parvulins. Individual PPIases are overexpressed in a number of cancers [581], and family members have been
targetted for immunosuppressant effects.
Searchable database: http://www.guidetopharmacology.org/index.jsp Peptidyl-prolyl cis/trans isomerases S397
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Further reading on Peptidyl-prolyl cis/trans isomerases
Annett S et al. (2020) FK506 binding proteins and inflammation related signalling pathways; basic
biology, current status and future prospects for pharmacological intervention. Pharmacol Ther
215: 107623 [PMID:32622856]
Bukrinsky M. (2015) Extracellular cyclophilins in health and disease. Biochim Biophys Acta 1850:
2087-95 [PMID:25445705]
Kang CB et al. (2008) FKBP family proteins: immunophilins with versatile biological functions.
Neurosignals 16: 318-25 [PMID:18635947]
Schiene-Fischer C. (2015) Multidomain Peptidyl Prolyl cis/trans Isomerases. Biochim Biophys Acta
1850: 2005-16 [PMID:25445709]
Schmidpeter PA et al. (2015) Control of protein function by prolyl isomerization. Biochim Biophys
Acta 1850: 1973-82 [PMID:25542300]
Wang T et al. (2004) The immunophilin FKBP12: a molecular guardian of the TGF-beta family
type I receptors. Front Biosci 9: 619-31 [PMID:14766396]
Nomenclature FKBP prolyl isomerase 1A FKBP prolyl isomerase 8 FKBP prolyl isomerase 5 FKBP prolyl isomerase 4 FKBP prolyl isomerase like
Common abbreviation FKBP12 FKBP38 FKBP51 FKBP52 –
HGNC, UniProt FKBP1A, P62942 FKBP8, Q14318 FKBP5, Q13451 FKBP4, Q02790 FKBPL, Q9UIM3
EC number 5.2.1.8 5.2.1.8 5.2.1.8 5.2.1.8 5.2.1.8
Inhibitors zotarolimus (Binding) (pIC50 8.6) [229] GPI-1046 (pKi 7.3) [174] SLF (pIC50 5.2) [247] SLF (pIC50 5) [247] –
Selective inhibitors tacrolimus (pKi 9.4) [272], pimecrolimus
(pIC50 8.2) [319] – Rat
DM-CHX (pKi 7.1) [174] SAFit1 (pKi 8.4) [220],
SAFit2 (pKi 8.2) [220]
– –
Comments – – – – Peptides based on the non-functional PPIase domain of
FKBPL (e.g. AD-01 and ALM201) have potent anti-tumour
activity by inhibiting angiogenesis and promoting the
differentiation of cancer stem cells [21, 461, 462, 696].
Nomenclature peptidylprolyl cis/trans isomerase, NIMA-interacting 1 peptidylprolyl isomerase A peptidylprolyl isomerase D
Common abbreviation – – cyclophilin D
HGNC, UniProt PIN1, Q13526 PPIA, P62937 PPID, Q08752
EC number 5.2.1.8 5.2.1.8 5.2.1.8
Inhibitors BJP-06-005-3 (pKi 7.8) [546], AG-17724 (pKi 7.1) [263] cyclosporin A (Inhibition of the phosphatase activity of
calcineurin in Jurkat cells.) (pIC50 8.3) [210], voclosporin
(Binding) (pKd 7.8) [385]
cyclosporin A [552]
Comments PIN1 isomerises phosphorylated serine/threonine-proline
bonds. It plays roles in cell cycle control, neuropathologies
and the immune system [183].
– Cyclosporin A (CsA) is the prototypical cyclophilin D (CyPD)
inhibitor, but it also inhibits cyclophilin A and the
calcineurin pathway, an effect that has long been used for
immunosuppression in humans [552].
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Poly ADP-ribose polymerases
Enzymes → Poly ADP-ribose polymerases
Overview: The Poly ADP-ribose polymerase family is a series of enzymes, where the best characterised members are nuclear proteins which are thought to function by binding to single strand breaks in
DNA, allowing the recruitment of repair enzymes by the synthesis of NAD-derived ADP-ribose polymers, which are subsequently degraded by a glycohydrolase (PARG, Q86W56). The most well defined
function of the tankyrases (TNKSs) is their regulatory action on Wnt/β-catenin signalling [449].
Further reading on Poly ADP-ribose polymerases
Curtin NJ et al. (2020) Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev
Drug Discov 19: 711-736 [PMID:32884152]
Grignani G et al. (2020) Delving into PARP inhibition from bench to bedside and back. Pharmacol
Ther 206: 107446 [PMID:31756364]
Lal S et al. (2021) A therapeutic update on PARP inhibitors: implications in the treatment of
glioma. Drug Discov Today 26: 532-541 [PMID:33157194]
Leung AKL. (2020) Poly(ADP-ribose): A Dynamic Trigger for Biomolecular Condensate Formation.
Trends Cell Biol 30: 370-383 [PMID:32302549]
Pandey N et al. (2021) Rapid Detection and Signaling of DNA Damage by PARP-1. Trends Biochem
Sci [PMID:33674152]
Rao PD et al. (2020) ’PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP)
inhibitors. Drug Discov Today 25: 1253-1261 [PMID:32371137]
Nomenclature poly(ADP-ribose) polymerase 1 poly(ADP-ribose) polymerase 2 poly (ADP-ribose) polymerase 3
Common abbreviation PARP1 PARP2 PARP3
HGNC, UniProt PARP1, P09874 PARP2, Q9UGN5 PARP3, Q9Y6F1
EC number 2.4.2.30 2.4.2.30 –
Selective inhibitors MC2050 (pIC50 6.9) [488] – –
Prolyl hydroxylases
Enzymes → Prolyl hydroxylases
Overview: Hypoxia-inducible factors (HIFs) are
rapidly-responding sensors of reductions in local oxygen
tensions, prompting changes in gene transcription. Listed here
are the 4-prolyl hydroxylase family, members of which have
been identified to hydroxylate proline residues in HIF1α (HIF1A;
Q16665) leading to an increased degradation through
proteasomal hydrolysis. This action requires molecular oxygen
and 2-oxoglutarate, and so reduced oxygen tensions prevents
HIF1α hydroxylation, allowing its translocation to the nucleus
and dimerisation with HIF1β (also known as ARNT; P27540),
thereby allowing interaction with the genome as a transcription
factor.
Further reading on Prolyl hydroxylases
Fan L et al. (2014) The hypoxia-inducible factor pathway, prolyl hydroxylase domain protein
inhibitors, and their roles in bone repair and regeneration. Biomed Res Int 2014: 239356
[PMID:24895555]
Jaakkola PM et al. (2013) The regulation, localization, and functions of oxygen-sensing prolyl
hydroxylase PHD3. Biol Chem 394: 449-57 [PMID:23380539]
Rabinowitz MH. (2013) Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen
sensors: tricking the body into mounting orchestrated survival and repair responses. J Med
Chem 56: 9369-402 [PMID:23977883]
Schödel J et al. (2019) Mechanisms of hypoxia signalling: new implications for nephrology. Nat
Rev Nephrol 15: 641-659 [PMID:31488900]
Searchable database: http://www.guidetopharmacology.org/index.jsp Prolyl hydroxylases S399
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Nomenclature egl-9 family hypoxia inducible factor 2 egl-9 family hypoxia inducible factor 1 egl-9 family hypoxia inducible factor 3
Common abbreviation PHD1 PHD2 PHD3
HGNC, UniProt EGLN2, Q96KS0 EGLN1, Q9GZT9 EGLN3, Q9H6Z9
EC number 1.14.11.29 1.14.11.29 1.14.11.29
Sphingosine 1-phosphate turnover
Enzymes → Sphingosine 1-phosphate turnover
Overview: S1P (sphingosine 1-phosphate) is a bioactive lipid
which, after release from cells via certain transporters, acts as a
ligand for a family of five S1P-specific G protein-coupled
receptors (S1P1-5). However, it also has a number of intracellular
targets. S1P is formed by the ATP-dependent phosphorylation of
sphingosine, catalysed by two isoforms of sphingosine kinase
(EC 2.7.1.91). It can be dephosphorylated back to sphingosine by
sphingosine 1-phosphate phosphatase (EC 3.1.3) or cleaved into
phosphoethanolamine and hexadecenal by sphingosine
1-phosphate lyase (EC 4.1.2.27). Recessive mutations in the S1P
lyase (SPL) gene underlie a recently identified sphingolipidosis:
SPL Insufficiency Syndrome (SPLIS). In general, S1P promotes cell
survival, proliferation, migration, adhesion and inhibition of
apoptosis. Intracellular S1P affects epigenetic regulation,
endosomal processing, mitochondrial function and cell
proliferation/senescence. S1P has myriad physiological
functions, including vascular development, lymphocyte
trafficking and neurogenesis. However, S1P is also involved in a
number of diseases such as cancer, inflammation and fibrosis.
Therefore, its GPCRs and enzymes of synthesis and degradation
are a major focus for drug discovery.
Sphingosine kinase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine kinase
Overview: SPHK1 and SPHK2 are encoded by different genes
with some redundancy of function; genetic deletion of both
Sphk1 and Sphk2, but not either alone, is embryonic lethal in
mice. There are splice variants of each isoform (SphK1a-c and
SphK2a, b), distinguished by their N-terminal sequences. SPHK1
and SPHK2 differ in tissue distribution, sub-cellular localisation,
biochemical properties and regulation. They regulate discrete
pools of S1P. Receptor stimulation induces SPHK1 translocation
from the cytoplasm to the plasma membrane. SPHK1
translocation is regulated by
phosphorylation/dephosphorylation, specific protein:protein
interactions and interaction with specific lipids at the plasma
membrane. SPHK1 is a dimeric protein, as confirmed by its
crystal structure which forms a positive cluster, between
protomers, essential for interaction with anionic phospholipids
in the plasma membrane. SPHK2 is localised to the ER or
associated with mitochondria or shuttles in/out of the nucleus,
regulated by phosphorylation. Intracellular targets of nuclear S1P
include the catalytic subunit of telomerase (TERT) and regulators
of gene expression including histone deacetylases (HDAC 1/2)
and peroxisome proliferator-activated receptor gamma (PPARγ).
SPHK2 phosphorylates the pro-drug FTY720 (fingolimod, which
is used to treat some forms of multiple sclerosis) to a mimic of
S1P and that acts as a functional antagonist of S1P1 receptors.
Inhibitors of SPHK1 and SPHK2 have therapeutic potential in
many diseases. Isoform-selective inhibitors are becoming
available; some early inhibitors have recognised off-target effects.
Searchable database: http://www.guidetopharmacology.org/index.jsp Sphingosine kinase S400
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Further reading on Sphingosine kinase
Adams DR et al. (2016) Sphingosine Kinases: Emerging Structure-Function Insights. Trends
Biochem Sci 41: 395-409 [PMID:27021309]
Pitman MR et al. (2016) Recent advances in the development of sphingosine kinase inhibitors.
Cell Signal 28: 1349-63 [PMID:27297359]
Powell JA et al. (2019) Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes
proteasomal degradation of sphingosine kinase 1. Biochem J 476: 3211-3226 [PMID:31652307]
Pulkoski-Gross MJ et al. (2018) An intrinsic lipid-binding interface controls sphingosine kinase 1
function. J Lipid Res 59: 462-474 [PMID:29326159]
Pyne NJ et al. (2017) Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the
Development of Sphingosine Kinase 2 Inhibitors. Trends Pharmacol Sci 38: 581-591
[PMID:28606480]
Pyne S et al. (2020) Sphingosine Kinases as Druggable Targets. Handb Exp Pharmacol 259: 49-76
[PMID:29460151]
Nomenclature sphingosine kinase 1 sphingosine kinase 2
Common abbreviation SPHK1 SPHK2
HGNC, UniProt SPHK1, Q9NYA1 SPHK2, Q9NRA0
EC number 2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP
dihydrosphingosine + ATP = dihydrosphingosine 1-phosphate + ADP
2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP
dihydrosphingosine + ATP = dihydrosphingosine 1-phosphate + ADP
Cofactors Mg2+ [618] Mg2+
Inhibitors compound 49 (pIC50 7.8) [6], SKI II (pKi 4.8) [207], MP-A08 (pIC50 4.6) [549] compound 49 (pIC50 7.8) [6], MP-A08 (pKi 5.2) [549], SKI II (pKi 5.1) [225]
Selective inhibitors PF-543 (pKi 8.4) [606] compound 59 (pIC50 7.8) [6], compound 60 (pIC50 7.5) [6], compound 55 (pIC50 7.4) [6], SLC4101431
(pKi 7.1) [106], compound 27d (pIC50 6.8) [605], opaganib (pKi 5) [207], ROMe (pKi 4.8) [412]
Comments SPHK1 inhibitors induce its proteasomal degradation [432, 465]. SPHK1
crystal structures confirm that it is dimeric [5]; there is no crystal structure
available for SPHK2.
There is no crystal structure available for SPHK2.
Comments: MP-A08 is competitive with ATP; other SPHK inhibitors are competitive with sphingosine. ABC294640 (opaganib) has known off-target effects on dihydroceramide desaturase (DEGS1)
[465, 701]) and induces proteasomal degradation of SPHK1 [465]. ABC294640 is in clinical trials for advanced cholangiocarcinoma, advanced hepatocellular carcinoma and refractory/relapsed multiple
myeloma (to view ClinicalTrials.gov list click here).
Searchable database: http://www.guidetopharmacology.org/index.jsp Sphingosine kinase S401
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Sphingosine 1-phosphate phosphatase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine 1-phosphate phosphatase
Further reading on Sphingosine 1-phosphate phosphatase
Huang WC et al. (2016) Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal
integrity, and contributes to ulcerative colitis in mice and humans. FASEB J 30: 2945-58
[PMID:27130484]
Kilbey A et al. (2017) Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance
in Lymphomagenesis. J Cell Biochem 118: 1432-1441 [PMID:27869314]
Lépine S et al. (2011) Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced
autophagy. Cell Death Differ 18: 350-61 [PMID:20798685]
Mandala SM et al. (2000) Molecular cloning and characterization of a lipid phosphohydrolase that
degrades sphingosine-1- phosphate and induces cell death. Proc Natl Acad Sci USA 97: 7859-64
[PMID:10859351]
Schwiebs A et al. (2017) Nuclear Translocation of SGPP-1 and Decrease of SGPL-1 Activity
Contribute to Sphingolipid Rheostat Regulation of Inflammatory Dendritic Cells. Mediators
Inflamm 2017: 5187368 [PMID:29375197]
Taguchi Y et al. (2016) Sphingosine-1-phosphate Phosphatase 2 Regulates Pancreatic Islet β-Cell
Endoplasmic Reticulum Stress and Proliferation. J Biol Chem 291: 12029-38 [PMID:27059959]
Nomenclature sphingosine-1-phosphate phosphatase 1 sphingosine-1-phosphate phosphatase 2
Common abbreviation SGPP1 SGPP2
HGNC, UniProt SGPP1, Q9BX95 SGPP2, Q8IWX5
EC number 3.1.3.-: sphingosine 1-phosphate -> sphingosine + inorganic phosphate
dihydrosphingosine 1-phosphate -> dihydrosphingosine + inorganic phosphate
3.1.3.-: sphingosine 1-phosphate -> sphingosine + inorganic phosphate
dihydrosphingosine 1-phosphate -> dihydrosphingosine + inorganic phosphate
Comments Depletion of S1P phosphohydrolase-1 (SPP1), which degrades intracellular S1P, induces the
unfolded protein response and endoplasmic reticulum stress-induced autophagy [402].
–
Comments: SGPP1 and SGPP2 are non-redundant endoplasmic reticulum enzymes that dephosphorylate intracellular S1P. The phenotype of Sgpp1(-/-) mice differ with genetic background. Sgpp2(-/-)
mice are also available. No specific SGPP inhibitors available [402].
Sphingosine 1-phosphate lyase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine 1-phosphate lyase
Further reading on Sphingosine 1-phosphate lyase
Bamborschke D et al. (2018) A novel mutation in sphingosine-1-phosphate lyase causing
congenital brain malformation. Brain Dev 40: 480-483 [PMID:29501407]
Choi YJ et al. (2019) Sphingosine phosphate lyase insufficiency syndrome (SPLIS): A novel inborn
error of sphingolipid metabolism. Adv Biol Regul 71: 128-140 [PMID:30274713]
Lovric S et al. (2017) Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis
and adrenal insufficiency. J Clin Invest 127: 912-928 [PMID:28165339]
Prasad R et al. (2017) Sphingosine-1-phosphate lyase mutations cause primary adrenal
insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest 127: 942-953
[PMID:28165343]
Schwiebs A et al. (2019) Cancer-induced inflammation and inflammation-induced cancer in
colon: a role for S1P lyase. Oncogene 38: 4788-4803 [PMID:30816345]
Searchable database: http://www.guidetopharmacology.org/index.jsp Sphingosine 1-phosphate lyase S402
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Nomenclature sphingosine-1-phosphate lyase 1
HGNC, UniProt SGPL1, O95470
EC number 4.1.2.27: sphingosine 1-phosphate -> phosphoethanolamine + hexadecenal
dihydrosphingosine 1-phosphate -> phosphoethanolamine + hexadecanal
Cofactors pyridoxal 5-phosphate
Inhibitors compound 31 (pIC50 6.7) [284, 424, 608, 728]
Comments: THI (2-Acetyl-5-tetrahydroxybutyl imidazole) inhibits the enzyme activity in intact cell preparations [609]. Recessive mutations in the S1P lyase (SGPL1) gene underlie a recently identified
sphingolipidosis: SPL Insufficiency Syndrome (SPLIS) [110]. A Phase 2 clinical trial of LX3305 (LX2931) for rheumatoid arthritis has been completed (see NCT00903383). A homozygous point mutation
results in mislocalisation of S1P lyase from the endoplasmic reticulum in pediatric alveolar rhabdomyosarcoma [7].
Thyroid hormone turnover
Enzymes → Thyroid hormone turnover
Overview:
The thyroid hormones triiodothyronine and thyroxine, usually
abbreviated as triiodothyronine and T4, respectively, are
synthesized in the thyroid gland by sequential metabolism of
tyrosine residues in the glycosylated homodimeric protein
thyroglobulin (TG, P01266) under the influence of the
haem-containing protein iodide peroxidase. Iodide
peroxidase/TPO is a haem-containing enzyme, from the same
structural family as eosinophil peroxidase (EPX, P11678),
lactoperoxidase (LPO, P22079) and myeloperoxidase (MPO,
P05164). Circulating thyroid hormone is bound to
thyroxine-binding globulin (SERPINA7, P05543).
Tissue deiodinases
These are 1 TM selenoproteins that remove an iodine from T4
(3,3’,5,5’-tetraiodothyronine) to generate triiodothyronine
(3,3’,5-triiodothyronine, a more potent agonist at thyroid
hormone receptors) or rT3 (rT3, 3,3’,5’-triiodothyronine, a
relatively inactive analogue). DIO1 is also able to deiodinate RT3
to form 3,3’-diidothyronine (T2). Iodotyrosine deiodinase is a
1TM homodimeric enzyme.
Further reading on Thyroid hormone turnover
Darras VM et al. (2015) Intracellular thyroid hormone metabolism as a local regulator of nuclear
thyroid hormone receptor-mediated impact on vertebrate development. Biochim Biophys Acta
1849: 130-41 [PMID:24844179]
Gereben B et al. (2015) Scope and limitations of iodothyronine deiodinases in hypothyroidism.
Nat Rev Endocrinol 11: 642-652 [PMID:26416219]
Marsan ES et al. (2020) A Halogen Bonding Perspective on Iodothyronine Deiodinase Activity.
Molecules 25: [PMID:32183289]
Mondal S et al. (2017) Novel thyroid hormone analogues, enzyme inhibitors and mimetics, and
their action. Mol Cell Endocrinol 458: 91-104 [PMID:28408161]
van der Spek AH et al. (2017) Thyroid hormone metabolism in innate immune cells. J Endocrinol
232: R67-R81 [PMID:27852725]
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Nomenclature thyroid peroxidase iodothyronine deiodinase 1 iodothyronine deiodinase 2 iodothyronine deiodinase 3 iodotyrosine deiodinase
Common abbreviation TPO DIO1 DIO2 DIO3 IYD
HGNC, UniProt TPO, P07202 DIO1, P49895 DIO2, Q92813 DIO3, P55073 IYD, Q6PHW0
EC number 1.11.1.8: [Thyroglobulin]-L-tyrosine + H2O2 + H+











1.22.1.1: 3-iodotyrosine -> L-tyrosine + I-
3,5-diiodo-L-tyrosine -> 3-iodotyrosine + I-
Cofactors Ca2+ – – – flavin adenine dinucleotide, NADPH
Inhibitors methimazole [499], propylthiouracil [499] – – – –
Comments Carbimazole is a pro-drug for methimazole – – – –
1.14.13.9 Kynurenine 3-monooxygenase
Enzymes → 1.14.13.9 Kynurenine 3-monooxygenase
Further reading on 1.14.13.9 Kynurenine 3-monooxygenase
Collier ME et al. (2021) Inflammation control and improvement of cognitive function in
COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition? Drug Discov
Today [PMID:33609782]
Erhardt S et al. (2017) The kynurenine pathway in schizophrenia and bipolar disorder.
Neuropharmacology 112: 297-306 [PMID:27245499]
Fujigaki H et al. (2017) L-Tryptophan-kynurenine pathway enzymes are therapeutic target for
neuropsychiatric diseases: Focus on cell type differences. Neuropharmacology 112: 264-274
[PMID:26767951]
Smith JR et al. (2016) Kynurenine-3-monooxygenase: a review of structure, mechanism, and
inhibitors. Drug Discov Today 21: 315-24 [PMID:26589832]
Song P et al. (2017) Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular
diseases. Cell Mol Life Sci 74: 2899-2916 [PMID:28314892]
Nomenclature kynurenine 3-monooxygenase
HGNC, UniProt KMO, O15229
EC number 1.14.13.9
L-kynurenine + NADPH + O2 <=> 3-hydroxy-L-kynurenine + NADP(+) + H2O
Comments Kynurenine 3-monooxygenase participates in metabolism of the essential amino acid tryptophan.
Searchable database: http://www.guidetopharmacology.org/index.jsp 1.14.13.9 Kynurenine 3-monooxygenase S404
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2.5.1.58 Protein farnesyltransferase
Enzymes → 2.5.1.58 Protein farnesyltransferase
Overview: Farnesyltransferase is a member of the
prenyltransferases family which also includes
geranylgeranyltransferase types I (EC 2.5.1.59) and II (EC
2.5.1.60) [87]. Protein farnesyltransferase catalyses the
post-translational formation of a thioether linkage between the
C-1 of an isoprenyl group and a cysteine residue fourth from the
C-terminus of a protein (ie to the CaaX motif, where ’a’ is an
aliphatic amino acid and ’X’ is usually serine, methionine,
alanine or glutamine; leucine for EC 2.5.1.59) [216].
Farnesyltransferase is a dimer, composed of an alpha and beta
subunit and requires Mg2+ and Zn2+ ions as cofactors. The active
site is located between the subunits. Prenylation creates a
hydrophobic domain on protein tails which acts as a membrane
anchor.
Substrates of the prenyltransferases include Ras, Rho, Rab, other
Ras-related small GTP-binding proteins, G-protein γ-subunits,
nuclear lamins, centromeric proteins and many proteins
involved in visual signal transduction.
In relation to the causative association between oncogenic Ras
proteins and cancer, farnesyltransferase has become an
important mechanistic drug discovery target.
Further reading on 2.5.1.58 Protein farnesyltransferase
Gao S et al. (2016) The Role of Geranylgeranyltransferase I-Mediated Protein Prenylation in the
Brain. Mol Neurobiol 53: 6925-6937 [PMID:26666664]
Shen M et al. (2015) Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism,
inhibitors and molecular modeling. Drug Discov Today 20: 267-76 [PMID:25450772]
Wang M et al. (2016) Protein prenylation: unique fats make their mark on biology. Nat Rev Mol
Cell Biol 17: 110-22 [PMID:26790532]
Zhao Y et al. (2020) The balance of protein farnesylation and geranylgeranylation during the
progression of nonalcoholic fatty liver disease. J Biol Chem 295: 5152-5162 [PMID:32139507]
Information on members of this family may be found in the online database.
3.5.3.15 Peptidyl arginine deiminases (PADI)
Enzymes → 3.5.3.15 Peptidyl arginine deiminases (PADI)
Overview: In humans, the peptidyl arginine deiminases (PADIs;
HGNC family link) are a family of five enzymes, PADI1-4 and
PADI6. PADIs catalyze the deimination of protein L-arginine
residues to L-citrulline and ammonia, generating
peptidyl-citrulline on histones, fibrinogen, and other biologically
relevant proteins. The human isozymes exhibit tissue-specific
expression patterns [344]. Overexpression and/or increased PADI
activity is observed in several diseases, including rheumatoid
arthritis, Alzheimer’s disease, multiple sclerosis, lupus,
Parkinson’s disease, and cancer [54]. Pharmacological PADI
inhibition reverses protein-hypercitrullination and disease in
mouse models of multiple sclerosis [489].
Further reading on 3.5.3.15 Peptidyl arginine deiminases (PADI)
Al-U’datt DGF et al. (2021) Current knowledge into the role of the peptidylarginine deiminase
(PAD) enzyme family in cardiovascular disease J Neurochem 891: 173765 [PMID:33249073]
Koushik S et al. (2017) PAD4: pathophysiology, current therapeutics and future perspective in
rheumatoid arthritis. Expert Opin Ther Targets 21: 433-447 [PMID:28281906]
Tu R et al. (2016) Peptidyl Arginine Deiminases and Neurodegenerative Diseases. Curr Med Chem
23: 104-14 [PMID:26577926]
Whiteley CG. (2014) Arginine metabolising enzymes as targets against Alzheimers’ disease.
Neurochem Int 67: 23-31 [PMID:24508404]
Information on members of this family may be found in the online database.
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3.6.5.2 Small monomeric GTPases
Enzymes → 3.6.5.2 Small monomeric GTPases
Overview: Small G-proteins, are a family of hydrolase enzymes that can bind and hydrolyze guanosine triphosphate (GTP). They are a type of G-protein found in the cytosol that are homologous to
the alpha subunit of heterotrimeric G-proteins, but unlike the alpha subunit of G proteins, a small GTPase can function independently as a hydrolase enzyme to bind to and hydrolyze a guanosine
triphosphate (GTP) to form guanosine diphosphate (GDP). The best-known members are the Ras GTPases and hence they are sometimes called Ras subfamily GTPases.
RAS subfamily
Enzymes → 3.6.5.2 Small monomeric GTPases → RAS subfamily
Overview: The RAS proteins (HRAS, NRAS and KRAS) are small
membrane-localised G protein-like molecules of 21 kd. They act
as an on/off switch linking receptor and non-receptor tyrosine
kinase activation to downstream cytoplasmic or nuclear events.
Binding of GTP activates the switch, and hydrolysis of the GTP
to GDP inactivates the switch.
The RAS proto-oncogenes are the most frequently mutated class
of proteins in human cancers. Common mutations compromise
the GTP-hydrolysing ability of the proteins causing constitutive
activation [648], which leads to increased cell proliferation and
decreased apoptosis [776]. Because of their importance in
oncogenic transformation these proteins have become the
targets of intense drug discovery effort [38].
Further reading on RAS subfamily
Chen H et al. (2020) Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer
Therapeutics. J Med Chem 63: 14404-14424 [PMID:33225706]
Dorard C et al. (2017) Deciphering the RAS/ERK pathway in vivo. Biochem Soc Trans 45: 27-36
[PMID:28202657]
Kattan WE et al. (2020) RAS Function in cancer cells: translating membrane biology and
biochemistry into new therapeutics. Biochem J 477: 2893-2919 [PMID:32797215]
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RAB subfamily
Enzymes → 3.6.5.2 Small monomeric GTPases → RAB subfamily
Overview: The Rab family of proteins is a member of the Ras
superfamily of monomeric G proteins. Rab GTPases regulate
many steps of membrane traffic, including vesicle formation,
vesicle movement along actin and tubulin networks, and
membrane fusion. These processes make up the route through
which cell surface proteins are trafficked from the Golgi to the
plasma membrane and are recycled. Surface protein recycling
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